Report Preview Details

0001104659-11-063886.txt : 20111114 0001104659-11-063886.hdr.sgml : 20111111 20111114155050 ACCESSION NUMBER: 0001104659-11-063886 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110930 FILED AS OF DATE: 20111114 DATE AS OF CHANGE: 20111114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCLINICA INC CENTRAL INDEX KEY: 0000822418 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 112872047 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11182 FILM NUMBER: 111202126 BUSINESS ADDRESS: STREET 1: 826 NEWTOWN-YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940-1721 BUSINESS PHONE: 2677573000 MAIL ADDRESS: STREET 1: 826 NEWTOWN-YARDLEY ROAD CITY: NEWTOWN STATE: PA ZIP: 18940-1721 FORMER COMPANY: FORMER CONFORMED NAME: BIO IMAGING TECHNOLOGIES INC DATE OF NAME CHANGE: 19960302 FORMER COMPANY: FORMER CONFORMED NAME: WISE VENTURES INC DATE OF NAME CHANGE: 19911023 10-Q 1 a11-26012_110q.htm 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2011

o Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File No. 001-11182

BIOCLINICA, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		11-2872047
(State or Other Jurisdiction of		(I.R.S. Employer Identification No.)
Incorporation or Organization)

826 Newtown-Yardley Road, Newtown, Pennsylvania 18940-1721

(Address of Principal Executive Offices) (Zip Code)

(267) 757-3000

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes: x No: o

Indicate by check mark if the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes: x No: o

Indicate by check mark if the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):

Large accelerated filer o		Accelerated filer o

Non-accelerated filer o (do not check if a smaller reporting company)		Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: o No: x

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of October 31, 2011:

Class		Number of Shares
Common Stock, $0.00025 par value		15,659,975

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

		Page

PART I.	FINANCIAL INFORMATION.

Item 1.	Financial Statements (unaudited)	1

	CONSOLIDATED BALANCE SHEETS as of September 30, 2011 and December 31, 2010	2

	CONSOLIDATED STATEMENTS OF INCOME For the Three Months Ended September 30, 2011 and 2010	3

	CONSOLIDATED STATEMENTS OF INCOME For the Nine Months Ended September 30, 2011 and 2010	4

	CONSOLIDATED STATEMENTS OF CASH FLOWS For the Nine Months Ended September 30, 2011 and 2010	5

	CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME For the Three and Nine Months Ended September 30, 2011 and 2010	7

	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

	Overview	17

	Forward Looking Statements	18

	Recent Accounting Pronouncements	19

	Results of Operations	20

	Business Segments	25

	Liquidity and Capital Resources	26

	Changes to Critical Accounting Policies and Estimates	28

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28

Item 4.	Controls and Procedures	28

PART II.	OTHER INFORMATION.

Item 1.	Legal Proceedings	29

Item 1A.	Risk Factors	29

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40

Item 3.	Defaults Upon Senior Securities	40

Item 4.	(REMOVED AND RESERVED)	40

Item 5.	Other Information	40

Item 6.	Exhibits	41

SIGNATURES		42

Table of Contents

PART I. FINANCIAL INFORMATION.

Item 1. Financial Statements.

References in this Quarterly Report on Form 10-Q to “BioClinica,” “we,” “us,” or “our” refer to BioClinica, Inc., a Delaware corporation, and its subsidiaries, doing business as BioClinica.

Certain information and footnote disclosures required under generally accepted accounting principles (GAAP) in the United States of America have been condensed or omitted from the following consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission, although we believe that such financial disclosures are adequate so that the information presented is not misleading in any material respect. The following consolidated financial statements should be read in conjunction with the year-end consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

The results of operations for the interim periods presented in this Quarterly Report on Form 10-Q are not necessarily indicative of the results to be expected for the entire fiscal year.

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(unaudited)

	September 30,			December 31,
(in thousands)	2011			2010
ASSETS
Current assets:
Cash and cash equivalents	$	12,292		$	10,443
Accounts receivable, net	13,482			11,866
Prepaid expenses and other current assets	2,594			2,501
Deferred income taxes	4,098			3,625
Total current assets	32,466			28,435

Property and equipment, net	15,459			14,029
Intangibles, net	1,963			2,430
Goodwill	34,302			34,302
Deferred income tax	87			128
Other assets	748			705

Total assets	$	85,025		$	80,029
LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	2,168		$	1,983
Accrued expenses and other current liabilities	4,185			4,283
Deferred revenue	13,377			13,395
Current maturities of capital lease obligations	342			168
Current liability for acquisition earn-out	2,000			—
Total current liabilities	22,072			19,829
Long-term capital lease obligations	1,296			710
Long-term liability for acquisition earn-out	—			1,886
Deferred income tax	3,107			1,845
Other liabilities	1,621			880
Total liabilities	$	28,096		$	25,150

Stockholders’ equity:
Preferred stock - $0.00025 par value; authorized 3,000,000 shares, none issued and outstanding at September 30, 2011 and at December 31, 2010	—			—
Common stock - $0.00025 par value; authorized 36,000,000 shares, issued and outstanding 15,662,550 shares at September 30, 2011 and 15,631,664 shares at December 31, 2010	4			4
Treasury stock — at cost, shares held: 160,113 at September 30, 2011 and 3,400 at December 31, 2010	(800		)	(16		)
Additional paid-in capital	49,231			48,074
Retained earnings	8,425			6,792
Accumulated other comprehensive income	69			25
Total stockholders’ equity	$	56,929		$	54,879

Total liabilities and stockholders’ equity	$	85,025		$	80,029

See Notes to Consolidated Financial Statements

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

	For the Three Months ended September 30,
(in thousands, except per share data)	2011			2010
Service revenues	$	16,623		$	15,969
Reimbursement revenues	4,847			2,352
Total revenues	21,470			18,321

Cost and expenses:
Cost of service revenues	10,434			10,212
Cost of reimbursement revenues	4,847			2,352
Sales and marketing expenses	2,081			2,090
General and administrative expenses	2,434			2,069
Amortization of intangible assets related to acquisition	155			194
Mergers and acquisitions related costs	—			119
Restructuring costs	1,040			—
Total cost and expenses	20,991			17,036

Operating income	479			1,285

Interest income	2			10
Interest expense	(14		)	—
Income before income tax	467			1,295

Income tax provision	(109		)	(487		)
Net income	$	358		$	808

Basic income per common share	$	0.02		$	0.05
Weighted average number of common shares	15,640			15,174

Diluted income per common share	$	0.02		$	0.05
Weighted average number of diluted shares	16,383			15,796

See Notes to Consolidated Financial Statements

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

	For the Nine Months ended September 30,
(in thousands, except per share data)	2011			2010
Service revenues	$	49,658		$	46,248
Reimbursement revenues	11,887			9,413
Total revenues	61,545			55,661

Cost and expenses:
Cost of service revenues	31,432			29,109
Cost of reimbursement revenues	11,887			9,413
Sales and marketing expenses	6,324			6,865
General and administrative expenses	7,027			6,057
Amortization of intangible assets related to acquisition	467			473
Mergers and acquisitions related costs	162			635
Restructuring costs	1,719			—
Total cost and expenses	59,018			52,552

Operating income	2,527			3,109

Interest income	6			18
Interest expense	(32		)	(7		)
Income before income tax	2,501			3,120

Income tax provision	(868		)	(1,198		)
Net income	$	1,633		$	1,922

Basic income per common share	$	0.10		$	0.13
Weighted average number of common shares	15,645			14,958

Diluted income per common share	$	0.10		$	0.12
Weighted average number of diluted shares	16,515			15,730

See Notes to Consolidated Financial Statements

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the Nine Months ended
	September 30,
(in thousands)	2011			2010
Cash flows from operating activities:
Net income	$	1,633		$	1,922
Adjustments to reconcile net income to net cash provided by operating activities, net of acquisition:
Depreciation and amortization	3,310			2,501
Provision for deferred income taxes	829			47
Bad debt recovery, net	(15		)	(9		)
Stock based compensation expense	1,019			791
Accretion of acquisition earn-out	114			245
Changes in operating assets and liabilities, net of acquisitions:
(Increase) decrease in accounts receivable	(1,603		)	278
Increase in prepaid expenses and other current assets	(89		)	(625		)
(Increase) decrease in other assets	(42		)	17
Increase (decrease) in accounts payable	113			(199		)
Decrease in accrued expenses and other current liabilities	(89		)	(1,136		)
Decrease in deferred revenue	(19		)	(1,127		)
Increase in other liabilities	742			368
Net cash provided by operating activities	$	5,903		$	3,073

Cash flows from investing activities:
Purchases of property and equipment	$	(1,352	)	$	(2,296	)
Capitalized software development costs	(2,843		)	(3,783		)
Net cash used in investing activities	$	(4,195	)	$	(6,079	)

Cash flows from financing activities:
Proceeds from sale/leaseback	918			195
Payments under equipment lease obligations	(157		)	—
Purchase of treasury stock	(784		)	—
Excess tax benefit related to stock options	—			35
Proceeds from exercise of stock options	138			21
Net cash provided by financing activities	$	115		$	251

Effect of exchange rate changes on cash	26			1

Net increase (decrease) in cash and cash equivalents	1,849			(2,754		)
Cash and cash equivalents at beginning of period	10,443			14,570
Cash and cash equivalents at end of period	$	12,292		$	11,816

Supplemental disclosure of cash flow information:
Cash paid during the period for interest	$	32		$	7
Cash paid during the period for income taxes	$	736		$	1,802

See Notes to Consolidated Financial Statements

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the Nine Months Ended September 30,
	2011		2010
Supplemental cash flow disclosure (in thousands)
Non cash investing and financing activities:
Increase in property, plant and equipment acquisitions in accounts payable	$	74	$	125
Equipment purchases under capital lease obligations	$	918	—

	For the Nine Months Ended September 30,
	2011	2010
Acquired business (in thousands)
Accounts receivable	—	$	309
Property and equipment	—	91
Other assets	—	58
Other Liabilities	—	(459		)
Customer Relationships	—	100
Technology	—	1,000
Goodwill, including Workforce	—	1,369
Total Fair Value of Purchase Price	—	$	2,468

See Notes to Consolidated Financial Statements

Table of Contents

BIOCLINICA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(unaudited)

	For the Three Months Ended September 30,
	2011			2010
Statement of comprehensive income (in thousands)
Net income	$	358		$	808
Equity adjustment from foreign currency translation	(47		)	166
Total comprehensive income	$	311		$	974

	For the Nine Months Ended September 30,
	2011		2010
Statement of comprehensive income (in thousands)
Net income	$	1,633	$	1,922
Equity adjustment from foreign currency translation	44		(37		)
Total comprehensive income	$	1,677	$	1,885

See Notes to Consolidated Financial Statements

Table of Contents

Note 1 - Interim Financial Statements

Basis of Presentation.

The financial statements included in this Quarterly Report on Form 10-Q have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP in the United States of America have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2010.

In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary for a fair statement of the results for the interim periods.

Interim results are not necessarily indicative of results for the full fiscal year.

As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010, the Company identified and corrected clerical billing errors in the quarter ending June 30, 2010 that overstated service revenue and income from operations by $155,000 ($94,000 net of tax) and understated the quarter ending September 30, 2010 service revenue and income from operations by $155,000 ($94,000 net of tax). The Company determined that these adjustments were not material to its consolidated financial statements for any of the quarterly periods affected. The Company has revised the financial statements for the quarter ended September 30, 2010 presented herein.

Functional Currency.

The functional currency of each of the Company’s foreign operations is the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. Increases and decreases in net assets resulting from foreign currency translation are reflected in stockholder’s equity as a component of accumulated other comprehensive income (loss).

The equity adjustment from foreign currency translation was $44,000 and $(37,000) for the nine months ended September 30, 2011 and 2010, respectively.

Recently Issued Accounting Pronouncements.

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (Topic 820)—Fair Value Measurement (ASU 2011-04), to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for level 3 fair value measurements. ASU 2011-04 is effective for the Company in the first quarter of fiscal 2012 and should be applied prospectively. The Company is currently evaluating the impact of the pending adoption of ASU 2011-04 on its consolidated financial statements.

Table of Contents

updates to the presentation of comprehensive income. Under this guidance, an entity has the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In addition, an entity is required to present on the face of the financial statements reclassification adjustments for items that are reclassified from other comprehensive income to net income in the statement(s) where the components of net income and the components of other comprehensive income are presented. This guidance will be effective for BioClinica, Inc. on January 1, 2012 and will impact the presentation of the Company’s consolidated financial statements.

In September 2011, the FASB issued authoritative guidance that allows an entity to use a qualitative approach to test goodwill for impairment. Under this guidance, an entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. In addition, an entity has the option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the first step of the two-step goodwill impairment test. This guidance will be effective for BioClinica’s goodwill impairment tests performed after December 31, 2011 and is not expected to have a material impact on the Company’s consolidated financial statements.

Table of Contents

Note 2 — Restructuring charges

In 2011, the Company realigned its global resources to eliminate certain duplicate functions and took a total restructuring charge of $1.7 million for the nine months ended September 30, 2011. This restructuring charge was comprised of $656,000 in employee severance, $884,000 write-off of facility lease obligations and $179,000 in legal and other costs.

The Company has paid $715,000 of the restructuring cost as of September 30, 2011 and the $1,004,000 remaining to be paid is included in Accrued Expense and Other Current Liabilities on the Consolidated Balance Sheet. $120,000 of the unpaid restructuring costs will be paid by December 31, 2011 and the remaining $884,000 of the unpaid restructuring cost consists of the facility lease obligations that will be paid out over the remaining term of the leases with the last lease payment in May 2014.

Note 3 — Stockholders’ Equity

The following summarizes the activity of the Stockholders’ equity accounts for the period from December 31, 2009 through September 30, 2011:

	Common Stock				Additional Paid-in			Treasury			Common Stock Consideration for			Accumulated Retained		Other Comprehensive Gain			Stockholders’
(in thousands)	Shares		Amount		Capital			Stock			Earnout			Earnings		(Loss)			Equity
Balance at December 31, 2009	14,394		$	4	$	43,104		—			$	1,309		4,039		79			48,535
Stock options exercised	265		—		122			—						—		—			122
Restricted shares issued	48		—		(55		)	—						—		—			(55		)
Stock consideration for acquisition	350		—		1,309			—			(1,309		)	—		—			—
Stock issues for acquisitions	578		—		2,468			—						—		—			2,468
Stock based compensation	—		—		1,080			—						—		—			1,080
Purchase of treasury stock	(3	)	—		—			(16		)				—		—			(16		)
Tax benefit on exercise of stock options	—		—		46			—						—		—			46
Equity adjustment from foreign currency translation	—		—		—			—						—		(54		)	(54		)
Net income	—		—		—			—						2,753		—			2,753
Balance at December 31, 2010	15,632		$	4	$	48,074		$	(16	)	—			$	6,792	$	25		$	54,879
Stock options exercised	124		—		216			—			—			—		—			216
Restricted shares issued	64		—		(78		)	—			—			—		—			(78		)
Stock based compensation	—		—		1,019			—			—			—		—			1,019
Purchase of treasury stock	(157	)			—			(784		)	—			—		—			(784		)
Equity adjustment from foreign currency translation	—		—		—			—			—			—		44			44
Net income	—		—		—			—			—			1,633		—			1,633
Balance at September 30, 2011	15,663		$	4	$	49,231		$	(800	)	—			$	8,425	$	69		$	56,929

Table of Contents

federal securities laws, including Rule 10b-18. Rule 10b-18 puts limitations on this repurchase program, including but not limited to, the manner of purchase, the time of the repurchases, the prices paid and the volume of shares repurchased. The timing of the repurchases and the exact number of shares of common stock to be purchased will be determined by the discretion of our management under the supervision of the audit committee of our board of directors, and will depend upon market conditions and other factors. The program will be funded using our cash on hand and cash generated from operations. On March 14, 2011, we entered into a 10b5-1 Stock Repurchase Agreement with our broker so we had the ability to repurchase shares of our common stock during our standard blackout periods. The program may be extended, suspended or discontinued at any time.

The following table provides information relating to our repurchase of common stock for the three months ended September 30, 2011:

	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
July 1 — July 31, 2011	26,200	$	4.78	26,200	$	1,317,507
August 1 — August 31, 2011	19,000	$	4.75	19,000	$	1,226,614
September 1 — September 30, 2011	6,500	$	4.84	6,500	$	1,194,918
Total	51,700			51,700

Note 4 — Earnings Per Share

Basic income per common share for the three and nine months ended September 30, 2011 and 2010 was calculated by dividing the net income available to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted income per share for the three and nine months ended September 30, 2011 and 2010 was calculated by dividing net income by the weighted average number of shares of Common Sstock outstanding, adjusted for the effect of potentially dilutive securities using the treasury stock method.

Table of Contents

The computation of basic income per common share and diluted income per common share was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except per share data)	2011		2010		2011		2010
Net income — basic and diluted	$	358	$	808	$	1,633	$	1,922

Denominator — basic:
Weighted average number of common shares	15,640		15,174		15,645		14,958

Basic income per common share	$	0.02	$	0.05	$	0.10	$	0.13

Denominator — diluted:
Weighted average number of common shares	15,640		15,174		15,645		14,958
Common share equivalents of outstanding convertible equity and unrecognized compensation expense	743		622		870		772
Weighted average number of dilutive common equity shares	16,383		15,796		16,515		15,730

Diluted income per common share	$	0.02	$	0.05	$	0.10	$	0.12

Options to purchase 536,000 and 576,000 shares of BioClinica’s common stock respectively, had been excluded from the calculation of diluted earnings per common share for the nine months ended September 30, 2011 and September 30, 2010, respectively, as they were all antidilutive. Options to purchase 563,000 and 779,000 shares of BioClinica’s common stock respectively, had been excluded from the calculation of diluted earnings per common share for the three months ended September 30, 2011 and September 30, 2010, respectively, as they were all antidilutive.

Note 5 — Commitments and Contingencies

On May 5, 2010, the Company entered into an unsecured, committed line of credit with PNC Bank expiring May 5, 2012. In April 2011, the Company extended the expiration date of this line of credit to May 4, 2013. Under the credit agreement, the Company has the ability to borrow $7.5 million at interest rates equal to LIBOR plus 1.75%. In addition, the Company pays a fee of 0.25% per annum on the loan commitment regardless of usage. The credit agreement requires our compliance with certain

Table of Contents

covenants, including maintaining a minimum stockholders’ equity of $35 million. As of September 30, 2011, the Company had no borrowings under this line of credit and was compliant with the covenants.

Note 6 — Accounts Receivable and Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts on a specific identification method for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of its customers were to deteriorate, resulting in an impairment of the customers’ ability to make payments, additional allowances may be required. The Company does not have any off-balance-sheet credit exposure related to its customers, and the trade accounts receivable do not bear interest.

(in thousands)	September 30, 2011		December 31, 2010
Billed trade accounts receivable	$	12,703	$	11,085
Unbilled trade accounts receivable	779		782
Other	—		14
Total Receivables	$	13,482	$	11,881

Allowance Rollforward (in thousands):
Balance at January 1, 2011	$	15
Additions	—
Write offs (Recoveries)	(15		)
Balance at September 30, 2011	$	0

Note 7 — Acquisitions

2010 Acquisition

On March 25, 2010, the Company acquired substantially all of the assets of privately held TranSenda International, LLC (“TranSenda”). Headquartered in Bellevue, WA, TranSenda was a provider of clinical trial management software (CTMS) solutions. TranSenda’s suite of web-based, Office-Smart CTMS solutions creates efficiencies for trial operations through interoperability with Microsoft Office tools. With this acquisition, BioClinica enhanced its ability to serve customers throughout the clinical research process with technologies that include improved efficiencies by reducing study durations and costs through integrated operational management. The acquisition was made pursuant to an Asset Purchase Agreement, dated March 25, 2010, by and between the Company and TranSenda (the “Purchase Agreement”). Pursuant to the terms of the Purchase Agreement, the Company purchased and acquired from TranSenda all rights, title and interest of TranSenda in and to the Purchased Assets (as defined in the Purchase Agreement) and assumed the Assumed Liabilities (as defined in the Purchase Agreement) of TranSenda.

Table of Contents

released and there were no indemnification claims. As part of the Purchase Agreement, TranSenda agreed not to directly or indirectly offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of the Company’s common stock received pursuant to the Purchase Agreement for a period beginning on the date the Purchase Agreement was executed and continuing to and including the date 12 months after such date. The Company recorded the fair value of the acquisition of $2,468,000 based on the Company’s market value per share of $4.27 for the stock consideration on March 25, 2010, the date of acquisition.

Pro Forma Results. The following schedule includes consolidated statements of income data for the unaudited pro forma results for the nine months ended September 30, 2010 as if the TranSenda acquisition had occurred as of the beginning of the periods presented after giving effect to certain adjustments. The unaudited pro forma information is provided for illustrative purposes only and is not indicative of the results of operations or financial condition that would have been achieved if the TranSenda acquisition would have taken place at the beginning of the periods presented and should not be taken as indicative of our future consolidated results of operations or financial condition. Pro forma adjustments are tax-effected at our effective tax rate.

(in thousands except per share data)	Nine Months Ended September 30, 2010

Total revenue	$	55,834

Income from operations	2,577

Net Income	1,583

Basic earnings per share	$	0.05

Diluted earnings per share	$	0.05

In connection with the acquisition of TranSenda, the Company performed an evaluation of the guidance included in FASB ASC 280, Segment Reporting (“FASB ASC 280”) and FASB ASC 350, Intangibles - Goodwill and Other (“FASB ASC 350”). Based on that evaluation, the Company included TranSenda as part of its clinical trials services reportable segment.

In accordance with FASB ASC 805, Business Combinations, the Company expensed all costs related to the acquisition.

The following table summarizes the amounts of identified assets acquired and liabilities assumed from TranSenda at the acquisition date fair value:

	TranSenda
Accounts Receivable	$	309
Property and Equipment	91
Other Assets	58
Other Liabilities	(459		)
Customer Relationships	100
Technology	1,000
Goodwill, including Workforce	1,369
Total Fair Value of Purchase Price	$	2,468

Table of Contents

Accounts receivable, other assets and other liabilities were stated at their historical carrying values, which approximate fair value given the short-term nature of these assets and liabilities. The goodwill is attributable to the workforce of the acquired business and synergies expected to arise after the acquisition of the business.

In accordance with FASB ASC 820, Fair Value Measurements (“FASB ASC 820”), the Company determined that the non-financial assets and liabilities summarized above are derived from significant unobservable inputs (“Level 3 inputs”) determined by management based on various market and income analyses and recent asset appraisals. The goodwill recorded in connection with these acquisitions will be deductible for tax purposes over 15 years.

2009 Acquisition

On September 15, 2009, BioClinica acquired substantially all of the assets of Tourtellotte Solutions, Inc. (“Tourtellotte”). Tourtellotte provides software applications and consulting services which support clinical trials in the pharmaceutical industry. The purchase price for Tourtellotte was $2.1 million in cash. Pursuant to the acquisition agreement, the Company agreed to pay up to an additional $3.2 million in cash and 350,000 shares of our common stock based upon achieving certain milestones, which include certain product development and revenue targets (the “earn-out”). In December 2010, the Company paid the first acquisition earn-out of $1,257,000 in cash and the issuance of 350,000 shares of the Company’s Common Stock. The remaining cash contingent consideration expected to be paid in the fair value amount of $2,000,000 was classified as a short-term liability on the financial statements at September 30, 2011. The difference between the fair value of the cash contingent consideration at date of acquisition and the expected payment will be recorded as an expense in the financial statements at the end of each reporting period. The Company recorded $114,000 and $245,000 for the nine months ended September 30, 2011 and 2010, respectively, of accretion expense in mergers and acquisition related costs on the income statement for this difference.

The following table represents changes in assets and liabilities measured at fair value using Level 3 inputs:

Fair value at September 15, 2009	$	2,747,000
Earn-out accretion	396,000
Payment on earn-out one	(1,257,000		)
Fair value at December 31, 2010	1,886,000
Earn-out accretion	114,000
Fair value at September 30, 2011	$	2,000,000

Table of Contents

Note 8 — Intangible Assets

At September 30, 2011, the composition of intangible assets were as follows:

(in thousands)	September 30, 2011			Estimated Useful Life
Amortized intangible assets:
Technology	$	1,843		5 years
Trademarks	48			5 years
Customer backlog	2,112			3 to 7 years
Non-competition agreement	349			2 to 3 years
	$	4,352
Accumulated amortization	(2,389		)
	$	1,963

Unamortized intangible assets:

Goodwill	$	34,302

Estimated future amortization of the intangible assets is as follows:

(in thousands)	Year Ending December 31,
Remainder of 2011	$	156
2012	534
2013	337
2014	309
2015	160
2016 and beyond	467
	$	1,963

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

BioClinica provides integrated clinical research technology solutions to pharmaceutical, biotechnology, medical device companies and other organizations such as contract research organizations, or CROs, engaged in global clinical studies. Our products and services include: medical image management, electronic image transport and archive solutions, electronic data capture, clinical data management, interactive voice and web response, clinical trial supply forecasting tools and clinical trial management software solutions. By supplying enterprise-class software and hosted solutions accompanied by expert services to fully utilize these tools, we believe that our offerings provide our clients, large and small, improved speed and efficiency in the execution of clinical studies, with reduced clinical and business risk.

Market for our Services

Our vision is to build critical mass in the complementary disciplines of clinical research related to data collection and processing — especially those which can benefit from our information technology products and support services — and to integrate them in ways that yield efficiency and value for our clients. Our goal is to provide demonstrable benefits to sponsor clients through this strategy, that is, faster and less expensive drug development. We believe that the outsourcing of these services should continue to increase in the future because of increased pressure on clients, including factors such as: the need to more tightly manage costs, capacity limitations, reductions in marketing exclusivity periods, the desire to reduce development time, increased globalization of clinical trials, productivity challenges, imminent patent expirations and more stringent regulation. We believe these trends will continue to create opportunities for companies like BioClinica that are focused on improving the efficiency of drug and medical device development.

Sales and Backlog

Our sales cycle, referring to the period from the presentation by us to a potential client to the engagement of us by such client, has historically ranged from three to 12 months. In addition, the contracts under which we perform services typically cover a period of three months to seven years, and the volume and type of services performed by us generally vary during the course of a project. We cannot assure you that our project revenues will be at levels sufficient to maintain profitability.

Our contracted/committed backlog, referred to as backlog, is the expected service revenue that remains to be earned and recognized on both signed and verbally agreed to contracts. In addition, our costs may increase to service our increased backlog. Our backlog as of September 30, 2011 was $115.6 million, compared to $106.3 million at September 30, 2010. Changes in backlog for the period reflect the net effect of new contract signings, addendums, cancellations, expansions, and reductions in scope of existing projects, all of which impacted our backlog at September 30, 2011.

Contracts included in backlog are subject to termination by our clients at any time. In the event that a contract is cancelled by the client, we would be entitled to receive payment for all services performed up to the cancellation date. The duration of the projects included in our backlog range from less than three months to 60 months. We do not believe that backlog is a reliable predictor of future results because service revenues may be incurred in a given period on contracts that were not included in the previous reporting period’s backlog and/or contract cancellations or project delays may occur in a given period on

Table of Contents

contracts that were included in the previous reporting period’s backlog.

Acquisitions

On March 25, 2010, we acquired substantially all of the assets of privately held TranSenda International, LLC, or TranSenda. Headquartered in Bellevue, WA, TranSenda was a provider of CTMS solutions. TranSenda’s suite of web-based, Office-Smart CTMS solutions create efficiencies for trial operations through interoperability with Microsoft Office tools. The CTMS solutions enable our clients to have their applications work together instead of being locked into a single suite vendor and serves as the foundation for operational data interchange among different software applications. This facilitates easier access to data with a consistent user interface and reduces training costs. With this acquisition, we enhanced our ability to serve customers throughout the clinical research process with technologies that include improved efficiencies by reducing study durations and costs through integrated operational management. The acquisition was made pursuant to an Asset Purchase Agreement, dated March 25, 2010, by and between BioClinica and TranSenda, referred to herein as the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, we purchased and acquired from TranSenda all right, title and interest of TranSenda in and to the Purchased Assets (as defined in the Purchase Agreement) and assumed the Assumed Liabilities (as defined in the Purchase Agreement) of TranSenda.

As consideration for the Purchased Assets and Assumed Liabilities, we issued 577,960 shares of our common stock, par value $0.00025 per share, valued at a volume weighted average price per share equal to $4.325560, and subject to a post-closing adjustment based on the Final Closing Net Working Capital (as defined in the Purchase Agreement). Pursuant to the terms of the Purchase Agreement, 15% of the aggregate consideration was held in escrow to cover any potential indemnification claims under the Purchase Agreement for a period of 12 months following the Closing Date (as defined in the Purchase Agreement). On March 25, 2011, the amounts held in escrow were released and there were no indemnification claims. As part of the Purchase Agreement, TranSenda agreed not to directly or indirectly offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of BioClinica’s common stock received pursuant to the Purchase Agreement for a period beginning on the date the Purchase Agreement was executed and continuing to and including the date 12 months after such date. We recorded the fair value of the acquisition of $2,468,000 based on our market value per share of $4.27 on March 25, 2010, the date of acquisition.

Forward Looking Statements

Certain matters discussed in this Form 10-Q are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes”, “expects”, “may”, “should” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding: our projected financial results; the demand for our services and technologies; growing recognition for the use of independent medical image review services; trends toward the outsourcing of imaging services in clinical trials; realized return from our marketing efforts; increased use of digital medical images in clinical trials; integration of our acquired companies and businesses; expansion into new business segments; the success of any potential acquisitions and the integration of current acquisitions; and the level of our backlog are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of revenues due to the variability in size, scope and duration of projects,

Table of Contents

estimates made by management with respect to our critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects and other factors, including general economic conditions and regulatory developments, not within our control. The factors discussed in this Form 10-Q and expressed from time to time in our filings with the SEC could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Recent Accounting Pronouncements

In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (Topic 820)—Fair Value Measurement (ASU 2011-04), to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for level 3 fair value measurements. ASU 2011-04 is effective for us in our first quarter of fiscal 2012 and should be applied prospectively. We are currently evaluating the impact of our pending adoption of ASU 2011-04 on our consolidated financial statements.

In June 2011, the FASB issued authoritative guidance that eliminates the option to present components of other comprehensive income as part of the statement of changes in stockholders’ equity, among other updates to the presentation of comprehensive income. Under this guidance, an entity has the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In addition, an entity is required to present on the face of the financial statements reclassification adjustments for items that are reclassified from other comprehensive income to net income in the statement(s) where the components of net income and the components of other comprehensive income are presented. This guidance will be effective for BioClinica, Inc. on January 1, 2012 and will impact the presentation of the our consolidated financial statements.

Table of Contents

Results of Operations

Three Months Ended September 30, 2011 and 2010

(in thousands)	Three Months ended September 30, 2011			% of Total Revenue		Three Months ended September 30, 2010			% of Total Revenue		$ Change			% Change
Service revenues	$	16,623		77.4	%	$	15,969		87.2	%	$	654		4.1	%
Reimbursement revenues	4,847			22.6	%	2,352			12.8	%	2,495			106.1	%
Total revenues	21,470			100.0	%	18,321			100.0	%	3,149			17.2	%

Cost and expenses:
Cost of service revenues	10,434			48.6	%	10,212			55.7	%	222			2.2	%
Cost of reimbursement revenues	4,847			22.6	%	2,352			12.8	%	2,495			106.1	%
Sales and marketing expenses	2,081			9.7	%	2,090			11.4	%	(9		)	(0.4	)%
General and administrative expenses	2,434			11.3	%	2,069			11.3	%	365			17.6	%
Amortization of intangible assets related to acquisitions	155			0.7	%	194			1.1	%	(39		)	(20.1	)%
Mergers and acquisitions related costs	—			0.0	%	119			0.6	%	(119		)	(100.0	)%
Restructuring costs	1,040			4.8	%	—			—		1,040			—
Total cost and expenses	20,991			97.8	%	17,036			93.0	%	3,955			23.2	%
Income from operations	479			2.2	%	1,285			7.0	%	(806		)	(62.7	)%
Interest income	2			0.0	%	10			0.1	%	(8		)	(80.0	)%
Interest expense	(14		)	(0.1	)%	—			—		(14		)	—
Income before income tax	467			2.2	%	1,295			7.1	%	(828		)	(63.9	)%
Income tax provision	(109		)	(0.5	)%	(487		)	(2.7	)%	378			(77.6	)%
Net income	$	358		1.7	%	$	808		4.4	%	$	(450	)	(55.7	)%

Service revenues were $16.6 million for the three months ended September 30, 2011 and $16.0 million for the same period in 2010, an increase of $654,000, or 4.1%. The increase in service revenues was due to an increase in work performed on the increased backlog from the prior year. Pfizer, Inc., encompassing 18 projects, represented 19.2% of our service revenue for the three months ended

Table of Contents

September 30, 2011. For the three months ended September 30, 2010, Pfizer Inc., encompassing 20 distinct projects, represented 19.7% of our service revenues.

Reimbursement revenues and cost of reimbursement revenues were $4.8 million for the three months ended September 30, 2011 and $2.3 million for the same period in 2010, an increase of $2.5 million, or 106.1%. Reimbursement revenues and cost of reimbursement revenues consist of payments received from the customer for reimbursable costs. Reimbursement revenues and cost of reimbursement revenues fluctuate significantly over the course of any given project, and quarter to quarter variations are a reflection of this project timing. Therefore, our management believes that reimbursement revenues and cost of reimbursement revenues are not a significant indicator of our overall performance trends. At the request of our clients, we may directly pay the independent radiologists who review our client’s imaging data. In such cases, per contractual arrangement, these costs are billed to our clients and are included in reimbursement revenues and cost of reimbursement revenues.

Cost of service revenues were $10.4 million for the three months ended September 30, 2011 and $10.2 million for the same period in 2010, an increase of $222,000, or 2.2%. Cost of service revenues for the three months ended September 30, 2011 and 2010 were comprised of professional salaries and benefits and allocated overhead. The increase is primarily attributable to the additional personnel to support the growth of our Trident IWR and OnPoint CTMS products. The cost of revenues as a percentage of total revenues also fluctuates due to work-flow variations in the utilization of staff and the mix of services provided by us in any given period. We expect that our cost of service revenues will increase for the remainder of fiscal 2011 due to increased servicing costs for our growth products.

Sales and marketing expenses were flat at $2.1 million for the three months ended September 30, 2011 and for the same period in 2010. Sales and marketing expenses for the three months ended September 30, 2011 and 2010 were comprised of direct sales and marketing costs, salaries and benefits and allocated overhead. We expect that our sales and marketing expenses will remain relatively flat for the remainder of fiscal 2011.

General and administrative expenses were $2.4 million for the three months ended September 30, 2011 and $2.1 million for the same period in 2010, an increase of $365,000, or 17.6%. General and administrative expenses for the three months ended September 30, 2011 and 2010 consisted primarily of salaries and benefits, allocated overhead, professional and consulting services and corporate insurance. The increase is due to increased information technology infrastructure costs to support our suite of clinical research solutions and increased professional fees. We expect that our general and administrative expenses will increase for the remainder of fiscal 2011 but decrease as a percentage of total revenue going forward.

Amortization of intangible assets related to acquisitions was $155,000 for the three months ended September 30, 2011 and $194,000 for the same period in 2010, a decrease of $39,000, or 20.1%. Amortization of intangible assets related to acquisitions consisted primarily of amortization of customer backlog, customer relationships, software and non-compete intangibles acquired from the acquisitions of PDS, Tourtellotte, TranSenda and Theralys. The decrease is primarily due to the completion of the amortization of the Theralys assets. We expect that the amortization of intangible assets related to acquisitions will remain relatively flat for the remainder of fiscal 2011.

There were no merger and acquisition related costs for the three months ended September 30, 2011, as compared to $119,000 for the same period in 2010. The three months ended September 30, 2010 included expenses resulting directly from merger and acquisition activities for the TranSenda acquisition

Table of Contents

such as legal, accounting and other due diligence and integration costs.

In the third quarter of 2011, we incurred $1.0 million of restructuring costs primarily related to the write-off of our office lease obligations for the facilities restructuring. We do not anticipate any additional restructuring costs for the remainder of 2011.

Net interest expense was $12,000 for the three months ended September 30, 2011, and net interest income was $10,000 for the three months ended September 30, 2010, a decrease of $22,000, or 220%. Interest income is comprised of interest income earned on our cash balance and interest expense is comprised of interest expense incurred on equipment lease obligations. The increase is due to the capital lease obligations we entered into during 2011.

Our income tax provision was $109,000 for the three months ended September 30, 2011 and $487,000 for the same period in 2010, a decrease of $378,000, or 77.6%. The effective tax rate is approximately 34.9% for fiscal 2011 as compared to 38.4% for fiscal 2010 at September 30, 2010. The lower effective tax rate in fiscal 2011 is due to the credits for increasing research activities that was not reflected in the three months ended September 30, 2010 partially offset by a New Jersey state tax assessment related to prior years.

Table of Contents

Nine Months Ended September 30, 2011 and 2010

(in thousands)	Nine Months ended September 30, 2011			% of Total Revenue		Nine Months ended September 30, 2010			% of Total Revenue		$ Change			% Change
Service revenues	$	49,658		80.7	%	$	46,248		83.1	%	$	3,410		7.4	%
Reimbursement revenues	11,887			19.3	%	9,413			16.9	%	2,474			26.3	%
Total revenues	61,545			100.0	%	55,661			100.0	%	5,884			10.6	%

Cost and expenses:
Cost of service revenues	31,432			51.1	%	29,109			52.3	%	2,323			8.0	%
Cost of reimbursement revenues	11,887			19.3	%	9,413			16.9	%	2,474			26.3	%
Sales and marketing expenses	6,324			10.3	%	6,865			12.3	%	(541		)	(7.9	)%
General and administrative expenses	7,027			11.4	%	6,057			10.9	%	970			16.0	%
Amortization of intangible assets related to acquisitions	467			0.8	%	473			0.8	%	(6		)	(1.3	)%
Mergers and acquisitions related costs	162			0.3	%	635			1.1	%	(473		)	(74.5	)%
Restructuring costs	1,719			2.8	%	—			—		1,719			—
Total cost and expenses	59,018			95.9	%	52,552			94.4	%	6,466			12.3	%
Income from operations	2,527			4.1	%	3,109			5.6	%	(582		)	(18.7	)%
Interest income	6			—		18			—		(12		)	(66.7	)%
Interest expense	(32		)	(0.1	)%	(7		)	—		(25		)	357.1	%
Income before income tax	2,501			4.1	%	3,120			5.6	%	(619		)	(19.8	)%
Income tax provision	(868		)	(1.4	)%	(1,198		)	(2.2	)%	330			(27.5	)%
Net income	$	1,633		2.7	%	$	1,922		3.4	%	$	(289	)	(15.0	)%

Service revenues were $49.7 million for the nine months ended September 30, 2011 and $46.2 million for the same period in 2010, an increase of $3.4 million, or 7.4%. The increase in service revenues was due to an increase in work performed on the increased backlog from the prior year. Pfizer, Inc. encompassing 19 projects, represented 20.3% of our service revenue for the nine months ended September 30, 2011. For the nine months ended September 30, 2010, Pfizer Inc., encompassing 21 distinct projects, represented 19.7% of our service revenues.

Table of Contents

Reimbursement revenues and cost of reimbursement revenues were $11.9 million for the nine months ended September 30, 2011 and $9.4 million for the same period in 2010, an increase of $2.5 million, or 26.3%. Reimbursement revenues and cost of reimbursement revenues consist of payments received from the customer for reimbursable costs. Reimbursement revenues and cost of reimbursement revenues fluctuate significantly over the course of any given project, and quarter to quarter variations are a reflection of this project timing. Therefore, our management believes that reimbursement revenues and cost of reimbursement revenues are not a significant indicator of our overall performance trends. At the request of our clients, we may directly pay the independent radiologists who review our client’s imaging data. In such cases, per contractual arrangement, these costs are billed to our clients and are included in reimbursement revenues and cost of reimbursement revenues.

Cost of service revenues were $31.4 million for the nine months ended September 30, 2011 and $29.1 million for the same period in 2010, an increase of $2.3 million, or 8.0%. Cost of service revenues for the nine months ended September 30, 2011 and 2010 were comprised of professional salaries and benefits and allocated overhead. The increase is primarily attributable to the progressive increase in personnel throughout 2010 to build operational readiness for our eClinical offerings, including supporting the operational launch of our Trident IVR/IWR product, increase in consulting activities and additional personnel assumed with the TranSenda acquisition and to support the growth of our OnPoint CTMS product. The cost of revenues as a percentage of total revenues also fluctuates due to work-flow variations in the utilization of staff and the mix of services provided by us in any given period. We expect that our cost of service revenues will increase for the remainder of fiscal 2011 due to increased servicing costs for our newly released products.

Sales and marketing expenses were $6.3 million for the nine months ended September 30, 2011 and $6.9 million for the same period in 2010, a decrease of $541,000, or 7.9%. Sales and marketing expenses for the nine months ended September 30, 2011 and 2010 were comprised of direct sales and marketing costs, salaries and benefits and allocated overhead. The decrease is primarily due to the higher marketing expenditures incurred last year to launch our OnPoint CTMS product and to ready the launch of our Trident IVR/IWR product. We expect that our sales and marketing expenses will remain relatively flat for the remainder of fiscal 2011.

General and administrative expenses were $7.0 million for the nine months ended September 30, 2011 and $6.1 million for the same period in 2010, an increase of $970,000, or 16.0%. General and administrative expenses for the nine months ended September 30, 2011 and 2010 consisted primarily of salaries and benefits, allocated overhead, professional and consulting services and corporate insurance. The increase is due to the inclusion of costs from the acquisition of TranSenda, increased professional fees and increased technology infrastructure costs to support our suite of clinical research solutions. We expect that our general and administrative expenses will increase for the remainder of fiscal 2011 but decrease as a percentage of total revenue going forward..

Amortization of intangible assets related to acquisitions were $467,000 for the nine months ended September 30, 2011 and $473,000 for the nine months ended September 30, 2010, a decrease of $6,000, or 1.3%. Amortization of intangible assets related to acquisitions consisted primarily of amortization of customer backlog, customer relationships, software and non-compete intangibles acquired from the acquisitions of PDS, Tourtellotte, TranSenda and Theralys. We expect that the amortization of intangible assets related to acquisitions will remain relatively flat for the remainder of fiscal 2011.

Mergers and acquisition related costs were $162,000 for the nine months ended September 30, 2011, and

Table of Contents

$635,000 for the same period in 2010, a decrease of $473,000, or 74.5%. The nine months ended September 30, 2010 included expenses resulting directly from merger and acquisition activities for the TranSenda acquisition such as legal, accounting and other due diligence and integration costs. The nine months ended September 30, 2011 includes $114,000 for the accretion related to the change in the fair value of the second earn-out payment associated with the Tourtellotte acquisition.

Restructuring costs were $1.7 million for the nine months ended September 30, 2011 and there were no restructuring costs for the nine months ended September 30, 2010. The launch of our BioPacs imaging management system and the release of our integrated BioRead image review software further enhances the quality of our imaging corelab service offering and has enabled us to gain efficiencies by better utilizing resources across our U.S. and European operations. As a result, in 2011, we realigned our global resources to eliminate certain duplicate functions and took a total restructuring charge of $1.7 million for the nine months ended September 30, 2011. This restructuring charge was comprised of $656,000 in employee severance, $884,000 write-off of facility lease obligations and $179,000 in legal and other costs. We do not anticipate any additional restructuring costs for the remainder of 2011.

Net interest expense was $26,000 for the nine months ended September 30, 2011, and net interest income was $11,000 for the nine months ended September 30, 2010, a decrease of $37,000, or 336%. Interest income is comprised of interest income earned on our cash balance and interest expense is comprised of interest expense incurred on equipment lease obligations. The increase in net interest expense is due to the capital lease obligations we entered into during 2011.

Our income tax provision was $868,000 for the nine months ended September 30, 2011 and $1.2 million for the nine months ended September 30, 2010, a decrease of $330,000, or 27.5%. The effective tax rate is approximately 34.9% for fiscal 2011 as compared to 38.4% for fiscal 2010 at September 30, 2010. The lower effective tax rate in fiscal 2011 is due to the credits for increasing research activities that was not reflected in the nine months ended September 30, 2010 partially offset by a New Jersey state tax assessment related to prior years.

Business Segments and Geographic Information

We view our operation and manage our business as one operating segment, clinical trials services.

Our corporate headquarters and operational facilities are in Pennsylvania, in the United States. We also have a European facility in Leiden, the Netherlands. We manage our services for European-based clinical trials from the Leiden facility. Our European facility has similar processing and analysis capabilities as our United States headquarters. We also have a facility in Lyon, France that provides product development and research activities. We have an office in Bhubaneshwar, India to provide information technology support.

Table of Contents

Liquidity and Capital Resources

Our principal liquidity requirements have been, and we expect will be, for working capital and general corporate purposes, including capital expenditures.

Statement of Cash Flow for the nine months ended September 30, 2011 compared to September 30, 2010

(in thousands)	Nine Months Ended September 30, 2011			Nine Months Ended September 30, 2010
Net cash provided by operating activities	$	5,903		$	3,073
Net cash used in investing activities	$	(4,195	)	$	(6,079	)
Net cash provided by financing activities	$	115		$	251

At September 30, 2011, we had cash and cash equivalents of $12.3 million. Working capital, defined as current assets minus current liabilities, at September 30, 2011 was $10.4 million.

Net cash provided by operating activities for the nine months ended September 30, 2011 was $5.9 million as compared to $3.1 million for the nine months ended September 30, 2010. This increase from the prior year is primarily due to the increase in accrued expenses and accounts payable as compared to the decrease in the same period in the prior year.

Net cash used in investing activities for the nine months ended September 30, 2011 was $4.2 million as compared to net cash used in investing activities of $6.1 million for the nine months ended September 30, 2010. This decrease is primarily due to less capitalized software costs for the nine months ended September 30, 2011 as compared to the nine months ended September 30, 2010. We currently anticipate that capital expenditures for fiscal 2011 will be approximately $6.0 million, funded by cash from operations, as compared to $7.2 million for fiscal 2010. These expenditures primarily represent capitalization of software costs and network and data center computer equipment.

Net cash provided by financing activities for the nine months ended September 30, 2011 was $115,000 as compared to $251,000 for the nine months ended September 30, 2010. The difference from the prior year was primarily due to our purchase of treasury shares for $784,000 for the nine months ended September 30, 2011 along with entering into $918,000 of sale/leaseback transactions to finance the purchase of property and equipment in 2011.

Table of Contents

The following table lists our cash contractual obligations as of September 30, 2011:

	Payments Due By Period
(in thousands) Contractual obligations	Total		Less than 1 year		1-3 years		3-5 years		More than 5 years
Facility rent operating leases	$	18,427	$	2,748	$	5,348	$	5,003	$	5,328
Capital lease	1,633		342		722		569		—
Employment agreements	1,291		1,015		276		—		—
Earn-out for Tourtellotte acquisition	2,000		2,000		—		—		—
Total contractual cash obligations	$	23,351	$	6,105	$	6,346	$	5,572	$	5,328

On May 5, 2010, we entered into an unsecured, committed line of credit with PNC Bank expiring May 5, 2012. In April 2011, we extended the expiration date of this line of credit to May 4, 2013. Under the credit agreement, we have the ability to borrow $7.5 million at interest rates equal to LIBOR plus 1.75%. In addition, we pay a fee of 0.25% per annum on the loan commitment regardless of usage. The credit agreement requires our compliance with certain covenants, including maintaining a minimum stockholders’ equity of $35 million. As of September 30, 2011, we had no borrowings under this line of credit, and we were compliant with the covenants.

Capital lease obligations consist of four equipment lease obligations with the same bank at September 30, 2011. In 2011, we entered into three capital lease obligations totaling $918,000 consisting of sale/leaseback transactions. The lease terms are for five years with interest rates ranging from 3.04% to 3.87% per annum.

We have neither paid nor declared dividends on our common stock since our inception and do not plan to pay dividends on our common stock in the foreseeable future.

We have not entered into any off-balance sheet transactions, arrangements or other relationships with unconsolidated entities or other persons that are likely to affect liquidity or the availability of or requirements for capital resources.

We anticipate that our existing capital resources together with cash flow from operations will be sufficient to meet our cash needs for the next 12 months. However, we cannot assure you that our operating results will maintain profitability on an annual basis in the future. The inherent operational risks associated with the following factors may have a material adverse effect on our future liquidity:

· our ability to gain new client contracts;

· project cancellations;

· the variability of the timing of payments on existing client contracts; and

· other changes in our operating assets and liabilities.

We may seek to raise additional capital from equity or debt sources in order to take advantage of unanticipated opportunities, such as more rapid expansion, acquisitions of complementary businesses or the development of new services. We cannot assure you that additional financing will be available, if at all, on terms acceptable to us.

Table of Contents

Changes to Critical Accounting Policies and Estimates

Our critical accounting policies and estimates are set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010. As of September 30, 2011, there have been no changes to such critical accounting policies and estimates.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

We invest in high-quality financial instruments, comprised of savings accounts, certificate of deposits and money market funds. Due to the short-term nature of our investments, we do not believe that we have any material exposure to interest rate risk arising from our investments.

Foreign Currency Risk

Under our current foreign exchange rate risk management policy, we monitor our exposure to variability in our cash flows resulting from the Euro denominated costs for our Netherlands and France subsidiaries. Accordingly, we had purchased monthly Euro call options in prior years and may purchase them in the future to hedge against this exposure. During the nine months ended September 30, 2011 and 2010, we did not purchase any Euro call options, because our foreign currency needs were generally met by the cash flow generated by our Euro denominated contracts. As of September 30, 2011, there were no outstanding derivative positions.

Upon expiration or ineffectiveness of any derivatives, we would record a gain or loss from such derivatives that are deferred in stockholders’ equity to cost of revenues and general and administrative expenses in the Consolidated Statement of Income based on the nature of the underlying cash flow hedged.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. We evaluated, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934 (“Exchange Act”), as amended) as of September 30, 2011, the end of the period covered by this report on Form 10-Q. Based on this evaluation, our Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal accounting and financial officer) have concluded that our disclosure controls and procedures were effective at September 30, 2011. Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and were operating in an effective manner for the period covered by this report, and (ii) is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Changes in internal control over financial reporting. There was no change in our internal controls over financial reporting that occurred during the third quarter of 2011 that materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Table of Contents

PART II. OTHER INFORMATION.

Item 1. Legal Proceedings.

In the normal course of business, we may be a party to legal proceedings. We are not currently a party to any material legal proceedings.

Item 1A. Risk Factors.

The more prominent risks and uncertainties inherent in our business are described below. However, additional risks and uncertainties may also impair our business operations. If any of the following risks actually occur, our business, financial condition or results of operations may suffer. Any of the following factors could harm our business and future results of operations, and you could lose all or part of your investment.

Risks Related to Our Company and Business

We may incur financial losses because contracts may be delayed or terminated or reduced in scope for reasons beyond our control.

Our clients may terminate or delay their contracts for a variety of reasons, including, but not limited to:

· unexpected or undesired clinical results;

· the client’s decision to terminate the development of a particular product or to end a particular study;

· insufficient patient enrollment in a study;

· insufficient investigator recruitment;

· failure to perform our obligations under the contract; or

· the failure of products to satisfy safety requirements.

In addition, we believe that companies that are regulated by the United States Food and Drug Administration, or FDA, may proceed with fewer clinical trials or conduct them without assistance of contract service organizations if they are trying to reduce costs as a result of cost containment pressures associated with healthcare reform, budgetary limits or changing priorities. These factors may cause such companies to cancel contracts with contract service organizations.

We cannot assure you that our clients will continue to use our services or that we will be able to replace, in a timely or effective manner, departing clients with new clients that generate comparable revenues. Further, we cannot assure you that our clients will continue to generate consistent amounts of revenues over time.

The loss, reduction in scope or delay of a large contract or the loss or delay of multiple contracts could materially adversely affect our business.

Table of Contents

The recent economic downturn may adversely impact our ability to grow our business.

The recent economic downturn and adverse conditions in the national and global markets may negatively affect our operations in the future. The fallen equity markets and adverse credit markets may make it difficult for us to raise capital or procure credit in the future to fund the growth of our business, which could have a negative impact on our business and results of operations and limit our ability to pursue acquisitions.

We depend on a small number of industries and clients for all of our business, and the loss of one such significant client could cause revenues to drop quickly and unexpectedly.

We depend on research and development expenditures by pharmaceutical, biotechnology and medical device companies to sustain our business. Our operations could be materially and adversely affected if:

· our clients’ businesses experience financial problems or are affected by a general economic downturn;

· consolidation in the pharmaceutical, biotechnology or medical device industries leads to a smaller client base for us; or

· clients reduce their research and development expenditures.

Contracts with one client, Pfizer, Inc., which encompassed 19 projects, represented 20.3% of our service revenues for the nine months ended September 30, 2011. For the nine months ended September 30, 2010, Pfizer, Inc. represented 29.7% of our service revenue, encompassing 21 projects. The loss of business from a significant client or our failure to continue to obtain new business to replace completed or canceled projects would have a material adverse effect on our business and revenues.

Our contracted/committed backlog may not be indicative of future results.

Our reported contracted/committed backlog of $115.6 million at September 30, 2011 is based on anticipated service revenue from uncompleted projects with clients. Backlog is the expected service revenue that remains to be earned and recognized on signed and verbally agreed to contracts. Contracts included in backlog are subject to termination by our clients at any time. In the event that a client cancels a contract, we would be entitled to receive payment for all services performed up to the cancellation date and subsequent client authorized services related to the cancellation of the project. The duration of the projects included in our backlog range from less than three months to seven years. We cannot assure you that this backlog will be indicative of future results. A number of factors may affect backlog, including:

· the variable size and duration of the projects (some are performed over several years);

· the loss or delay of projects;

· the change in the scope of work during the course of a project; and

· the cancellation of such contracts by our clients.

Also, if clients delay projects, the projects will remain in backlog, but will not generate revenue at the rate originally expected. Accordingly, the historical relationship of backlog to revenues may not be indicative of future results.

Table of Contents

We made one acquisition in the first quarter of 2010, two acquisitions in the third quarter of 2009, and may engage in future acquisitions, which may be expensive and time consuming, and from which we may not realize anticipated benefits.

On March 25, 2010, we acquired substantially all of the assets of privately held TranSenda International, LLC, headquartered in Bellevue, WA. In the third quarter of 2009, we acquired the CardioNow unit from AGFA Healthcare and substantially all of the assets of Tourtellotte Solutions, Inc. We may acquire additional businesses, technologies and products if we determine that these additional businesses, technologies and products complement our existing business, or otherwise serve our strategic goals. Either as a result of the recent acquisitions or future acquisitions undertaken, the process of integrating the acquired business, technology or product may result in operating difficulties and expenditures, and may absorb significant management attention that would otherwise be available for ongoing development of our business. Moreover, we may never realize the anticipated benefits of any such acquisition. Such acquisitions could result in potentially dilutive issuances of our securities, the incurrence of debt and contingent liabilities and amortization expenses related to intangible assets, all of which could adversely affect our results of operations and financial condition.

Loss of key personnel, or failure to attract and retain additional personnel, may cause the success and growth of our business to suffer.

Future success depends on the personal efforts and abilities of the principal members of our senior management to provide strategic direction, develop business, manage operations and maintain a cohesive and stable environment. Specifically, we are dependent upon Mark L. Weinstein, President and Chief Executive Officer, Ted I. Kaminer, Executive Vice President of Finance and Administration and Chief Financial Officer, and Peter Benton, Executive Vice President, President of eClinical Solutions. Although we have employment agreements with Mr. Weinstein, Mr. Kaminer and Mr. Benton, this does not necessarily mean that they will remain with us. Although we have executive retention agreements with our officers, we do not have employment agreements with any other key personnel. Furthermore, our performance also depends on our ability to attract and retain management and qualified professional and technical operating staff. Competition for these skilled personnel is intense. The loss of services of any key executive, or inability to continue to attract and retain qualified staff, could have a material adverse effect on our business, results of operations and financial condition. We do not maintain any key employee insurance on any of our executives.

We may not be able to effectively manage our international operations.

We maintain facilities in France, the Netherlands and India, and we may continue to expand our international operations in the future. There are significant risks associated with the establishment of foreign operations, including, but not limited to: geopolitical risks, foreign currency exchange rates and the impact of shifts in the U.S. and local economies on those rates, compliance with local laws and regulations, the protection of our intellectual property and that of our customers, the ability to integrate our corporate culture with local customs and cultures, and the ability to effectively and efficiently supply our international facilities with the required equipment and materials. If we are unable to effectively manage these risks, these locations may not produce the revenues, earnings, or strategic benefits that we anticipate which could have a material adverse affect on our business.

Our revenues, earnings and operating costs are exposed to exchange rate fluctuations.

During the nine months ended September 30, 2011, a portion of our service revenues were denominated in foreign currency. Our financial statements are denominated in United States dollars. In the event a greater portion of our service revenues are denominated in a foreign currency, changes in foreign currency exchange rates could affect our results of operations and financial condition. Fluctuations in

Table of Contents

foreign currency exchange rates could materially impact the operating costs of our European facilities in Leiden, the Netherlands and Lyon, France, which are primarily Euro denominated.

We may be required to record additional significant charges to earnings if our goodwill becomes impaired.

Under accounting principles generally accepted in the United States, we review our goodwill for impairment each year as of December 31 and when events or changes in circumstances indicate the carrying value may not be recoverable. The carrying value of our goodwill may not be recoverable due to factors such as a decline in stock price and market capitalization, reduced estimates of future cash flows and slower growth rates in our industry. Estimates of future cash flows are based on an updated long-term financial outlook of our operations. However, actual performance in the near-term or long-term could be materially different from these forecasts, which could impact future estimates. For example, a significant decline in our stock price and/or market capitalization may result in impairment of our goodwill valuation. We may be required to record a charge to earnings in our financial statements during a period in which an impairment of our goodwill is determined to exist, which may negatively impact our results of operations.

Our software products and hosted solutions are at varying stages of market acceptance and the failure of any of our products to achieve or maintain wide acceptance would harm our operating results.

We began offering our electronic data capture software solution for clinical trials in March 2008. Continued use of our current electronic data capture software products, and broad and timely acceptance of newly-introduced electronic data capture software products, as well as integrated solutions combining one or more of our software products, is critical to our future success and is subject to a number of significant risks, some of which are outside our control. These risks include:

· our customers’ and prospective customers’ desire for and acceptance of our electronic data capture, clinical data management, drug safety and interactive response technology solutions;

· our ability to meet product development and release schedules;

· our software products and hosted solutions’ ability to support large numbers of users and manage vast amounts of data;

· our ability to significantly expand our internal resources and increase our capital and operating expenses to support the anticipated growth and continued integration of our software products, services and hosted solutions; and

· our customers’ ability to use our software products and hosted solutions, train their employees and successfully deploy our technology in their clinical trial and safety evaluation and monitoring activities.

Our failure to address, mitigate or manage these risks would seriously harm our business, particularly if the failure of any or all of our software products or hosted solutions to achieve market acceptance negatively affects our sales of our other products and services.

Table of Contents

We may be unable to adequately protect, and we may incur significant costs in defending, our intellectual property and other proprietary rights or in defending claims that we are infringing upon the intellectual property rights of others.

Our success depends on our ability to protect our intellectual property and other proprietary rights. We rely upon a combination of trademark, trade secret, copyright, patent and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. In addition, we attempt to protect our intellectual property and proprietary information by requiring certain of our employees and consultants to enter into confidentiality, non-competition and assignment of inventions agreements. To the extent that our intellectual property and other proprietary rights are not adequately protected, third parties might gain access to our proprietary information, develop and market products or services similar to ours or use trademarks similar to ours, each of which could materially harm our business. Existing U.S. federal and state intellectual property laws offer only limited protection. Moreover, the laws of other countries in which we market our software products, services and hosted solutions may afford little or no effective protection of our intellectual property. If we are involved in legal proceedings to enforce our intellectual property rights, to determine the validity and scope of the intellectual property or other proprietary rights of others or to defend against claims of infringement by third parties, the proceedings could be burdensome and expensive, even if we were to prevail. Any potential infringement actions brought against us could require us to stop using the product or service which incorporates such third party intellectual property, obtain a license to use such third party intellectual property (which could be costly or unavailable) or redesign our products or services that incorporate such third party intellectual property (which could be time consuming and costly and affect the market acceptance of such product or service). The failure to adequately protect our intellectual property and other proprietary rights or acknowledge third party intellectual property rights may have a material adverse effect on our business, results of operations or financial condition.

Risks Related to Our Industry

Our failure to compete effectively in our industry could cause our revenues to decline.

Significant factors in determining whether we will be able to compete successfully include:

· consultative and clinical trials design capabilities;

· reputation for on-time quality performance;

· expertise and experience in specific therapeutic areas;

· the scope of service offerings;

· strength in various geographic markets;

· the price of services;

· ability to acquire, process, analyze and report data in a time-saving and accurate manner;

· ability to manage large-scale clinical trials both domestically and internationally;

· our size;

· the service and product offerings of our competitors; and

· our ability to upgrade our products, services and hosted solutions so such offerings are not deemed obsolete in comparison to the service and product offerings of our competitors.

If our services are not competitive based on these or other factors, our business, financial condition and results of operations could be materially harmed.

Table of Contents

The biopharmaceutical services industry is highly competitive, and we face numerous competitors in our business, including hundreds of CROs. If we fail to compete effectively, we will lose clients, which would cause our business to suffer. We primarily compete against in-house departments of pharmaceutical companies, full service CROs, small specialty CROs, and to a lesser extent, universities and teaching hospitals. Some of these competitors have substantially greater capital, technical and other resources than we do. In addition, certain of our competitors that are smaller specialized companies may compete effectively against us because of their concentrated size and focus.

Changes in outsourcing trends in the pharmaceutical and biotechnology industries could adversely affect our operating results and growth rate.

Service revenues depend greatly on the expenditures made by the pharmaceutical and biotechnology industries in research and development. Accordingly, economic factors and industry trends that affect our clients in these industries also affect our business. For example, the practice of many companies in these industries has been to hire outside organizations like us to conduct clinical research projects. This practice has grown significantly in the last decade, and we have benefited from this trend. However, if this trend were to change and companies in these industries were to reduce the number of research and development projects they outsource, our business could be materially adversely affected.

Additionally, numerous governments have undertaken efforts to control growing healthcare costs through legislation, regulation and voluntary agreements with medical care providers and pharmaceutical companies. If future regulatory cost containment efforts limit the profits that can be derived from new drug sales, our clients might reduce their research and development spending, which could reduce our business.

Consolidation among our customers could cause us to lose customers, decrease the market for our products and result in a reduction of our revenues.

Our customer base could decline because of industry consolidation, and we may not be able to expand sales of our products and services to new customers. Consolidation in the pharmaceutical, biotechnology and medical device industries has accelerated in recent years, and we expect this trend to continue. As these industries consolidate, competition to provide products and services to industry participants will become more intense and the importance of establishing relationships with large industry participants will become greater. These industry participants may try to use their market power to negotiate price reductions for our products and services. Also, if consolidation of larger current customers occurs, the combined organization may represent a larger percentage of business for us and, as a result, we are likely to rely more significantly on the combined organization’s revenues to continue to achieve growth.

The recent economic downturn coupled with the current regulatory environment could have a negative impact on the pharmaceutical, biotechnology and medical device industries.

The recent economic downturn and adverse conditions in the national and global markets may negatively affect our operations in the future. Our revenues are contingent upon the research and development expenditures by pharmaceutical, biotechnology and medical device companies. Some companies in these industries have found it difficult to raise capital in the equity and debt markets or through traditional credit markets to fund research and development. In addition, increased regulatory scrutiny from the FDA may have increased the costs of research and development for these companies. These companies have responded to the recent economic downturn and regulatory environment by postponing, attenuating or cancelling clinical trials projects, or portions thereof, which may reduce the need for our services. As

Table of Contents

a result, our revenues may be similarly decreased. Furthermore, while our revenues may decrease, our costs may remain relatively fixed, resulting in decreased earnings.

Failure to comply with existing regulations could result in increased costs to complete clinical trials.

Our business is subject to numerous governmental regulations, primarily relating to pharmaceutical product development and the conduct of clinical trials. In particular, we are subject to 21 CFR Part 11 of the Code of Federal Regulations that provides the criteria for acceptance by the FDA of electronic records. If we fail to comply with these governmental regulations, it could result in the termination of ongoing clinical research or the disqualification of data for submission to regulatory authorities. We also could be barred from providing clinical trial services in the future or be subjected to fines. Any of these consequences would harm our reputation, our prospects for future work and our operating results.

We may be affected by health care reform.

In March 2010, the United States Congress enacted health care reform legislation intended over time to expand health insurance coverage and impose health industry cost containment measures. This legislation may significantly impact the pharmaceutical and biotechnology industries. In addition, the U.S. Congress, various state legislatures and European and Asian governments may consider various types of health care reform in order to control growing health care costs. We are presently uncertain as to the effects of the recently enacted legislation on our business and are unable to predict what legislative proposals will be adopted in the future, if any.

Implementation of health care reform legislation may have certain benefits but also may contain costs that could limit the profits that can be made from the development of new drugs. This could adversely affect research and development expenditures by pharmaceutical and biotechnology companies, which could in turn decrease the business opportunities available to us both in the United States and abroad. In addition, new laws or regulations may create a risk of liability, increase our costs or limit our service offerings.

In addition to healthcare reform legislation, the expansion of managed care organizations in the healthcare market may result in reduced spending on research and development. Managed care organizations’ efforts to cut costs by limiting expenditures on pharmaceuticals and medical devices could result in pharmaceutical, biotechnology and medical device companies spending less on research and development. If this were to occur, we would have fewer business opportunities and our revenues could decrease, possibly materially.

Changes in governmental regulation could decrease the need for the services we provide, which would negatively affect our future business opportunities.

Governmental agencies throughout the world, but particularly in the United States, strictly regulate the drug development/approval process. Our business involves helping pharmaceutical and biotechnology companies navigate the regulatory drug approval process. Changes in regulation, such as relaxation in regulatory requirements or the introduction of simplified drug approval procedures or an increase in regulatory requirements that we may have difficulty satisfying could eliminate or substantially reduce the need for our services. If these changes in regulations were to occur, our business, results of operations and financial condition could be materially adversely affected. These and other changes in regulation could have a material adverse impact on our available business opportunities.

Table of Contents

If governmental agencies do not accept the data and analyses generated by our services, the need for our services would be eliminated or substantially reduced.

The success of our business is dependent upon continued acceptance by the FDA and other regulatory authorities of the data and analyses generated by our services in connection with the evaluation of the safety and efficacy of new drugs and devices. The FDA has formal guidelines that encourage the use of “surrogate measures” through submission of digital image data, for evaluation of drugs to treat life-threatening or debilitating conditions. We cannot assure you that the FDA or other regulatory authorities will accept the data or analyses generated by us in the future and, even assuming acceptance, the FDA or other regulatory authorities may not require the application of imaging techniques to the number of patients and over time periods substantially similar to those required of traditional safety and efficacy techniques. If the governmental agencies do not accept data and analyses generated by our services in connection with the evaluation of new drugs and devices, the need for our services would be eliminated or substantially reduced, and, as a result, our business, results of operations and financial condition could be materially adversely affected.

In the course of conducting our business, we possess or could be deemed to possess personal medical information in connection with the conduct of clinical trials. If we fail to keep this information properly protected we could be subject to significant liability.

Our software solutions are used to collect, manage and report information in connection with the conduct of clinical trial and safety evaluation and monitoring activities. This information is or could be considered to be personal medical information of the clinical trial participants or patients. Regulation of the use and disclosure of personal medical information is complex and growing. Increased focus on individuals’ rights to confidentiality of their personal information, including personal medical information, could lead to an increase of existing and future legislative or regulatory initiatives giving direct legal remedies to individuals, including rights to damages, against entities deemed responsible for not adequately securing such personal information. In addition, courts may look to regulatory standards in identifying or applying a common law theory of liability, whether or not that law affords a private right of action. Since we receive and process personal information of clinical trial participants and patients from customers utilizing our hosted solutions, there is a risk that we could be liable if there were a breach of any obligation to a protected person under contract, standard of practice or regulatory requirement. If we fail to properly protect this personal information that is in our possession or deemed to be in our possession, we could be subjected to significant liability.

We may be exposed to liability claims as a result of our involvement in clinical trials.

We may be exposed to liability claims as a result of our involvement in clinical trials. We cannot assure you that liability claims will not be asserted against us as a result of work performed for our clients. We maintain liability insurance coverage in amounts that we believe are sufficient for the pharmaceutical services industry. Furthermore, we cannot assure you that our clients will agree to indemnify us, or that we will have sufficient insurance to satisfy any such liability claims. If a claim is brought against us and the outcome is unfavorable to us, such outcome could have a material adverse impact on us.

Table of Contents

In the event we are unable to satisfy regulatory requirements relating to internal control over financial reporting, or if these internal controls are not effective, our business and financial results may suffer.

Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports and to effectively prevent fraud. If we cannot provide reasonable assurance with respect to our financial reports and effectively prevent fraud, our brand and operating results could be harmed. Pursuant to the Sarbanes-Oxley Act of 2002, we are required to furnish a report by management on internal control over financial reporting, including management’s assessment of the effectiveness of such control. Internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of the effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and operating results could be harmed, we could fail to meet our reporting obligations, and there could also be a material adverse effect on our stock price.

Risks Related to Our Common Stock

Your percentage ownership and voting power and the price of our common stock may decrease as a result of events that increase the number of our outstanding shares.

As of September 30, 2011, we had the following capital structure (in thousands):

Common stock outstanding		15,663

Common stock issuable upon:
Exercise of options which are outstanding		1,720
Restricted stock units outstanding		445
Number of shares remaining under equity plan which have not been granted		837

Total common stock outstanding assuming exercise or conversion of all of the above		18,665

As of September 30, 2011, there were outstanding options to purchase 1.7 million shares of our common stock at exercise prices ranging from $1.10 to $8.06 per share (exercisable at a weighted average price of $5.01 per share), of which 1.2 million options were then exercisable. Exercise of the outstanding options into shares of our common stock may significantly and negatively affect the market price for our common stock as well as decrease your percentage ownership and voting power. In addition, we may conduct future offerings of our common stock or other securities with rights to convert the securities into shares of our common stock. As a result of these and other events, such as future acquisitions, that

Table of Contents

increase the number of our outstanding shares, your percentage ownership and voting power and the price of our common stock may decrease.

Shares of our common stock eligible for public sale may have a negative impact on its market price.

Future sales of shares of our common stock by existing holders of our common stock or by holders of outstanding options, upon the exercise thereof, could have a negative impact on the market price of our common stock. As of September 30, 2011, we had 15.7 million shares of our common stock issued and outstanding, substantially all of which are currently freely tradable. As additional shares of common stock become available for resale in the public market pursuant to registration statements and releases of lock-up agreements, the market supply of shares of common stock will increase, which could also decrease its market price.

We are unable to estimate the number of shares that may be sold because this will depend on the market price for our common stock, the personal circumstances of the sellers and other factors. Any sale of substantial amounts of our common stock or other securities in the open market may adversely affect the market price of our securities and may adversely affect our ability to obtain future financing in the capital markets as well as create a potential market overhang.

There are a limited number of stockholders who have significant control over our common stock, allowing them to have significant influence over the outcome of all matters submitted to our stockholders for approval, which may conflict with our interests and the interests of our other stockholders.

Our directors, officers and principal stockholders (stockholders owning 10% or more of our common stock), including Covance Inc., beneficially owned 22% of the outstanding shares of common stock and restricted stock units and stock options that could have been converted to common stock at September 30, 2011, and such stockholders will have significant influence over the outcome of all matters submitted to our stockholders for approval, including the election of our directors and other corporate actions. In addition, such influence by these affiliates could have the effect of discouraging others from attempting to take us over, thereby increasing the likelihood that the market price of the common stock will not reflect a premium for control.

Because we do not intend to pay dividends, stockholders will benefit from an investment in our common stock only if it appreciates in value.

We have never declared or paid any cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance further research and development and do not expect to pay any cash dividends in the foreseeable future. As a result, the success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

Trading in our common stock may be volatile, which may result in substantial declines in its market price.

The market price of our common stock has experienced historical volatility and might continue to experience volatility in the future in response to quarter-to-quarter variations in:

· operating results;

Table of Contents

· analysts’ reports;

· market conditions in the industry;

· changes in governmental regulations; and

· changes in general conditions in the economy or the financial markets.

The overall market (including the market for our common stock) has also experienced significant decreases in value in the past. This volatility and potential market decline could affect the market prices of securities issued by many companies, often for reasons unrelated to their operating performance, and may adversely affect the price of our common stock. Between January 1, 2011 and September 30, 2011, our common stock has traded at a low of $4.20 per share and a high of $5.60 per share.

Our common stock began trading on the NASDAQ Global Market, formerly called the NASDAQ National Market, on December 18, 2003 and has a limited trading market. We cannot assure that an active trading market will develop or, if developed, will be maintained. As a result, our stockholders may find it difficult to dispose of shares of our common stock and, as a result, may suffer a loss of all or a substantial portion of their investment.

Certain provisions of our stockholder rights plan, charter and Delaware law could make a takeover difficult and may prevent or frustrate attempts by our stockholders to replace or remove our management team.

We have an authorized class of 3,000,000 shares of undesignated preferred stock, of which 1,250,000 shares were previously issued and converted into common stock and 36,000 shares designated as Series A Junior Participating Preferred Stock under our stockholder rights plan as previously disclosed. The remaining 1,714,000 shares may be issued by our board of directors, on such terms and with such rights, preferences and designations as the board of directors may determine. Issuance of such preferred stock, depending upon the rights, preferences and designations thereof, may have the effect of delaying, deterring or preventing a change in control of our company. In addition, we are subject to provisions of Delaware corporate law which, subject to certain exceptions, will prohibit us from engaging in any “business combination” with a person who, together with affiliates and associates, owns 15% or more of our common stock for a period of three years following the date that the person came to own 15% or more of our common stock, unless the business combination is approved in a prescribed manner. Our board of directors also adopted a stockholder rights plan, dated as of July 20, 2009, as amended and restated on March 23, 2011, similar to plans adopted by many other publicly traded companies. The stockholder rights plan is intended to protect stockholders against unsolicited attempts to acquire control of us that do not offer a fair price to our stockholders as determined by our board of directors.

These provisions of our certificate of incorporation, stockholders rights plan and of Delaware law, may have the effect of delaying, deterring or preventing a change in control of our company, may discourage bids for our common stock at a premium over market price and may adversely affect the market price, and the voting and other rights of the holders, of our common stock. In addition, these provisions make it more difficult to replace or remove our current management team in the event our stockholders believe this would be in the best interest of our company and our stockholders.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Purchases of Equity Securities by the Issuer

On December 15, 2010, our Board of Directors authorized $2 million in funds for use in our common stock repurchase program over the following 18 months from December 2010. Repurchase under the program may be made through open market purchases or privately negotiated transactions in accordance with applicable federal securities laws, including Rule 10b-18. Rule 10b-18 puts limitations on this repurchase program, including but not limited to, the manner of purchase, the time of the repurchases, the prices paid and the volume of shares repurchased. The timing of the repurchases and the exact number of shares of common stock to be purchased will be determined by the discretion of our management under the supervision of the audit committee of our board of directors, and will depend upon market conditions and other factors. The program will be funded using our cash on hand and cash generated from operations. On March 14, 2011, we entered into a 10b5-1 Stock Repurchase Agreement with our broker so we had the ability to repurchase shares of our common stock during our standard blackout periods. The program may be extended, suspended or discontinued at any time.

The following table provides information relating to our repurchase of common stock for the three months ended September 30, 2011:

	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
July 1 — July 31, 2011	26,200	$	4.78	26,200	$	1,317,507
August 1 — August 31, 2011	19,000	$	4.75	19,000	$	1,226,614
September 1 — September 30, 2011	6,500	$	4.84	6,500	$	1,194,918
Total	51,700			51,700

Item 3. Defaults Upon Senior Securities.

None.

Item 4. (Removed and Reserved)

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

31.1 Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2 Certification of principal financial and accounting officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1 Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (furnished herewith).

32.2 Certification of principal financial and accounting officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (furnished herewith).

101.1 Financial statements from the Quarterly Report on Form 10-Q of BioClinica, Inc. for the quarter ended September 30, 2011, filed on November 14, 2011, formatted in XBRL (Extensible Business Reporting language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Cash Flows, (iv) the Consolidated Statements of Comprehensive Income and (v) the Notes to the Consolidated Financial Statements.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOCLINICA, INC.


DATE: November 14, 2011	By:	/s/ Mark L. Weinstein
	Mark L. Weinstein, President and Chief Executive Officer (Principal Executive Officer)


DATE: November 14, 2011	By:	/s/ Ted I. Kaminer
	Ted I. Kaminer, Executive Vice President of Finance and Administration and Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 a11-26012_1ex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark L. Weinstein, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioClinica, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 14, 2011		/s/ Mark L. Weinstein
		Mark L. Weinstein
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 a11-26012_1ex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ted I. Kaminer, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioClinica, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 14, 2011	/s/Ted I. Kaminer
	Ted I. Kaminer
	Executive Vice President of Finance and Administration and Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 a11-26012_1ex32d1.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of BioClinica, Inc. (the “Company”) for the quarter ended September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mark L. Weinstein, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of BioClinica, Inc.

Dated: November 14, 2011	/s/ Mark L. Weinstein*
	Mark L. Weinstein, President and Chief
	Executive Officer
	(Principal Executive Officer)

*A signed original of this written statement required by Section 906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 a11-26012_1ex32d2.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of BioClinica, Inc. (the “Company”) for the quarter ended September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Ted I. Kaminer, Executive Vice President of Finance and Administration and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of BioClinica, Inc.

Dated: November 14, 2011	/s/ Ted I. Kaminer*
	Ted I. Kaminer, Executive Vice President of Finance and
	Administration and Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.CAL 6 bioc-20110930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 7 bioc-20110930_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information [Abstract] Document And Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Consolidated Balance Sheets [Abstract] Assets [Abstract] ASSETS Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Accounts Receivable, Net, Current Accounts receivable, net Accounts Receivable, Net, Current, Total PrepaidExpenseAndOtherAssetsCurrent Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current, Total Deferred Tax Assets, Net, Current Deferred Tax Assets, Net, Current, Ending Balance Deferred Tax Assets, Net, Current, Beginning Balance Deferred income taxes Deferred Tax Assets, Net, Current, Total Assets, Current Total current assets Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Property, Plant and Equipment, Net, Total Intangible Assets, Net (Excluding Goodwill) Intangibles, net Intangible Assets, Net (Excluding Goodwill), Total Goodwill Goodwill, Ending Balance Goodwill, Beginning Balance Goodwill Goodwill, Total Deferred Tax Assets, Net, Noncurrent Deferred income tax Deferred Tax Assets, Net, Noncurrent, Total Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Other Liabilities, Current Accrued expenses and other current liabilities Other Liabilities, Current, Total Deferred Revenue, Current Deferred revenue Deferred Revenue, Current, Total Capital Lease Obligations, Current Current maturities of capital lease obligations Short term portion of additional payment from acquisitions based on certain criteria as determined in the acquisition agreements. Current Liability for Acquisition Earn-Out Current liability for acquisition earn-out Liabilities, Current Total current liabilities Capital Lease Obligations, Noncurrent Long-term capital lease obligations Long term portion of additional payment from acquisitions based on certain criteria as determined in the acquisition agreements. Long-Term Liability for Acquisition Earn-Out Long-term liability for acquisition earn-out Deferred Tax Liabilities, Noncurrent Deferred income tax Other Liabilities, Noncurrent Other liabilities Other Liabilities, Noncurrent, Total Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred stock - $0.00025 par value; authorized 3,000,000 shares, none issued and outstanding at September 30, 2011 and at December 31, 2010 Preferred Stock, Value, Issued, Total Common Stock, Value, Issued Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common stock - $0.00025 par value; authorized 36,000,000 shares, issued and outstanding 15,662,550 shares at September 30, 2011 and 15,631,664 shares at December 31, 2010 Common Stock, Value, Issued, Total Treasury Stock, Value Treasury stock - at cost, shares held: 160,113 at September 30, 2011 and 3,400 at December 31, 2010 Treasury Stock, Value, Ending Balance Treasury Stock, Value, Beginning Balance Treasury stock - at cost, shares held: 41,013 at March 31, 2011 and 3,400 at December 31, 2010 Additional Paid in Capital Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional paid-in capital Additional Paid in Capital, Total Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained earnings Retained Earnings (Accumulated Deficit), Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Treasury Stock, Shares Treasury Stock, Shares, Ending Balance Treasury Stock, Shares, Beginning Balance Treasury stock, shares Consolidated Statements Of Income [Abstract] Sales Revenue, Services, Net Service revenues Sales Revenue, Services, Net, Total Reimbursement Revenue Reimbursement revenues Revenues Total revenues Operating Costs and Expenses [Abstract] Cost and expenses: Cost of Services Cost of service revenues Cost of Services, Total Cost of Reimbursable Expense Cost of reimbursement revenues Selling and Marketing Expense Sales and marketing expenses Selling and Marketing Expense, Total General and Administrative Expense General and administrative expenses General and Administrative Expense, Total Amortization of Acquired Intangible Assets Amortization of intangible assets related to acquisition Business Combination, Acquisition Related Costs Mergers and acquisitions related costs Restructuring Charges, Restructuring costs Restructuring Charges, Total Operating Costs and Expenses Total cost and expenses Operating Income (Loss) Operating income Investment Income, Interest Interest income Interest Expense Interest expense Interest expense Interest Expense, Total Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income before income tax Income Tax Expense (Benefit) Income tax provision Income tax provision Income Tax Expense (Benefit), Total Net Income (Loss) Attributable to Parent Net income Net income Earnings Per Share, Basic Basic income per common share Earnings Per Share, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares Weighted Average Number of Shares Outstanding, Basic, Total Earnings Per Share, Diluted Diluted income per common share Earnings Per Share, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted average number of diluted shares Weighted Average Number of Shares Outstanding, Diluted, Total Consolidated Statements Of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities, net of acquisition: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Deferred Income Tax Expense (Benefit) Provision for deferred income taxes Deferred Income Tax Expense (Benefit), Total Allowance for Loan and Lease Losses, Recoveries of Bad Debts Bad debt recovery, net Share-based Compensation Stock based compensation expense Share-based Compensation, Total Accretion of acquisition earn-out. Accretion of Acquisition Earn-Out Accretion of acquisition earn-out Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Accounts Receivable (Increase) decrease in accounts receivable (Increase) decrease in accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase in prepaid expenses and other current assets Increase in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Other Operating Assets (Increase) decrease in other assets (Increase) decrease in other assets Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Accounts Payable, Trade Increase (decrease) in accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Decrease in accrued expenses and other current liabilities Increase (Decrease) in Deferred Revenue Decrease in deferred revenue Increase (Decrease) in Other Operating Liabilities Increase in other liabilities Increase (Decrease) in Other Operating Liabilities, Total Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Capitalized Computer Software, Additions Capitalized software development costs Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Sale Leaseback Transaction, Net Proceeds Proceeds from sale/leaseback Payments to Acquire Equipment on Lease Payments under equipment lease obligations Payments under equipment lease obligations Payments for Repurchase of Equity Purchase of treasury stock Purchase of treasury stock Payments for Repurchase of Equity, Total Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options Excess tax benefit related to stock options Excess tax benefit related to stock options Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Net cash provided by financing activities Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents, Total Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Net decrease in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow information: Interest Paid Cash paid during the period for interest Interest Paid, Total Income Taxes Paid, Net Cash paid during the period for income taxes Income Taxes Paid, Net, Total Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non cash investing and financing activities: Noncash or Part Noncash Acquisition, Fixed Assets Acquired Increase in property, plant and equipment acquisitions in accounts payable Equipment Purchases under Capital Lease Obligations Equipment purchases under capital lease obligations Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract] Acquired business Business acquisition purchase price allocation, accounts receivable. Business Acquisition Purchase Price Allocation Accounts Receivable Accounts receivable Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment Property and equipment Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment, Total Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets Other assets Business Acquisition, Cost of Acquired Entity, Liabilities Incurred Other Liabilities Finite-Lived Customer Relationships, Gross Customer Relationships Business acquisition purchase price allocation, technology. Business Acquisition Purchase Price Allocation Technology Technology Business acquisition purchase price allocation, goodwill including workforce. Business Acquisition Purchase Price Allocation Goodwill Including Workforce Goodwill, including Workforce Business Acquisition, Cost of Acquired Entity, Purchase Price Total Fair Value of Purchase Price Business Acquisition, Cost of Acquired Entity, Purchase Price, Total Consolidated Statements Of Comprehensive Income [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Statement of comprehensive income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Equity adjustment from foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive income Interim Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Interim Financial Statements Restructuring Charges [Abstract] Restructuring and Related Activities Disclosure [Text Block] Restructuring Charges Stockholders' Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share Commitments And Contingencies [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments And Contingencies Accounts Receivable And Allowance For Doubtful Accounts [Abstract] Accounts receivable and allowance for doubtful accounts. Accounts Receivable and Allowance for Doubtful Accounts [Text Block] Accounts Receivable And Allowance For Doubtful Accounts Acquisitions [Abstract] Mergers, Acquisitions and Dispositions Disclosures [Text Block] Acquisitions Intangible Assets [Abstract] Intangible Assets Disclosure [Text Block] Intangible Assets EX-101.PRE 8 bioc-20110930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.INS 9 bioc-20110930.xml XBRL INSTANCE DOCUMENT 0000822418 2009-12-31 0000822418 2011-07-01 2011-09-30 0000822418 2010-07-01 2010-09-30 0000822418 2011-10-31 0000822418 2010-12-31 0000822418 2011-09-30 0000822418 2010-09-30 0000822418 2010-01-01 2010-09-30 0000822418 2011-01-01 2011-09-30 iso4217:USD xbrli:shares xbrli:shares iso4217:USD Note 6 – Accounts Receivable and Allowance for Doubtful Accounts   The Company maintains allowances for doubtful accounts on a specific identification method for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of its customers were to deteriorate, resulting in an impairment of the customers' ability to make payments, additional allowances may be required. The Company does not have any off-balance-sheet credit exposure related to its customers, and the trade accounts receivable do not bear interest.   <table style="border-collapse: collapse; font-family: 'Calibri','sans-serif'; margin-left: 4.8pt; font-size: 11pt;" class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0"> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> (in thousands)</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> September 30, 2011</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> December 31, 2010</td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Billed trade accounts receivable </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> $12,703</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> $11,085</td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Unbilled trade accounts receivable </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> 779</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> 782</td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Other </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> -</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> 14</td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Total Receivables </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> $13,482</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> $11,881</td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313">      </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Allowance Rollforward (in thousands):</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Balance at January 1, 2011 </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> $15</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Additions </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> -</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Write offs (Recoveries) </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="144"> (15)</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td></tr> <tr style="height: 13.2pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 234.6pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="313"> Balance at September 30, 2011 </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144"> $0</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 13.5pt; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="top" width="18">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 1.5in; padding-right: 5.4pt; height: 13.2pt; padding-top: 0in;" valign="bottom" width="144">  </td></tr></table> 245000 114000 309000 1369000 1000000 2000000 1886000 false --12-31 Q3 2011 2011-09-30 10-Q 0000822418 15659975 Smaller Reporting Company BIOCLINICA INC

1983000

2168000

11866000

13482000

25000

69000

48074000

49231000

473000

194000

467000

155000

80029000

85025000

28435000

32466000

-459000

2468000

58000

91000

635000

119000

162000

-3783000

-2843000

168000

342000

918000

710000

1296000

14570000

11816000

10443000

12292000

-2754000

1849000

Note 5 – Commitments and Contingencies   On May 5, 2010, the Company entered into an unsecured, committed line of credit with PNC Bank expiring May 5, 2012. In April 2011, the Company extended the expiration date of this line of credit to May 4, 2013.  Under the credit agreement, the Company has the ability to borrow $7.5 million at interest rates equal to LIBOR plus 1.75%.  In addition, the Company pays a fee of 0.25% per annum on the loan commitment regardless of usage.  The credit agreement requires our compliance with certain covenants, including maintaining a minimum stockholders' equity of $35 million. As of September 30, 2011, the Company had no borrowings under this line of credit and was compliant with the covenants.

0.00025

36000000

15631664

15662550

15631664

15662550

4000

1885000

974000

1677000

311000

9413000

2352000

11887000

4847000

29109000

10212000

31432000

10434000

47000

829000

13395000

13377000

3625000

4098000

128000

87000

1845000

3107000

2501000

3310000

0.13

0.05

0.10

0.02

0.12

0.05

0.10

0.02

Note 4 – Earnings Per Share   Basic income per common share for the three and nine months ended September 30, 2011 and 2010 was calculated by dividing the net income available to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted income per share for the three and nine months ended September 30, 2011 and 2010 was calculated by dividing net income by the weighted average number of shares of Common Sstock outstanding, adjusted for the effect of potentially dilutive securities using the treasury stock method. The computation of basic income per common share and diluted income per common share was as follows:   <table style="border-collapse: collapse; font-family: 'Times New Roman','serif'; margin-left: 0px !important; font-size: 10pt;" class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" width="666"> <tr style="height: 32.85pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 32.85pt; padding-top: 0in;" width="252"> (in thousands, except per share data)</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 148.75pt; padding-right: 5.4pt; height: 32.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" width="198" colspan="3"> Three Months Ended September 30,</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 32.85pt; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 148.75pt; padding-right: 5.4pt; height: 32.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" width="198" colspan="3"> Nine Months Ended September 30,</td></tr> <tr style="height: 18.5pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 18.5pt; padding-top: 0in;" width="252">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 18.5pt; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> 2011</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 18.5pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 18.5pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91"> 2010</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 18.5pt; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 18.5pt; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> 2011</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 18.5pt; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 18.5pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91"> 2010</td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Net income  – basic and diluted</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $358</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $808</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $1,633</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $1,922</td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Denominator – basic:</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Weighted average number</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">    of common shares</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,640</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,174</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,645</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 14,958</td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Basic income per common share</td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.02</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.05</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.10</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.13</td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Denominator – diluted:</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Weighted average number</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">    of common shares</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,640</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,174</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,645</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 14,958</td></tr> <tr style="height: 36.45pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="252"> Common share equivalents    of outstanding convertible equity and    unrecognized compensation expense</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="91">   743</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="91">   622</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="91">   870</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 36.45pt; padding-top: 0in;" width="91">   772</td></tr> <tr style="height: 14.9pt;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 14.9pt; padding-top: 0in;" width="252"> Weighted average number  of</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 14.9pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 14.9pt; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 14.9pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 14.9pt; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 14.9pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 14.9pt; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 14.9pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">    dilutive common equity shares</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 16,383</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,796</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 16,515</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91"> 15,730</td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252"> Diluted income per </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="91">  </td></tr> <tr style="height: 0.2in;"><td style="padding-bottom: 0in; padding-left: 5.4pt; width: 189.05pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="252">    common share</td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.02</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.05</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.10</td> <td style="padding-bottom: 0in; padding-left: 5.4pt; width: 12.95pt; padding-right: 5.4pt; height: 0.2in; padding-top: 0in;" width="17">  </td> <td style="border-bottom: windowtext 3px double; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.9pt; padding-right: 5.4pt; height: 0.2in; border-top: medium none; border-right: medium none; padding-top: 0in;" width="91"> $0.12</td></tr></table>  Options to purchase 536,000 and 576,000 shares of BioClinica's common stock respectively, had been excluded from the calculation of diluted earnings per common share for the nine months ended September 30, 2011 and September 30, 2010, respectively, as they were all antidilutive. Options to purchase 563,000 and 779,000 shares of BioClinica's common stock respectively, had been excluded from the calculation of diluted earnings per common share for the three months ended September 30, 2011 and September 30, 2010, respectively, as they were all antidilutive.

1000

26000

-35000

100000

6057000

2069000

7027000

2434000

34302000

3120000

1295000

2501000

467000

1802000

736000

1198000

487000

868000

109000

-199000

113000

-278000

1603000

-1136000

-89000

-1127000

-19000

-17000

42000

368000

742000

625000

89000

2430000

1963000

7000

32000

14000

7000

32000

18000

10000

6000

2000

25150000

28096000

80029000

85025000

19829000

22072000

251000

115000

-6079000

-4195000

3073000

5903000

1922000

808000

1633000

358000

125000

74000

52552000

17036000

59018000

20991000

3109000

1285000

2527000

479000

Note 1 - Interim Financial Statements Basis of Presentation. The financial statements included in this Quarterly Report on Form 10-Q have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP in the United States of America have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2010. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary for a fair statement of the results for the interim periods. Interim results are not necessarily indicative of results for the full fiscal year. As  previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, the Company identified and corrected clerical billing errors in the quarter ending June 30, 2010 that overstated service revenue and income from operations by $155,000 ($94,000 net of tax) and understated the quarter ending September 30, 2010 service revenue and income from operations by $155,000 ($94,000 net of tax). The Company determined that these adjustments were not material to its consolidated financial statements for any of the quarterly periods affected. The Company has revised the financial statements for the quarter ended September 30, 2010 presented herein. Functional Currency. The functional currency of each of the Company's foreign operations is the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. Increases and decreases in net assets resulting from foreign currency translation are reflected in stockholder's equity as a component of accumulated other comprehensive income (loss). The equity adjustment from foreign currency translation was $44,000 and $(37,000) for the nine months ended September 30, 2011 and 2010, respectively. Recently Issued Accounting Pronouncements.   In May 2011, the FASB issued Accounting Standards Update (ASU) No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards (Topic 820)—Fair Value Measurement (ASU 2011-04), to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. GAAP and International Financial Reporting Standards. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for level 3 fair value measurements. ASU 2011-04 is effective for the Company in the first quarter of fiscal 2012 and should be applied prospectively. The Company is currently evaluating the impact of the pending adoption of ASU 2011-04 on its consolidated financial statements.   In June 2011, the FASB issued authoritative guidance that eliminates the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity, among other updates to the presentation of comprehensive income. Under this guidance, an entity has the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In addition, an entity is required to present on the face of the financial statements reclassification adjustments for items that are reclassified from other comprehensive income to net income in the statement(s) where the components of net income and the components of other comprehensive income are presented. This guidance will be effective for BioClinica, Inc. on January 1, 2012 and will impact the presentation of the Company's consolidated financial statements. In September 2011, the FASB issued authoritative guidance that allows an entity to use a qualitative approach to test goodwill for impairment. Under this guidance, an entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. In addition, an entity has the option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the first step of the two-step goodwill impairment test. This guidance will be effective for BioClinica's goodwill impairment tests performed after December 31, 2011 and is not expected to have a material impact on the Company's consolidated financial statements.

705000

748000

-37000

166000

44000

-47000

4283000

4185000

880000

1621000

784000

157000

2296000

1352000

0.00025

3000000

2501000

2594000

21000

138000

14029000

15459000

-9000

-15000

9413000

2352000

11887000

4847000

<a name="_DV_M587"> </a>Note 2 – Restructuring charges   In 2011, the Company realigned its global resources to eliminate certain duplicate functions and took a total restructuring charge of $1.7 million for the nine months ended September 30, 2011. This restructuring charge was comprised of $656,000 in employee severance, $884,000 write-off of facility lease obligations and $179,000 in legal and other costs.   The Company has paid $715,000 of the restructuring cost as of September 30, 2011 and the $1,004,000 remaining to be paid is included in Accrued Expense and Other Current Liabilities on the Consolidated Balance Sheet. $120,000 of the unpaid restructuring costs will be paid by December 31, 2011 and the remaining $884,000 of the unpaid restructuring cost consists of the facility lease obligations that will be paid out over the remaining term of the leases with the last lease payment in May 2014.

1719000

1040000

6792000

8425000

55661000

18321000

61545000

21470000

195000

918000

46248000

15969000

49658000

16623000

6865000

2090000

6324000

2081000

791000

1019000

54879000

56929000

Note 3 – Stockholders' Equity   The following summarizes the activity of the Stockholders' equity accounts for the period from December 31, 2009 through September 30, 2011:   <table style="border-bottom: medium none; border-left: medium none; border-collapse: collapse; font-family: 'Times New Roman','serif'; margin-left: 0px !important; font-size: 10pt; border-top: medium none; border-right: medium none;" class="MsoNormalTable" border="1" cellspacing="0" cellpadding="0" width="732"> <tr style="height: 50.85pt;"><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="162">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 94.9pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="127" colspan="3">     Common Stock</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61">   Addi-tional Paid-in</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="51"> Treas-ury</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">   Common Stock Considera-tion for</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="66">     Accumulated Retained Earning</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="55">   Other Compre-hensive Gain</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; height: 50.85pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="56">       Stock-holders'</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="162"> (in thousands)</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="53"> Shares</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="top" width="57"> Amount</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="61"> Capital</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> Stock</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="16">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71"> Earnout</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="66"> s</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="55"> (Loss)</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="56"> Equity</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Balance at December 31, 2009 </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 14,394</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> $4</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> $43,104</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">   $1,309</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> 4,039</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> 79</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 48,535</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Stock options exercised </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 265</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 122</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 122</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Restricted shares issued </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 48</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> (55)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> (55)</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Stock consideration for acquisition </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 350</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 1,309</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">   (1,309)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> -</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Stock issues for acquisitions.. </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 578</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 2,468</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 2,468</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Stock based compensation </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 1,080</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 1,080</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Purchase of treasury stock </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> (3)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> (16)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> (16)</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Tax benefit on exercise of stock options </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 46</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 46</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Equity adjustment from foreign currency translation </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> (54)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> (54)</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Net income </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> 2,753</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 2,753</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Balance at December 31, 2010 </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 15,632</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> $4</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> $48,074</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="top" width="51">   $(16)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="top" width="71"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> $6,792</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> $25</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: windowtext 1pt solid; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> $54,879</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Stock options exercised </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 124</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 216</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 216</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Restricted shares issued </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 64</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> (78)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> (78)</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Stock based compensation </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> 1,019</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 1,019</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Purchase of treasury stock </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> (157)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> (784)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> (784)</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Equity adjustment from foreign currency translation </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> 44</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 44</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Net income </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> -</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> -</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> -</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51"> -</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71"> -</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> 1,633</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> -</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> 1,633</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162"> Balance at September 30, 2011 </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53"> 15,663</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57"> $4</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61"> $49,231</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">   ($800)</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">   -</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66"> $8,425</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55"> $69</td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56"> $56,929</td></tr> <tr><td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 121.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="162">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 39.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="53">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.9pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="57">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 45.45pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="61">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 38.4pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="51">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 11.8pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="16">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 53.6pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="top" width="71">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 49.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="66">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 41.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="55">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 12.5pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="17">  </td> <td style="border-bottom: medium none; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 42.3pt; padding-right: 5.4pt; border-top: medium none; border-right: medium none; padding-top: 0in;" valign="bottom" width="56">  </td></tr></table> On December 15, 2010, our Board of Directors authorized $2 million in funds for use in our common stock repurchase program over 18 months from December 2010. Repurchases under the program may be made through open market purchases or privately negotiated transactions in accordance with applicable federal securities laws, including Rule 10b-18. Rule 10b-18 puts limitations on this repurchase program, including but not limited to, the manner of purchase, the time of the repurchases, the prices paid and the volume of shares repurchased. The timing of the repurchases and the exact number of shares of common stock to be purchased will be determined by the discretion of our management under the supervision of the audit committee of our board of directors, and will depend upon market conditions and other factors. The program will be funded using our cash on hand and cash generated from operations. On March 14, 2011, we entered into a 10b5-1 Stock Repurchase Agreement with our broker so we had the ability to repurchase shares of our common stock during our standard blackout periods. The program may be extended, suspended or discontinued at any time. The following table provides information relating to our repurchase of common stock for the three months ended September 30, 2011: <table style="border-bottom: medium none; border-left: medium none; border-collapse: collapse; font-family: 'Times New Roman','serif'; font-size: 10pt; border-top: medium none; border-right: medium none;" class="MsoNormalTable" border="1" cellspacing="0" cellpadding="0"> <tr style="height: 58pt;"><td style="border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 153.9pt; padding-right: 5.4pt; height: 58pt; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="205">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 58pt; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> Total Number of Shares Purchased</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 58pt; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> Average Price Paid per Share</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 94.5pt; padding-right: 5.4pt; height: 58pt; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="126"> Total Number of Shares Purchased as Part of Publicly Announced Program</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 95.4pt; padding-right: 5.4pt; height: 58pt; border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="127"> Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program</td></tr> <tr style="height: 0.1in;"><td style="border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 153.9pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="205"> July 1 – July 31, 2011</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> 26,200</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> $4.78</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 94.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="126"> 26,200</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 95.4pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="127"> $1,317,507</td></tr> <tr style="height: 0.1in;"><td style="border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 153.9pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="205"> August 1 – August 31, 2011 </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> 19,000</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> $4.75</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 94.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="126"> 19,000</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 95.4pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="127"> $1,226,614</td></tr> <tr style="height: 0.1in;"><td style="border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 153.9pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="205"> September 1 – September 30, 2011 </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> 6,500</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> $4.84</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 94.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="126"> 6,500</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 95.4pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="127"> $1,194,918</td></tr> <tr style="height: 0.1in;"><td style="border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding-bottom: 0in; padding-left: 5.4pt; width: 153.9pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="205"> Total</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90"> 51,700</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 67.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="90">  </td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 94.5pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="126"> 51,700</td> <td style="border-bottom: windowtext 1pt solid; border-left: medium none; padding-bottom: 0in; padding-left: 5.4pt; width: 95.4pt; padding-right: 5.4pt; height: 0.1in; border-top: medium none; border-right: windowtext 1pt solid; padding-top: 0in;" valign="top" width="127">  </td></tr></table>

3400

160113

16000

800000

15730000

15796000

16515000

16383000

14958000

15174000

15645000

15640000

EX-101.SCH 10 bioc-20110930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements Of Income link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements Of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Consolidated Statements Of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Interim Financial Statements link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accounts Receivable And Allowance For Doubtful Accounts link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink XML 11 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2011	Dec. 31, 2010
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.00025	$ 0.00025
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00025	$ 0.00025
Common stock, shares authorized	36,000,000	36,000,000
Common stock, shares issued	15,662,550	15,631,664
Common stock, shares outstanding	15,662,550	15,631,664
Treasury stock, shares	160,113	3,400

XML 12 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements Of Income (USD $) In Thousands, except Per Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Consolidated Statements Of Income [Abstract]
Service revenues	$ 16,623	$ 15,969	$ 49,658	$ 46,248
Reimbursement revenues	4,847	2,352	11,887	9,413
Total revenues	21,470	18,321	61,545	55,661
Cost and expenses:
Cost of service revenues	10,434	10,212	31,432	29,109
Cost of reimbursement revenues	4,847	2,352	11,887	9,413
Sales and marketing expenses	2,081	2,090	6,324	6,865
General and administrative expenses	2,434	2,069	7,027	6,057
Amortization of intangible assets related to acquisition	155	194	467	473
Mergers and acquisitions related costs		119	162	635
Restructuring costs	1,040		1,719
Total cost and expenses	20,991	17,036	59,018	52,552
Operating income	479	1,285	2,527	3,109
Interest income	2	10	6	18
Interest expense	(14)		(32)	(7)
Income before income tax	467	1,295	2,501	3,120
Income tax provision	(109)	(487)	(868)	(1,198)
Net income	$ 358	$ 808	$ 1,633	$ 1,922
Basic income per common share	$ 0.02	$ 0.05	$ 0.10	$ 0.13
Weighted average number of common shares	15,640	15,174	15,645	14,958
Diluted income per common share	$ 0.02	$ 0.05	$ 0.10	$ 0.12
Weighted average number of diluted shares	16,383	15,796	16,515	15,730

XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2011	Oct. 31, 2011
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2011
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2011
Entity Registrant Name	BIOCLINICA INC
Entity Central Index Key	0000822418
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		15,659,975

XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R12.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies

9 Months Ended

Sep. 30, 2011

Commitments And Contingencies [Abstract]

Commitments And Contingencies

Note 5 – Commitments and Contingencies

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 16 R8.htm IDEA: XBRL DOCUMENT

Interim Financial Statements

9 Months Ended

Sep. 30, 2011

Interim Financial Statements [Abstract]

Interim Financial Statements

Note 1 - Interim Financial Statements

Basis of Presentation.

Interim results are not necessarily indicative of results for the full fiscal year.

As previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, the Company identified and corrected clerical billing errors in the quarter ending June 30, 2010 that overstated service revenue and income from operations by $155,000 ($94,000 net of tax) and understated the quarter ending September 30, 2010 service revenue and income from operations by $155,000 ($94,000 net of tax). The Company determined that these adjustments were not material to its consolidated financial statements for any of the quarterly periods affected. The Company has revised the financial statements for the quarter ended September 30, 2010 presented herein.

Functional Currency.

The functional currency of each of the Company's foreign operations is the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. Increases and decreases in net assets resulting from foreign currency translation are reflected in stockholder's equity as a component of accumulated other comprehensive income (loss).

The equity adjustment from foreign currency translation was $44,000 and $(37,000) for the nine months ended September 30, 2011 and 2010, respectively.

Recently Issued Accounting Pronouncements.

In June 2011, the FASB issued authoritative guidance that eliminates the option to present components of other comprehensive income as part of the statement of changes in stockholders' equity, among other updates to the presentation of comprehensive income. Under this guidance, an entity has the option to present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In addition, an entity is required to present on the face of the financial statements reclassification adjustments for items that are reclassified from other comprehensive income to net income in the statement(s) where the components of net income and the components of other comprehensive income are presented. This guidance will be effective for BioClinica, Inc. on January 1, 2012 and will impact the presentation of the Company's consolidated financial statements.

In September 2011, the FASB issued authoritative guidance that allows an entity to use a qualitative approach to test goodwill for impairment. Under this guidance, an entity has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. In addition, an entity has the option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the first step of the two-step goodwill impairment test. This guidance will be effective for BioClinica's goodwill impairment tests performed after December 31, 2011 and is not expected to have a material impact on the Company's consolidated financial statements.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Name FASB Interpretation (FIN)

-Publisher FASB

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

+ Details

XML 17 R14.htm IDEA: XBRL DOCUMENT

Acquisitions

9 Months Ended

Sep. 30, 2011

Acquisitions [Abstract]

Acquisitions

Note 7 – Acquisitions

2010 Acquisition

On March 25, 2010, the Company acquired substantially all of the assets of privately held TranSenda International, LLC ("TranSenda"). Headquartered in Bellevue, WA, TranSenda was a provider of clinical trial management software (CTMS) solutions. TranSenda's suite of web-based, Office-Smart CTMS solutions creates efficiencies for trial operations through interoperability with Microsoft Office tools. With this acquisition, BioClinica enhanced its ability to serve customers throughout the clinical research process with technologies that include improved efficiencies by reducing study durations and costs through integrated operational management. The acquisition was made pursuant to an Asset Purchase Agreement, dated March 25, 2010, by and between the Company and TranSenda (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Company purchased and acquired from TranSenda all rights, title and interest of TranSenda in and to the Purchased Assets (as defined in the Purchase Agreement) and assumed the Assumed Liabilities (as defined in the Purchase Agreement) of TranSenda.

As consideration for the Purchased Assets and Assumed Liabilities, the Company issued 577,960 shares of common stock, par value $0.00025 per share, of the Company, valued at a volume weighted average price per share equal to $4.325560, and subject to a post-closing adjustment based on the Final Closing Net Working Capital (as defined in the Purchase Agreement). Pursuant to the terms of the Purchase Agreement, 15% of the aggregate consideration was held in escrow to cover any potential indemnification claims under the Purchase Agreement for a period of 12 months following the Closing Date (as defined in the Purchase Agreement). On March 25, 2011, the amounts held in escrow were released and there were no indemnification claims. As part of the Purchase Agreement, TranSenda agreed not to directly or indirectly offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of the Company's common stock received pursuant to the Purchase Agreement for a period beginning on the date the Purchase Agreement was executed and continuing to and including the date 12 months after such date. The Company recorded the fair value of the acquisition of $2,468,000 based on the Company's market value per share of $4.27 for the stock consideration on March 25, 2010, the date of acquisition.

(in thousands except per share data)	Nine Months Ended September 30, 2010

Total revenue	$55,834
Income from operations	2,577
Net Income	1,583
Basic earnings per share	$0.05
Diluted earnings per share		$0.05

In connection with the acquisition of TranSenda, the Company performed an evaluation of the guidance included in FASB ASC 280, Segment Reporting ("FASB ASC 280") and FASB ASC 350, Intangibles - Goodwill and Other ("FASB ASC 350"). Based on that evaluation, the Company included TranSenda as part of its clinical trials services reportable segment.

In accordance with FASB ASC 805, Business Combinations, the Company expensed all costs related to the acquisition.

The following table summarizes the amounts of identified assets acquired and liabilities assumed from TranSenda at the acquisition date fair value:

	TranSenda
Accounts Receivable	$309
Property and Equipment	91
Other Assets	58
Other Liabilities	(459)
Customer Relationships	100
Technology	1,000
Goodwill, including Workforce	1,369
Total Fair Value of Purchase Price	$2,468

In accordance with FASB ASC 820, Fair Value Measurements ("FASB ASC 820"), the Company determined that the non-financial assets and liabilities summarized above are derived from significant unobservable inputs ("Level 3 inputs") determined by management based on various market and income analyses and recent asset appraisals. The goodwill recorded in connection with these acquisitions will be deductible for tax purposes over 15 years.

2009 Acquisition

On September 15, 2009, BioClinica acquired substantially all of the assets of Tourtellotte Solutions, Inc. ("Tourtellotte"). Tourtellotte provides software applications and consulting services which support clinical trials in the pharmaceutical industry. The purchase price for Tourtellotte was $2.1 million in cash. Pursuant to the acquisition agreement, the Company agreed to pay up to an additional $3.2 million in cash and 350,000 shares of our common stock based upon achieving certain milestones, which include certain product development and revenue targets (the "earn-out"). In December 2010, the Company paid the first acquisition earn-out of $1,257,000 in cash and the issuance of 350,000 shares of the Company's Common Stock. The remaining cash contingent consideration expected to be paid in the fair value amount of $2,000,000 was classified as a short-term liability on the financial statements at September 30, 2011. The difference between the fair value of the cash contingent consideration at date of acquisition and the expected payment will be recorded as an expense in the financial statements at the end of each reporting period. The Company recorded $114,000 and $245,000 for the nine months ended September 30, 2011 and 2010, respectively, of accretion expense in mergers and acquisition related costs on the income statement for this difference.

The following table represents changes in assets and liabilities measured at fair value using Level 3 inputs:

Fair value at September 15, 2009	$2,747,000
Earn-out accretion	396,000
Payment on earn-out one	(1,257,000)
Fair value at December 31, 2010	1,886,000
Earn-out accretion	114,000
Fair value at September 30, 2011	$2,000,000

XML 18 R15.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2011

Intangible Assets [Abstract]

Intangible Assets

Note 8 – Intangible Assets

At September 30, 2011, the composition of intangible assets were as follows:

(in thousands)	September 30, 2011	Estimated Useful Life
Amortized intangible assets:
Technology	$1,843	5 years
Trademarks	48	5 years
Customer backlog	2,112	3 to 7 years
Non-competition agreement	349	2 to 3 years
	$4,352
Accumulated amortization	(2,389)
	$1,963

Unamortized intangible assets:
Goodwill	$34,302

Estimated future amortization of the intangible assets is as follows:

(in thousands)	Year Ending December 31,
Remainder of 2011	$156
2012	534
2013	337
2014	309
2015	160
2016 and beyond	467
	$1,963

XML 19 R13.htm IDEA: XBRL DOCUMENT

Accounts Receivable And Allowance For Doubtful Accounts

9 Months Ended

Sep. 30, 2011

Accounts Receivable And Allowance For Doubtful Accounts [Abstract]

Accounts Receivable And Allowance For Doubtful Accounts

Note 6 – Accounts Receivable and Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts on a specific identification method for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of its customers were to deteriorate, resulting in an impairment of the customers' ability to make payments, additional allowances may be required. The Company does not have any off-balance-sheet credit exposure related to its customers, and the trade accounts receivable do not bear interest.

(in thousands)	September 30, 2011	December 31, 2010
Billed trade accounts receivable	$12,703	$11,085
Unbilled trade accounts receivable	779	782
Other	-	14
Total Receivables	$13,482	$11,881

Allowance Rollforward (in thousands):
Balance at January 1, 2011	$15
Additions	-
Write offs (Recoveries)	(15)
Balance at September 30, 2011	$0

XML 20 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements Of Cash Flows (Parenthetical) (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Non cash investing and financing activities:
Increase in property, plant and equipment acquisitions in accounts payable	$ 74	$ 125
Equipment purchases under capital lease obligations	918
Acquired business
Accounts receivable		309
Property and equipment		91
Other assets		58
Other Liabilities		(459)
Customer Relationships		100
Technology		1,000
Goodwill, including Workforce		1,369
Total Fair Value of Purchase Price		$ 2,468

XML 21 R9.htm IDEA: XBRL DOCUMENT

Restructuring Charges

9 Months Ended

Sep. 30, 2011

Restructuring Charges [Abstract]

Restructuring Charges

Note 2 – Restructuring charges

XML 22 R10.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2011

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 3 – Stockholders' Equity

The following summarizes the activity of the Stockholders' equity accounts for the period from December 31, 2009 through September 30, 2011:

	Common Stock		Addi-tional Paid-in	Treas-ury	Common Stock Considera-tion for	Accumulated Retained Earning	Other Compre-hensive Gain	Stock-holders'
(in thousands)	Shares	Amount	Capital	Stock	Earnout	s	(Loss)	Equity
Balance at December 31, 2009	14,394	$4	$43,104	-	$1,309	4,039	79	48,535
Stock options exercised	265	-	122	-		-	-	122
Restricted shares issued	48	-	(55)	-		-	-	(55)
Stock consideration for acquisition	350	-	1,309	-	(1,309)	-	-	-
Stock issues for acquisitions..	578	-	2,468	-		-	-	2,468
Stock based compensation	-	-	1,080	-		-	-	1,080
Purchase of treasury stock	(3)	-	-	(16)		-	-	(16)
Tax benefit on exercise of stock options	-	-	46	-		-	-	46
Equity adjustment from foreign currency translation	-	-	-	-		-	(54)	(54)
Net income	-	-	-	-		2,753	-	2,753
Balance at December 31, 2010	15,632	$4	$48,074	$(16)	-	$6,792	$25	$54,879
Stock options exercised	124	-	216	-	-	-	-	216
Restricted shares issued	64	-	(78)	-	-	-	-	(78)
Stock based compensation	-	-	1,019	-	-	-	-	1,019
Purchase of treasury stock	(157)		-	(784)	-	-	-	(784)
Equity adjustment from foreign currency translation	-	-	-	-	-	-	44	44
Net income	-	-	-	-	-	1,633	-	1,633
Balance at September 30, 2011	15,663	$4	$49,231	($800)	-	$8,425	$69	$56,929

On December 15, 2010, our Board of Directors authorized $2 million in funds for use in our common stock repurchase program over 18 months from December 2010. Repurchases under the program may be made through open market purchases or privately negotiated transactions in accordance with applicable federal securities laws, including Rule 10b-18. Rule 10b-18 puts limitations on this repurchase program, including but not limited to, the manner of purchase, the time of the repurchases, the prices paid and the volume of shares repurchased. The timing of the repurchases and the exact number of shares of common stock to be purchased will be determined by the discretion of our management under the supervision of the audit committee of our board of directors, and will depend upon market conditions and other factors. The program will be funded using our cash on hand and cash generated from operations. On March 14, 2011, we entered into a 10b5-1 Stock Repurchase Agreement with our broker so we had the ability to repurchase shares of our common stock during our standard blackout periods. The program may be extended, suspended or discontinued at any time.

The following table provides information relating to our repurchase of common stock for the three months ended September 30, 2011:

	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
July 1 – July 31, 2011	26,200	$4.78	26,200	$1,317,507
August 1 – August 31, 2011	19,000	$4.75	19,000	$1,226,614
September 1 – September 30, 2011	6,500	$4.84	6,500	$1,194,918
Total	51,700		51,700

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 23 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 24 0001104659-11-063886-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-11-063886-xbrl.zip M4$L#!!0````(`&%^;C_<3=M+CTT``*6M!0`1`!P`8FEO8RTR,#$Q,#DS,"YX M;6Q55`D``S5_P4XU?\%.=7@+``$$)0X```0Y`0``[%WI<^,VEO^>JOP/&&U/ M.E-E23QTNMT]Y:NWO-.Q>VQG9_:3"R(A"=,4H?#PD;]^'T!2HB3*(BE*)F4D MZ;1$`7@_/+P+!Q]._OX\L=`C<5S*[,\UM:'4$+$-9E)[]+GFNW7L&I36_O[E MYY]._E*O__OL]ALRF>%/B.TAPR'8(R9ZHMX8G3O,=8?4(6CP@F[I(_'0'1MZ M3QB>A.VC5D-KJ&JWH:"QYTV/F\VGIZ>&P\NZ8=&&P2;U>DCM#+O0.M039*'J M[)?SD#*SCY&J-N$_35%5I&K'+>U8T]'WWX*BSP/'0M!#V_U`+"K^O%+^21>EU7Z_WQ2_1D4'E!D+)?D# M*$`-S#LN.J'T=24J3UW6TM3N:]B#$E$%D]!985'0)49CQ!Z;\(-HO:ZH=5V= M08YF2SS673J86!R2>C1TR_%SC7*Q'O&L\NV8--8.&N*@P MVR//((S$\$`&A5S`+T;XF)J?:Z?NP\WP0=4>=/4!@/4#%%`(A)QZ+^$W^$Y- M_F1(B8,$.K+0M8C7YU?_J'U1X)^>IK74WDES7BUJN+G0\LF4.)29,3J"'=X7 M#J:N:L#.DV;T+&HA5N>D&?9FM6L7OH-YMQ^Z#[QOJOIPSQ[Z#[HBOKQY1Z%+ MCG&+10'HOH6 MS6R/6@G;H^[>]BQSI.3^*0U'CBKWDRN+YJ](#:;4'M=PR*` M/';'$+F[ZUI>;>*D&>M!4"BIP]JLPYO)K6]EI9&US(BW`2-R[T.@N3PD\/S2 M(F+VL_0+#T*/3PV#^;;GWA*#T$<\L,BI;9Y:%GOBT>U7YEPP?^`-?2LJ>`\R M<&8QXP<*!>*6![2;M.(7R_LT1:[W8H'@\UIU;-$1S(7^X[L@WR^?T`0[(PH/ M%&H'?Z;>)S0$$O4AGE#KY1A]O*<3XJ)K\H1NV03;'X\^NB"@PX]A.9?^26!R MI4'%&C(L[,(4ZC>773-G@JW:+R/O$T'TU7O]AXHF:U\PCJ(-^ MP9/II__J::KZ"44,07/6(6R;:,8\0.6@B'VSXIQTD].+<#1GB)I3_NGGGW[^ M:3.[Q$-J<_,`/&NTJ;T_%L8Y9Q'/(T[=G6(#)N#'`4V#6)`8+I.88^=`3T!2;A+_-OA_#Y-T'UJX.R:8Q7*1KBRYL;F4% MFC-6)&&==?&>0ZBA@/CGF@(EB&6%=F;V?X!?H MG0CZ.-1^56\(1D9L\\RH1-A`?<`\$"@Q8)]0]#"`W&ZT..0G:GKC8Z3IK4:' M?X\*.0&)L-02Q5DICTV#QFOH40@0YRLG60L:_ES3(?A-%+I2RM*O``2LG`\C M;;I_6Z,_XI-GQD;&7!*JB.U/H#_L24(\=@]NS1D'TZ]T2Y$">'1?&!ZF\?%(-R![&]@`GJU=09;:M@[T+`+ M"&4"!5.%@BF;%2SXZ$B?N$^?>$8MBX>H:P/1K=UDDJI(W2VS[GY0M:.NHA^R M2WR[P=C*(4I=>NOARZY+ZI'2:TOO5TKO][L]*-[_[5;[WJTF=;M]Z9'>WB-) MZ=Z-=/KI2>[IYY MV(J=\W'EY*0YKS>NPL'M\RRALQYPHZ)%D_X M'&OD*,%4:^;<(SLW@_3JY@5`:FR[WL*5%KXIL2XM>.HO^+X=ZA+_R[*)? M;XG!'H$>I81,E5[E;1>#5M_(EG.'LACZ M#RE>WI5F7IKY"C`U9N:#C_R<(_]VTMPR3]QBLCF'\/6/F^&I\8=/7;$8OUYD#3$GPZ(;;)4ZE]M?`H4W[,(2`@)\V51N9MA\SZ2ET# M6_]'L',9)&O-1*8>97!^K<4YS8OPWH2@R'>1#?8K/',S$?VG'M!;V]HZ@AQ3 M=G+\_TD$9ZVMD@NPY&%H/'ONVA97"=Z_3+/1497Z/Q9YM8Q20_G&=N7]%"+ M*^+5]5?H<;O3[O>[[04TKY!;AO:56L0Y!^Z/F).-$W>``NJB6S)ECLBI&.8Z MC$-9:'Z9]BT941?X9GO7>))MH,^N;LZ_75U?G9^BJ^OS.,7%1L/$P<$M%K/H M[#M^XPRUT\L-8QY^7!.O$*:HO4XG$4X2J:U` MI8\G]59/RX_)G_@B&:=XFY<+ND/&Q';I(X$XATW(-^:Z4/UF>(^?M^*=UEX& MF85TT;A3LS>,%8N!;4;I5;]C:E[9YWA*O2#;:VZVMGI*M[4(,9E*7BBI.=7J M:[J:`\F$6]D_<6P6Y!`H#'9]1/D\TW6)]WH(D&UVV.HN&;94`(H#G7R-RT9S MW'I3T+FFNJU.MPRW![T**JM>@]?3EDQ/%D*IN]MK*\N6>2V=(ERH MUFOI2?22_=,&LJE[J6NM9<>]GFK"+/J<-F=O,Y.NM M]N)XYX>1JSL+"P7;=`18WM#?V)0N2 MO-WZ[K`I<8!'%L3_I[9Y"16FD]>58F/7^FK.KJU%D]P]B)$&_#H5L3`X:_LV M2`+/):%([]Y9LB[I010+/I^75Y--P+[!YUO8[FB%@`^C1/HG_W4R]3WB1/=R MSL]/%B=.M!C(WPBH]\W`HB.!IQ`7OSQE?YW4EK#2 MAP`MK6A4B6Y_NZ'MJZEXE^SIUQ2>.Z&MAK6K*FF@S:EM#RZ][='ZG>W`N6-P M9/PO[LP>L<4O1#GUSK'CO%![]+_8\I."HM@5K)L0MMK=9?ZEH%D,S`P.J*N"2)-P`08;"(;<"!;;PTK[UP:5Z,D>*NIP56KAZF&BP>JRK7S6E% ML"CA+-]@W6F=:AQ=O+'1;_@%M8/++8[$;5[176'B^A,(EZCM,7Y+F6^[!-PQ M,8]`9;A@B+O58-+`+RT++PU[HMX8?;\^1V?8_L&O$*,.WY*;T]`:Z,I&IU.' M6N)XY!+)9X^`Z@2WBHG:P;5N)A;']N$Q=9=)`CC>?$LTKS?0?#!^YS?9!=>I M!47QR"'B[`HSQ.]QJ,TM/9?$4S4@=6V M/^'7W/'"%@/.&S,]1`X98<>T8*+&*_DN'I%XE^\3.AM=!0W-;6H.*\J M!LL@#K]X#_&7(6PL[I6CT9&9V;5\_#,&1MAT`M!)`[0A>SO7G;G>_[,N& M3U?5O/#X9MDMH9.![[C\/,_E\Q2J%3G?[[?4I065=42WPI9+[C2]K>T!6\[3 M_+W>LM3MD'$9SU_T6EM@NR/.(^7W/Q?X8D9?5?H)B")2V6'DVV93-#5)HO+# MR"4[NMK2BX61[\"+TM*7#?MZ&!=D2!QQ`(8;++!5H02=$9L,:9%O\2S)[@;" MQ:',QKW>TBF=7#!O"IZOYV(:)%(3B`9CJ7JW>0!3(,#^!8T9*9DD!H&T09HL]^KSA`!>WPJ=IF3.MVT#+#2J]AR6*4$53LF%11W.JU MULI4(K6ML67P+,I:IJ6"!H&I0855A,^6>$.1O^\9.PI99%305M0EM)OI%XPX MH^?6E_;"LR/F+X_QYL,N]38@JD+RVH:7U13]3F^1&JY`:4*NE8!*>U= M`4HUB`D<4G;,H:R`%&TK0!?4\KT-QU$R2]$KD$)Z6X#:@21M#VH'TE08IXJ4 MJ%2@=K6K_::[M*FVKE_=VEW=R6TM;'1';$3`1R08N;J/5)VM[N)VN-/L:Y>F MJRGR]'`/0,543^RT&F(9&;EB4VS(@KUB;^P0(C8;;;[_"`6\L8N";>F$]#Z\ M(#>#P=8DMHS@=3.431X'+\BDCU1L%'`0-O$BH/@14TMDAO`8"A:^T5UL!Q9! M75[E2:1"`+8'L66Q1$`:^@C0>)XA`C5 M$3],'7#3XP>4?.(8A#A9'0B#X,41[OFXBO67"006LIM":IGX:D+[46?TH,)NA+FV MMXA42;3O]QQ.+4Q7^;D&,:9!+,N=8@/4:O8]3/8DOH=9G3J=3NVUY'>ZUNBU M"\I^I_;Z$-IN3O85T4Q*3A7"UMK:YF14ACB0E>:$87%R$V6F"FAO5$8E21D7 M;K,Y0N39`'<0\R`F]G".#)Q[S\#:ZC6Z68:[H"RL4;ZR?J_&%1&4`,9C37K$ M0Q"7>Q%(_!;$#Y<\?E@C&P?9^X50:1_Y"K5&?TL;EIBQL%L=`2WY!=[2[.Q% M\:[YK$5:G516)TV6X5YCWW%62'+;,"O#FQR[C\]+9(@ZW48__2`4:X7Z:GK# MLZ]DK=OH&U\"V3KB36)K(1XG74B0--*O"F%&QY,B@I"J6K2J%CB`!ZBS>TD@ MGDW[I`*52X'VZ^NJ%F?F\WOEUJ&RC,6A:M0;N:2W'L[=N*<4,S>EH7&>[7'B M%E#<=M[&$;S-L''*.1<=9GN6L1>&XP<3@EVKV.Y4:6<-Z10\'.K]>\SP)H^W M$(]T5]8DRL<'O=TKC[_F..48 M"JE$[TB)^IHF9V)O/!,[+(7;\QK(KJ\]O+1-FWGB986WN%!2AFU2`:0"2`60 M"K`P;'N1]D.3[W($J5+6*RKK#(6K4`L^J_D[`4R")5N7[I]*8U2 M&@]1&LL2"U1*V&00>CB")X/04@6AL=&:'U#G5S+%$B,EW`17->DO41"0=834 M]E&G5:(7$V7X(.4XIQRKW9:48RG'E9?C3JM]8'(L(^SW+=.MHWZ:%]%D\%ZB M,\U2_N5"FXPPI#1*:2R_-)9E]:U2PB:#TL,1/!DYEFK9]]6;,K+/;=(YGL,X,]C M@3HB?_CT$5N`?%W,?G#]7S>!8;[G>MCFX@"3&?N1.!X=6`&+O!<$O[QK#OFV M0PPVLJ&>R2=[4V*[V*,@2>29?\[QQO&.['$*Y:Z`14YP;66&FU7&NJT2W6&= M0F)D;"_UKHQPL^I=)\VUUU+OI-Y)O2M4[WK=$JW(%J1W<@U`ZF"5=+#;3>'[ M4JQ8J"TA$OM[)9RPXI M')4J(%5`JL"[5X&RG/.JEH17<>XCI;T\TIYBFB%/-;[QEI=XRYL^DNAL8[@3 M*(\XOOE,7NTU#?"G3 MA=IF/<6FG8SD95+6U!G,Y))F19U!58(:J0!2`:0"O&\%*,L:9Z7DNXK1OI3U MTLBZG`64:CW_(DC0&K\=3R[8R\"FRH&-E$8IC5(:RQX'5$K8JACS2L&3`6@% M`M#$`R7R@N8#6MO+*A'R@N;2+`I*U:F>ZAS:Z0*I.E)UY`7-[V;:(M6H\FJ4 M[>7AX".&8;XI%WD, M37W'&&.7H+;>.5(4A:?G0NUN\#DXH,]S>IU1=FY1FQKXHSN;?7G,^(&@P)08 M_'2_]7*$QMA$`T)X+BO#\DUBHJ'#)L@;$V1@R_"M(-,5M!C>_(8(=FR0?E=L M+<3G==`-1U2$GPF"Q][81<3F;=Z1J4?XN\M(5XZ0IJBJ@+WR&/Z_"`^[O,47 M]$2@?6Q94,VCT=L)#93(EXX^XTNWVR\17[RQ0_;#F`5)/6GZ;GV$\?3X,H3X MG3AW'!FW$6<6=/[+SS\A=#(K-AP"H9OAY3-PU!Z16^R1&_LQW+/ MW>/G,V*3(4<$QO1/8GX%^;Q\)HY!77(SO.,R':E'<6-4U]N+O2P:ZR(KOOX_ M>\_:I#:NY?>MVO^@ZNVMFZFB&8PQC]D[4T4ZR6QV\^B;SNS4?DH)6X!NC,WX M08?]]7N.)!L;W(T--FUH5SZD`5LZ.F])YP&2&K`/P-+6+9@*=\&\+TR*GC_G M2_]WS_73RQO[WSY/B_%<!U/T`$K]A;61RP1.3W M.\8@!>V>J4N`GKO"#A=UWK@8"%VQ43K M?M.U7"35>WJGFX9!#9M[LMS+S3O7>Q'A\`$$$M7)+4S(G1#,VV!H#!]"AO1:+C1Q;,7?AE!8\L2K9RNM9-JYP3 M+J-F^#M(N6C=D='@[P@WQ>AH#?X.5\:]_J!.Z!,#WE%N?6)!F;[X<$L%[\YV M%#0%#;7>/PP891"5]UDF?K31,!ND])1'P'60=NP-L[BS3+`.(N"P?R)L%0-+ MZXP.`LMCL,5YP^3_[YVQ:;HAR.<=7>.IUU>/6F6Z_3?::`?,'!"4#G5!W&IZ MA4!_82:#W3-6J2\1T=W!#IONG;]DB`LBN=_)B^5"$'LALSYP.N$V#SCSP4!] M#N;,4S;-F25^*Y71M5U%?Q1P)UQJ,<+=#'.(=(D+?<.FS/.8]86MF!.6JYVT M[H[->7KV,H$MB'9M']H+@IHFR-CW6:F;Q1MM'VJS`"@=Z((>\H[G6#K,U>@? M?==+R0M%->`7])(+(KX`^'<>6X*C'0F'[.UO\`P"J?%$%?>!] MJN>0-074F6&O'OGK&^Z;MNN'B9N=(@OX;?\];66WUI]<#U`57\Q.#KJA_>0& MC`R)N)K]MV%7T_Z#;%!$)(YVK[(GZ4OM?!?6IT)$R3?4]5V[HK\-6W\E<_5><\4K%XOQZ!8;#9+;M M+ZD)]BO^K.)QQ&<5B-,;C:Z2"0$E1/YWNYK\G!U7E!$4M%*HA*\V8?\CHT"$ MY!DPURL`*YB[H4\=R_^IS-A^K6WLI$Z7$1\VZ+>?B->%#<9SPGH)AK637^4%0Y:E;SW]6>1]F&OWL)^ MG`"]!0Y;4(Q[^\-GT]`F'_@T1V971JY>8YHK\Y$7KA>(KJ4[/O!C/F]^P:VJ MY$J]K7/5P=M;\GK"3/_&-IVNJE!CD')ZGXWE>![+D97#GCNX_C7(&M&O1R-11HC4",C M@/$ZL(SO?F,$ZF`$>L/&`#0&H#$`C0$XD0&($N3(!(:#S4!C!NI@!KHM+4^^ M?F,)&DM01TN@8R[_H#$'YV<./KG.#8;>L$"&WM"9QQCF+1U@%YZX)'R!(0'G M:HKTWJ@Q1(TA.D]#U$5#I#>&J`;,W=P\G[$1N.ZU=*/9D#1VH+E7O@3-7>D6 M8FR:X0)+JS&+4!F\)/)5F@W$R[0=K[HM?3@Z(*B\,1Z-\6B,1^V,1\T+!S=* MO*+@I%&_"4YJ='BCPU^\#F^.;IJD@4;C-AIW1^-&"XBZ,VA#TYLL?0:5F/;+;_&_:;X6A8_E%U>32)'Z:111SJH27A+JKE6LA^H)Q\XS`<< MUL[&''D/?G8UUD9/=."LTM'3:UYA[3@^^%]&/?+604R0-\Q4!VC_1S_%H<:WJTN2$,BIA*B:FM=F/Y;CA-OI/LLT^IZ`1 MW[J(+TAL]Q1YK$_)WHN5(T/O-6)T*6*D-V+T3&*DZX-&C"Y%C'J-&#V7&'5& MC1A=BA@9C1@]DQAI_4XC1I;Z@T8L MZQ)277W81IW/\L]5A/(FQ22D2/X9W9TG&\GM;0+W=->X3RQX^\.T0R1*'$Z4 M;!LW]K]]GG[3NM]T+5?[OFX/F])V'@P?SR(HGN[ZM-78OO# M[9Z?J7D.!Z)8NT)]NYGDL5`JQE;6'; M8&A&FEJ/MJ%]>LK\JQUV1OW",XX=ZSX`TSEW;?!C_+=_A3Q8'[5RD)WNZ#$X M,J<[&KC\O6F-SE;+W8-ANPT]#XO^'8,J;31\'%5J@@,`R,\RW=-HFO7%YZDO>(:;=B*+OW<8D)Y M]$=XT')1Q).TW25M/.[/O"'R.2SNLT,^4L^QI,Z:4"2V MQS+.!`O-XH<3'[9A`:>V#8/"%D\%$:O(8?BT]/B*!@Q^GC/;PB84SCUS+$J$ MV^((#4KM%OGPX9:\NHI_OOJI3?Z34>NOD'KHWF".(WG-;)NM0M8B?XY;B:$> MJ$\HS.2NN`KD,FWN<)/:)/``-B"10V>RMJWO3H,'ZC'RZO;KQ_N?\!`S%/JL M?20N8G#^YA,?+"Y#.![8Y&9"?6:UR.?IE)OLYA[8)2`X]V9J@AWE`^`0AL]P MYICH0DU=3X'O+IDT-3X@UW/#V1RCM)DGOA=F;DT>>#`G'[GIN;A"-1L)7->& ME?V)/P9S#.3>2'F+O.;NK4048PV^8J\N%FRX)0%A?F7H>>'P+FX1NK( M5O/D+H05`+7(."J%W"*6&'];E@!0>;`>/##FI$7+27+Y*_SI:G=@Y.^[!`SX M&%!TX4<2E`5+7YROD%:#.8E/N2%G,AO$G"8WOAPMX#)\9J[^3FX.<0R6ARY#. ML]?1%VV`QF(/Z*-"ENDE0IUE,19R3`:7I-F=PP/PNS$8M&!S2/PYJ'`A*[`# M7L#H/FYX6F1)/3R;#AFY[K1A0]`U"&@&^7@K$BTU9DL^">P:@/58@3)>,%#8 M*"WXY0H`GS&T7Z!'XT$(`XMDHY!<]]IZUS#ZH`UP!6`*_\E,J4\(;"*"&]P] MH"*C%E)*&!]A"H@K6?X=1VUUJY[Z!/KG3]?[CG_?TB4/X+=\<#13=#9'A'Z!W8'PO`3C)Y>.!S4N'P3&('# M]*$(JLZ&0#`#1:QRUT)(M"X!*@;S*,T(L2!(I;#S!@',BXYMWT>3K$07;N@$ M.ZMZ`%4(5L=FL3*%ASTFOW?<1Y;7!I9%;@N>0G-"#^.7%@PG:&2!JC8#<(D` M"S!\_&DZ95X+3*X-_A#N-#TJ&4I^L[29-0,N!I,'&$0:N$L!$3P168,6*(/O M3/SHSUV`SJ>@\V$:%Q?UP`$^2^QQA7X4#D"_-#.\C:;?Q\V-#(Y!NEZ9MS<*!M%CG:T@ICH(;P8V&W M%@AA$Q+/Q?DQ\AV-^35T*`@8/@L..GX+,'L2YO@9$&@6"1VH-WCVGBT#E=W4 MD2R-*:-H9Y_$7.*M`+2]`Y:!@H]"@]P(1']E+D;!E4RB<9!DJ56YH1>E"J?8 MJ,A*P3V)L9X@#4%M&=`?-Y*`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`FF76UC\!\[V"@M8,!TQ@8+M-\=[)9XC#RK112YF%8M@@()PPS M65*-H&8AMS`G.$HE$$E3[\;WK\GX_I9TAYV60+/(6KAG,Y'"\X4ML:.4,Y,4 M$+^]NDJ^="531..O=",YSJ:JET]N-KT2\8W/F,&4/2R,@?FTKS>9.C1(+&@K MDS!:32*X?I/*A>G/Z>1Q7^1`WK..4@2-3%% M3+"\D*28OX8=HQ6S*'D=^MS!%'?@J`EW$K<6XO%$?AJ)\/@S5J?W=8\;!86^QJ@JTR8<7. M].HJ*LE"R"@G^8"DBDXULE5+V3*& MC6R=KVPE:_PU`E9+`7O5,T8Y:C(T,E8_&;M515AA)V;+0^F9M#A7WT^=%"=N&>EI+[X]R4*F1N[K)7>X;]&3%951=;34 MWK",,@ITQNBZO*"4^-[0B^\-6[(*>1QVXECJBV3,B2B[+LH46RK0!+31G,/6 MUQ,Q>2;UO#5Z#B+0Q&^1ASDWYX0NEY[[@R_2<2A8)%BUYQ#ET&^P,CYQJ*AH M*\,$;8IJOFJ4JD/#2N2=@]CER?"[;C)$-&&>/C** M_=ED/6&!D^W(4'CUZJ=T1)[%D`E$$P$1)RH*6KO.S:9T<38_;$*J@#$G[HJ) M"L9@'$1A?!$BY0/61:,`6'CHN!,,'!7,PIUEB"U4KCZP%;.)KKZX^BD)S62= M[%,4EYU?P9QN&!><5U7PL7`"/&ROL30U?H=BAFT!1",;E`;*?6IOD6QZ-NW2.J-*VZ6] MN#C[6B[NLY,H:Z^)3@V=4:II5JSK<_1!^^J&7L!L&[Q81NZCSE\MK#'0QL9G MB9\QECWUN*I.[V^:EX&`VZHA2=09R\&2[&@8XW!U:1G]<(E1ZSM1[:J#RG). M`44F`WA,V/ZVY;(T`X6Y37!U5#_?EN MFYJDN:/97:Y4WQ3L<$+7)%RJ=EWH>:MN7]=ZN[L]E<`()A9@_XY-@Q.L+I]J M:R)U;+ATH\K[B+ZHC0",R>`Q9^-C1+W+HB>`+*@603N"4G=%R(92Q:+2%JA) M;R8Z9XD>8)@6>>.&V/DK@5&P>V]`VVW3M\36U*)A"??\((6P:#C1<41K MP3Y8K#:)`7P1^R8)DPJ/[6(DW=+D5N)&](YM;U$=K"PL6>`'AY>=66:J;6NB MM4G2O0'#(1:@."WAELEP9-5H!4`28"'C"!&,@I,)37IMD2E>1[U8-@8[T=4" M#/I.S5YM>S$6QTX[#-&2[."VVQ7FZ;7"7!DM6V+4QZ@`UI7];90UC8TP+M&) M4@1B-#VR+#&D([HE,>!6E8R"%)$-'K87N=/XYEK3>@+1".!UMV>(#P5Z>FCB M3H4BJ(4")D0H>BIO)IXU0HT<+PW M]$HN,L>&K,JF$'4QTA4WBCCWC456<@2(CNR%`@IG3D&TA35\Q.U?R$V&V(TF M-$0H^I*E_?DF[>$BTAXN]B#X7<("!QG.;5WN8)H;SZW`[FYKT!N4=^W9R-UI MY>YMY*O'3E(C:+44-'W4;Z3L7*7L3FVS4IMCI]PKRXH:&140U9*JS;](\7X5 MGY,T(;!G*>)I!S8^.-.U36^FHR2]LE8[C8"?*#1P.&PL^-F*]ZZ?W!CO1K8C MV9:GUTT`XOG)]6/G3O&]PN5&%98@Y9<;3+BY_"LIBO#O/X?^S8S2Y2\?Y^__>N_$/+W:(Q/++BE_OQ.]89_ MO?[#9]9[YYV\H'-F8[S_DI<$>$<(@WQATU^OWH3R?O";!O_0+?WVU?TV^J9W MQ(+G1KW[K&AK@8[.0_$!4`KR6!%[;![RF&54" M_]Y9,3^H"O,W_`Z&(+RV;NC7J`^)$S:._Z#6;*@Q5B%HFEE\DQW2Y\4AZ;:Y13# M^Z!7[FIB6;[%*!;P+M[*P)6&YS`&ZPZ-BN`YB*>Z1G=0+7Z*P=,; M%"67-Z,._S\QY2WL@?`P3'P`AKN3(5'BX^?INR@*\3X.0MQLF.+]4A'<_E;\ M&*.DV+'=+V1B4_-[CA"Z3V[`B$9NR'N,Y.(+$J.,;'"VNZ_= MJGY9XS`[7@*2L&F5B#1.)AHG9M_D#E=8>0RPQ!TMJ2>3!X*,5"=!W-Q@!Y:/&AAK'XJ MXMX+[3A=:!:J*C)1L/,],T-/%7[&,H0_9&RD"`OGOB$=ZM"W[F#G0-H'.\\ M==T`^UD0:W.J0APA=/8ZM;S,]/S0\_!YF8?:(@X0R_>IMQ:4I#+* M>!,&K\03)"JT`9*(VER9'1G]?^X)HH7I*QS(XQ;28SNR>8Q`5BP3S/]>+\M+^D)<1)\,?_"AVV68>Z0.K(3%[, M1%69XRH'+D[%2F3-;K4;1\MYK1DR&>;5]4BFR#A,RAW](=O5A+#$:.P,J.(K MK0S02@2EG4KLR4ADQOS=C7*2N?0H%I@6CUE_:/^XU&9[])W01,XZ4CY_Q?Z( M4C>$3J>"?FF8YA03_E?<9];CR4P1\R20F)5NU"$J2P-^1*/(,QW'\RF?4(8_ M_4[Y&(#06[`BS#'7+]N;WN##5/B($^1V\AN![Q@L.2EQ7+9'@;WLU@@B^P^3 M%#TT),J42Y MQ0J%(R+R@&42(>8C@T\;516P6/0)`$)-I!8IK2F^*W18A-D8@Q$`8G_@H?*; MVE+=M38W;BO9[UNU_X%WXJIUJF1'I-YYW"I/ M)MG*K9L9U]BY6_O)15&0S1N)5/@8C_?7;P,@)>I-4:0$B.=#*AZ)(AIHG.X& M#KHATCUY2.9[2=!#$5H\C64O9)T0_G7`7JB?W*DG1O2:O%?X;U,&NAU2YZ'+2,/M%KS7'%IGS*L\V=1@X.\B*"WTITHZ9S$K@M_4*RTY"5WO#;4FD;`T![O0\ MT8-Y'9_,U].5#B\VILAF93K,O5/HDDYI(9,6`R@\`A0(+#HUSRU.ZT5LD6Y& M/MAQ9^F&%/->N*.7@4&TY6';]'M?_#9Z]8V0 M\PO&&U^7G@SE%)-+I4P1'+E#M'V$2)[,`">F>][X=?@MK5R9$!EZH6+ M.=^;X88^,Y7F56Z6/.%>9-%%Z1HVS>WEI?U^ M=[!6+F;%/I94*D;-D_B<\@Z,[S9VI%S;NE@L'FY@;5ZE)1@R M27\C*GWR_1UN]!C%*//BA@),-"/<0%S-?;BA2ZILA2$OVYEMDT`>\3UI>F:^ MZ\J1)2`B:SV)<%6:`KXKPS%$Z'$#)Y[RTG`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`FG+4:PICF+;AV5,2XNG#OYY^[_1[F4[8.Q.[\Z5R M6\;\S*+Y@[$T6_BAG."9E97-?:H!*S88&\X]#/68(`=U\S2D)VG M*9#[>Y[X0Y&P&?IQX,AC5O-#8/-3G:-87L6V2$:1YS@CW__3L),#4\&&Z21O M[KKMS6\O.^0(?D(#;WRON$B+;YB+F)&WTNUTT]O!V'0V\=\8,T+&HM$C7#S M(7?=9XUN-O.@SJTF\HG+VZYZIDQ(7*0A9V><+P[,\"^WI(GPWUR9]`8YPQ;W MR&4OB%NN@$"!8,"W59(UGGB-6.49Z8(RLQ6_.&J0.6#P/DF6>N#)4K?4OM7, M]B'V1+/K75G<>"H>&+ZM9;4N.K7HR1P^^UZ?GFN?EUS8`3%Q<&9)&G&?P9?D MP%%F'/GE>,G[)C)7:UZ`@/0;)>].+Z%SYUD([?U'+HK$3#NBKI^E&RTS-.V9 M@Y4X<+V]HA(5BDS-9KMYL$3WZ0=[P@13R&\]S%#^'UF4[F"56C1S>3ARM%ZNN(<-XF"EX%TA M<<-DX!^26X17]\Z.&]%VUVJO"[FAS2,$*P:[SJ`[J%BP8@>*!MW.B4;LT%*J M7:M50#`FJGQ0,/&[N-">_D[CO/*F6;??74'NUE:/DZ[8#I^HLG@"Z8IY@9;5 M/N78'5HYLV\6DX[SA._YA=]\B4/?RZ/WYOOZE6AN#8I>TM;1+^K"4 MH9BH2K-=4NS_;+XJ.XRG)"4]'B;U\L2:?UX:UD[;QKO-&_[6VYR.]4-@)9YF^.6J%30*N\0,KOI8.W` MDKR?_G2W",GVWFV#AOA+C?O>!NW;P?D4N7+EFVGU^`$SCA'Z,L>588KI%;*6 M(.NVB&[K>8#!)O^4U`P2?GUO")Q,';SJ@V[SM*X+N'+?@`MTKZNNT;KMJJ*^G.+3K%VUEUW[B))U+*K9% M_,6W^9&.0Y!*30E@&0M MD;S[^$^5L78M@%SVP>KJ8;SSO`^.]R@*X]WG?&I\K*<<&',NWH^UBJQWGXVI M\5&8Z?(#932&V[#V;4^!Q&.1"^_J`[7?3ZMJWH\+2==60%(E5;742"]`D`!4`WIQP)E([1%:*MA M-@%3P/3RN46E=*6HI$<9DQMUS<@I.EQ,8C9: MS8&RMN2D-.MJ)*JT+3E*Z^U&LZ6NTA&':N5`3LJCKN[GY*!2-<5H#P`%0/4C M2%L%.M-_HM#K[00HZ5'\Z5%;Q\F?R'DGVE06.N`A661,-)K02S%O='("' M5U9,Y:IZ9="@M=H7!3ZUPB=8T&H.$UD6(`J(@@%5$YX*^T_PBCJ!$[RB/KH" MS58W6XI`1RM\@F(#/H%/=?$)ANUL6P6@U_2GUSZS,`I0\@,?*J*3]!KE0#TNM,YO@8],`J,@E^KFP,%OZ83 M.,&OZ:,K\&MULZ4(=+3")_@UX!/X5!>?X-?.MU<`@DU_@DWFKSF^%[HT#C9/ M8Z/?!(;M_!6[H2O^K:RQ!M=6"?I;G::R*H=_ULT_@VQ#_`Q\JHI/D&W5'%!3 MNG@60*H52,&VU;D0G\*^'KR@3F8$O&"=S`TPH M\`E\*HQ/,*%GPB=HT$NA045N8;C*?X:WMZ!`:T:!=GK(-X1C!@6J+D(1.`.? MH$`5!JC5:'?A1`%24*"*`E1A#PIB42=P@EC41U>@V>IF2Q'H:(5/T&S`)_"I M+CY!LYUQLP!4VZ50;4.;WY+G^-,9\T(;:88UY-C@D^&3P;`!G\#GI>,3#%M% M28;-/C+U`5(P;(H"5&$/"H9-)W""8=-'5V#8ZF9+$>AHA4\P;,`G\*DN/L&P MG7&S``R;_@S;?1PX+W;(#']L1`&SPSAXHS=QVDU9(PV.K9JJ'RUU*W[`+^OF ME\&R(6X&/E7%)U@V`!0`51>@8-BJJ&K753C`!4FF39_)FI' M@G&K&>,&%PT7#;X-^`0^+QV?X-LJ`6B["X0"H2#<<.'5Q3IZ\((ZF1'P@OKH M"KQ@W6PI0C*M\`E>$/@$/M7%)WC!<^UI@!74GQ7\Y:_8C=X,>_3O.(RFC%XS M#OPI_2Q@U%/#B8.`>#(`0^@4]5\0F"$``% M0-4%*/A!\(-*FA'P@SJ9$?"#^N@*_&#=;"E",JWP"7ZPDKRD3EOA,@F`J%80 M!45X/HB")-2?)/S((L/U''_*P/V!^U-$X7#"NCEA<'_`)_"I*C[!_0&@`*BZ M``7W5RMP@E'3"9Q@U/31%1BU2FRIU>AU6NK:4P0[6F$4K%K-XAW@4RM\@E([ MHP\%IZ8_I_;>GMB>PPP[,CXPATV'+#!:9L.PFF;S$EBV5]<;^:\U85<]%>E<5%Z(T=)XY*?9ZS*N*A- M.%[H[GA^RK+*6%!IN!YGK+N-W@#;+@@%S\5B5KGM8&/C2A@=A@';_0F M3MPI:Z3!TE5#S)N='O(`X)G!U-5/74"75NH"SX:%*0"J,$#!L55R<+2M<'P* MGDTG@()GJY/W!,]6,X4C7-+*&H-G`SZ!3X7Q"9[MC"L:\&SZ\VR__!6[T9MA MC_X=A]&4T6O&@3^EGP6,>FHX<1`PSWDSHL#VP@G2Y.I(P,%=PUV#?`,^@<]+ MQR?H.P`4`%47H*#O\NI*44DOU8R`9-3)C(!DA!E1T8R`#JV9PA%^:N4W0(=6 M@L\V;@H"0,&'Z@U0D*'ZDZ$?662XGN-/V?$$**K*6 M<`735U&!M&ZKI;[V$5OI::S!_]757@.QFB(6A.`9_2PX0?TYP??VQ/8<9MB1 M\WR$C>,Z6KEIY$-J!=(KG*<#0,'_ M*8W00<-JF8`I8`K.#_E,QQF3ZZM^LXD"K#5C)I$;>6Y=*2KIF;?BD1NIE<*O M^HVVU5%6ZPA$M7(>($BK`6D7E\P#H2!$%49HI]L86+B;41=*5$EL@K/4RI3" M\VFE+I"-6JD+Z-)*76`*]=(7X*65NL#PZ:,K$%Y:J0N$ESZZ`@FDE;H09&BE M+K`W6JD+Z-)*76!>BJDKPYC(/^WAA.WM#;_.S1V__6"(#UUOQ+PH4=)J#X6D MQW>QTPP/(Y),[Y7MZ=Z^?9ZW&1HD(+TU M>EDT/[7?C"&C_XT8?1[X\?.+X<^8QQ7V)XN,Q6^I6[/`_6)';/)F>.S9CUSZ M>R0OZ;,=?DE?R#MM.PZA1Z2OO;K1BV'/9A/7X?/'&#-JWIX8(7/BP(U<>NO$ M?@T;O/[E).:P,C['])S9'-Z8_=OL/TB0B)YVIVYDRZ9H4*,7-]PPIMGW#>.( M@!O)7W)I_8;H/\TOCX:"%)O^6GX>T1SDG_*_%V\.&\F@N0[)/+/=D6%[(_'9 M%W\2RY^$+W;`LO*,;HU'^4HNR?I+Y^]@7VG\#"\6.E^\B?Y:FCV1SU4U?SL- M[V3"/QFQB`74!GTT?!,O'+FA$S!Q;R*]A$]#ZJ_]S,1=BXM)$,8S%GQQP^0Y M_I%-PQ:)9MTH8BS]^3"%P2B%04-(+T08,9HP(R.>^?-IX_@>O4?HB3_FTZL# M8VR+7\I122=@V@D.'NI`'(JQXL"QPQ>NY!?^`OZ?^."9D=K$O!-(H:D:R/EP M:Q"(?[=I;`RS+1,E&\8KC:U'@T./NQX-G\UG4^?&-![$@"Z@8=P]!TP.CYBT MHL^!_R=)'?K\-2^V5)4]="?\[DIZ66;B+12V!OD1S?2D1V%$W>#C*,R23S.3 MI'?]T%,_,DQR%5+D'>]F/YM1S0R;V+2;C`3.4Y,JF.Q M]]HQ/D1C?S+Q7_EX"H?$A^R+.V+<[HRYIQ,S/F#\RE#^C"^&/:.G541Q6RU0 M_T+:3TVP'.KUO-OO]PRP%.FH^";YAKS7Q)Z%-!3I7\4&OEDPR%F/(!YYW]XE M/Z%(E)Y@DTDXLQT:Z)_>->6_D]B(_SM[UB(=DQ>61%]\IVX^"8ZI4[#YD<.# M^DYK%TVY)/?2>.X4,7G);AGW;%=9S1Q+--ZE$R,X#2AYTSJ4I.CV=BW;SJC@ M07._?AWAP\ZD8=GX@4%V>9X?TZ)V1#-/Q.D:3+;.+O[ZK),MQT[FA4RVNQDM4KZZM#9AQ@<>S0?& MO^Q)S#(3+WJA==SOM.K[7UHYOV>9B?C'?*F>>])M..N\&G\W;TVN&OT"<"EX MWA5-30+OXZ;G/V*R;:8APO=O^I9I_F"(CUJF7/2J;^7R!64GG#IY@K%DW_\L M4Z=`^L7FN6-U&U:SB1F"&;)MAERU;WM]]2=(OJC\A!,D5S1^$3-$%QN2+Y8^ MZ13)?QI`[RER939:9J_1:?80_2+Z+37ZO8N?XS!:B7^3#[,1\)`_+`FVX7R: M*6VO$/.0F=6E5;P&;@T3Y(RA_:]R%E]\2.$O M?\5N]/;1C]@'-W0F?A@'[)$Z^'Y"S_S]/__#,'Y,?_88,)N^?A,_3TX<\PQ2 M>OHS&__T[BY\^C1^,JVGEOG$\\W?&;'GRJ_^H#],ZYTQ8HX[M2?4M]\^_OKN M[ZUVL[D0:\/[BP@P>&HU>?OF_O;-+CW6*BJ!/'U]R`AD!;AIB?:W#H!X>X'6 MMW9_M?%^LWE0Z_\C4,E&2=Z,S'KX-/[@3F+Z5([6IS@2N_;FDNR>*&*=.K[4L[('"5-"37M&>#+J*]231B9GMR6[PR+G;,3N* M]:17L">M?JORGJS]ZKT=NDZI*&D/.OT\_=@L2NF]*(H0L]=6J!<%T='IMG.A MX[2Z*-"+7'9W5R_^=G/SJ^]''H48Q@,3Y5UN;NBK'[_[.@PF],?_`U!+`P04 M````"`!A?FX_&YBZ>VD*``"`F```%0`<`&)I;V,M,C`Q,3`Y,S!?8V%L+GAM M;%54"0`#-7_!3C5_P4YU>`L``00E#@``!#D!``#M76USXC@2_GY5]Q]\[&?" M6S*S226W19AD*U5DH4CV:K]-";L!W1B+D^P$]M>?)&PP8-FRF0R6F:I4)8%N M64\_K9;4>O'M;\NY:[T!99AX=[761;-F@6<3!WO3NUK`ZHC9&-=^^_<__W'[ MKWK]K_M1WW*('#Y]VCQ@OG>O)QW+5S3>] M\,G$N[%:K0;_:3=;+:O5OKELWW1^M8;/&]%GCF6"-61=['T;\R=:W"(>NZO% MJK@<4_>"T"G7;'8:D6!M+7FS9'A'^KT3R;8:?SWW7^P9S%$=>\Q'GKW5$L4D MZ;6NKZ\;\ELNRO`-D_I]8B-?NJ+C\;$9A>4"+_H M$8\1%SN"H7OD"M`O,^`,+:1(+\A1!HZ934^I,*;#]E@ M\L0;PAR.K'52@1]?]1YBLT>7O!]K`XXFT^Q+Y["`T>S:=6M37'\[WB)5EBD%98I MZ\UK[A)[IWA7Q`Q"=[D((*7 M\..O7<9B:%PT!E=V%SM?-DY6L5Y`*;=;:OU"F:^?.I=7GSZUVJVKS^W+R^O. M53M6\Y@S=.DN"$3MJ'S^YX%_[$;>4*+!@OEKE)7IY/:;$X<1@?O)\Y$WQ;P;VCCIP])V`Y$>^IT0YQV[KH)8'563 M""Z,QX@(G4&FB83ID%+N<)K41_Q!/#MWS[E5,HG``DA"6J]*36ML9)?)9J*L M223J`PBY^U1J[OH8C;&+?0R,=_(O/K&_S8C+*\Y$A^^O%#1FJYT83':]R^=T MNES$W3$+D!&9DQB(]%G4H6"I6=2<.FFB,H+**-\S1"N1[-%+?^T*EYK28MDO M#8!&L"L[/^W6JI"N$+]Y$!HQ/XZ&J"-X`R_(:+[)PA6B-P=`(R;%/;3`/G+[ M@!@,QBZ>2LMEM.)TI0JQ70#H!\^Z#[<9B$^^AC6*@*X>">W:?(3(L'C\`Z+> M(-AG4U^Q`HP>"=:(2;?"6S,GX)EZI>;_N*:L-V'_J!Y:T9K[Q)N^`IWG;\YZ MFB;S>2Q,(WKE6%HP9ID\>=%$-9-Y/PJC$:GP_9F#7N*TLD3G1&=$#ZV=3#T4 M+#6EVKE)35Q&3(R'-`Q%$E3:AKX$R?+1J4E-TK8`/71&I+-Z9#XG7B:C^V(5 MHE,+FA$-])7RP7Y`5YEL'@I6B$]-<)GCXGH9*.TZ#EY7;(BP\^2%LSK58D*R M=(7(S8/0B$'P"'R$/7#$%`Y[4]:U[6`NZ`"'C_RQC56#X6S%"M%>$*P18^08 M%CD%2#C'U"=,;)093/@D4+V.F*>4"OG&]T!><)_*;6/O8-G'G#9+.FX8YT1Y MY*R=?N1L6ZXUF%AAR2=H`9R:+4\*_]Z3.HCR9SSE&)4M<7[R$W!VX2/O8#W*X,%T'6:_!XFA,(&.;!G[,DZ M/WD^4&!B._AN*>N8]0S^C/!OWKB(;%FIWO%#:F"LQYW..D;,]D)C>-/,V)D@ M63ZG.#7G"0E93;/ER_-T3C7/D/LW5"X2?5T^O]!E(6G2D(+)B.3<"W*!A3!> M@+YA&YCZV)5"NGR4IA*3D$//@`Y^.`,CGV#H$IV^6AJ/&$:H,RJQ_N M$>:+E:%PF)S9&^_+EX_7XK$W'\A,GDLQ:^C."?7QW])H@XGB>Q#5'TRB+D\<@0B-I%QI5/&\+E!N@Z<^QAY@NSO&4TX`RM'7-<58'N(H"-6)D;`8<2V'Y`A7%FB$Y3 M\B>'HM5C6ANE$>>^7\#E94ZY&9X1_0;"+NDM6ZU0/:IS8@T)_UQJPKY;)=O''^B!'J$(#U$[$G]=!4=5\DV6<[->AL7.<$& MC=B-REI[-#IY]FB(PJUUZ:6YXW4(W.["(\2^2_@"Z]^JJ4^N(D[1SA\F$[#Y M].5A:<^0-X41M__`2ZZW`F2>(LH7(8JP'&_/1Z,W(N\GKG;D6(:4O&'>K.]7 M?S*1UGS$'O)L,7"R^10H[1H>_0*JYR)'8C/A(Y@$5`>M`6ZU--ZJ3IGX#_Y\9NQPAGA>B7A0MWFQMN! MUT\9U67JG9%/Y+.!&:>0N)5L`$=.]N)A+PJ&CLHOLO3.P2\*V<"(]1&Q,4NZ M]AC9WUXIXAVG+>K);1BA3MFJEJ%Y!JY1U`I&+)XHK+7.#QTQ04HHH'RN\D$3 M)%WL1BR5'W28RNOV=4<=R@+*YR!'$JPQ_,AG##/F*N%I7S$7$S.UP`<:O8\R M.ABLW'.AH7H&;E+8#$;D7!3FVJR%%NUS$@HHGZ]\4)^CB_TT]T!V;0XHMK1OQ(Z!<2C/U)X$;73JMGIDJ5"GM!8?A& MA/_HJKQ\![4SM,[`&XI8P(@IQA=84+"Q-"C_VY6Q3^Q3C!U*4'I%MNI9N$9! M,QB1P-H?%CUY>V\K>*7(46_UT5$^`Q\YPA!&9++4^+9O=,WM(UO5L_:0##-D M[B-6[/LJ@8/0`)S=&T/E[40;(V:_J.G88L_5L8XUD2%[F?>1[[VI0]NI]O3. MTFMT;!"ZQ:^&N<6N[Z>>4=93/DL'T39$Z"77IO58QW=./_NAXM:(TFQ-PX)+ M^(;[*'PFONE>VX%T"CM+7RILF,BM=)?U3A2-`9>D(TW(K?<.=GDO;6J M;4&)PF?`=@[@$>UY,Z^G.`IU>!.OYJ&HRUR'HN*/.>$UM@EP,RYM3M7X&8F+ M+8-GLU`LSI8ZS*INOGXDE-?26[$T%[%-AGRX8/\+Z3'^6^P/K89&6LH$OS\ M"]^G>!SX,H]+ABCK]4P_J@[&.][IK55P33>I([EM"'QCWH'Q?_X/4$L#!!0` M```(`&%^;C]\J2:TR"0``$T=`@`5`!P`8FEO8RTR,#$Q,#DS,%]L86(N>&UL M550)``,U?\%.-7_!3G5X"P`!!"4.```$.0$``.5=>V_<.)+__X#[#KSL`9L` M[=A.9G*7W,P>.G8\9ZR3]MF>?6!Q&*@EMJT=M=0KJ1U[/OV1%"51+5(D]2KF M#IA!VMU5I?I15<7BJ_C#?SYM(_2(TRQ,XA]?G+X^>8%P["=!&-__^&*?'7F9 M'X8O_O,/__Q//_S+T=%?/MY7UZ^F^O3]!#GN\^'!]__?KU=4II,T[ZVD^V M1T?\:1^]C$@G?.RQA+7ZY8P_.8D_H-/38_+?FY/34W3ZYL-W;SZ\_7=T_;DB M_4RP;$(#VBB,?UV3)R+2(G'VXPM!Q:=U&KU.TGO">?+VN"1\45!^>,K"!O77 MMR7MZ?%?/E_=^@]XZQV%<99[L5]S43$ROM/W[]\?LU$:19^R!C_5>)[.7M' M6KV0DH+^=522'=&OCD[?'+T]??V4!2](&R#T0YI$^`9O$%/@0_Z\PS^^R,+M M+J**L^\>4KR1:Q&EZ3'E/X[Q/7T]]`GOZ1-.W]$G_(Y_?>6M!D'G^(\S)\OXTV2;IF1 M+==9GGI^7@IBZA>2#/F.*Q4IZS)MZNFE?BF:?-3`YA3'?D*\9YRR#*'M2WW8N-"/QA'#2>(WCHY]O M7_RA9$5>'*""&0G.2ZTQ@L:&]+2%I*)BW`\#,O&R]8,$.G\ M[CUOQWJ+8QSE6?D-.'_'O_[EEKQ,3)6\\]9U(.(-H"*:UU&Z5:5> M(:>8Q`5D=M+U^)915$3H;XS,A7=/@CR^)!\S'3"!$-@&6BI+[:"B@K.%`Q6Z M[(&2(D8[V"@R[+^^3QZ/`QP6]D`^')H!^:J*;G=$[`&2]L_SOG*5>O1%'_XV MV^N5/U@=^2G-7.]R29X8T*=>1-Z]1.^#W^=_FU(%R]?9^''6]REY=]^6?$`%,ONHP#_/1'_*P$U**#>OT*A9OO_X`( MP`"D&J@L@!,C1HT(^5PV<+9/TT:\4N>,:M+Y+4&G=FD,*KI9[:%;B99);6Y"&,O]D,R?$JRL&--SHX5>*;9`)9T[KF##VXV6JM4N_]* MXBR)PH!M7?CH170[`+$_C//,B06L9981532&=D@$8U)R547C:5+,;B:RQ[>G M0AG1U.NQ.4XS?#58U]O;3W>W<,9YYF4/RSB@_WSZQSY\]"+B@]DR/_/2])E$ M[3]YT5ZUZ&K("V/*5L!$"S=BG-WP+;1J!TC"Q#8ML`\"^P)Y.2HE("9B$E?9 ME;/87>XR"D*??L`U.P6(R??)!A5*3(B/=&%I#H)PC>_#.*;O<%J)\0$G/`"2I@"3&$P'0^?T4KP+PG6XQR[PD#!>I)7@ST8,T@97,B.=.F8;`)ETEW?=`I`PU'#!1E M-JG)C>8<:R0DO*C/?6+GY(D^!I&J@8Q8X6)W3:PQ!ANPC=[+#=7JF6!-:N8 MS:*7%3\J!;R"B0RC8,L`P\(\+P<\3FAB`;2_=_DTF-]J7G_Y,UQ69:B@2WF2 ML!D]!<2%*SGHT4F=Z:DVU!TL](UAQ,3TX?J6$RKU:SN MS&^:PZFG.-V9X!SE98"[O+"DIO5T!2V,@WBMPRC,0YPM MXX"=)WI(HH!$!#I[EC]K3E*8L\/8JBT\T9I->6>W=SO%6H8GL%?3I/DS^`F. MH:@NEQ\OKR[O+C_=HN67$L/N]96K+MOEVZ0$V]\K4T.]G913.[*CUT[W74$-NX=W6'.#)UPL M$Q1B4+>+*JD!1T)JY5MCH38IS&A(I8D>=VZRC6I9@*.F M$=X'N".7TU7JR*&G;&4JRZ;J6Q2@LU0RM103X9Q:F`7[J=[6E## MSD$.:VYP#SWS=B%%BKT,K]91>,_J7VMZ7!T3U,%G$RC-$\]='`!'G?7J2(Y< M,B;$N)#`!NS2_<#P'GCKY?NT&!4G&^1SB!&#F-3"^KB-XOH"_N2R%WV^2-*E M3\:Z12&.3UX:K_;2^PL,&0$N,+""5-U@8,0%$#!>8EQDW,8J1-(&1%XM-D/K\MH8'Z>Y%Y)_B6GB-/20EZ$`4YEA MS%;%$,G$1%[DW:>8%7?)7L][-<*0IBJ=L&)&FR1%`CNB_$=$P+R1931@40.8 M^+XP!9:T@8',`7?WP>X,>,W&N@X,.;BICBBWFZGF<&S,#%S.-H6-=$*F8;/'5,$& MOLNT$XYBGZF4!W*G:8="W=L;&PDL=.<\%)!ZMRG@EW[`[3_=V==KMXW1HYZ;UKD:1X??E3LUEGJ?A>I_3#50H3]"UQR;@H#=P#@2' M&2EZI*S_@;Q] M_I"DX6^$[.V"_$K_1QF[<66!XB3&*&0-4&SJJZ]@H=6G;XGWXNV:9*=O3Q:( MQAU&17XYQS[_X93]<`)67W.DMP^]IZB^2J?S%H46&="RCD+=QBK.`+=NS>+[[\O*3O" M-*4EX?G=N^\$6D<"]Q@6`1RR[U+L9?OT61NT980P85NMLABXVU2SAVZ5"NV) M"4[8,)%Q3?I]H6Z,[^FE85U&;:]U&1^(8_I)EB]*1WW`4?`!G;X[69R>ONUP M\;>+[TC,F,VMC;JN8>_.I6YK*!)'NJRQS?*[T\5)896?2>QY*$W.UB)G/+U: M;26X]L+@,N9;7Q3-I:0&.K_:K7SC`*N<=/X3K%UZM$^7U1L]*#G=J\$9X&+8 M6`A!W`>?(/ISBL_O MM_N()DOG>!/ZH6IAQH01)N::0Q+#KYYK]DALJE++WDI&5'*BEP(OXLS35((U MBM!3(W,IR;!NZ]VCM\ MC+<"N;-53-;-M*D\!(+%JE)/Z1 M[(0M=5WC])8N7BG:Q939A=VQ.FCJ#;,J3N`]M-UJZ;?P$7Z4I*B04"RZ(B(# M,2$N[-[L#3`K`%:[A5SQ+J9]MJQV+AFU0IO)!6]205%[T2$'L/?(U=%[3<&' M:D87/,4:#/>045`[X1FB*L9>,>&^WUX> M80BBZ0WAA"#L=N0/?A/@;#"P8'T8&CN#*$%*(;CYTX.<*\Q&3EWD$-ZB>$PL^D=C@R8>\-P;ZC<@M(Y M3E92.^()ZA&R@A3>`SI'9#+KG_1$K+WIF^COSIAXO.8''PZWH.C'PMTLCOBP M9A3<10_OS?I1AMRFG!C]3H'&I8'O-/@<&?/V!^?@:+=Q3K*`HX`MI73@2'=3 M:>69[H(,]E"WJ(/V/&U![,B1YAZ:NQ2/AF-Q)/;T`-((.G"!IM@ARV8T:`%R M3?U")35,P-$H+P8=!>GL@:=3#TD'%6=)%`9L+JQBRM!J4VYM5E+M;D:&.EY,!R%F2Y70_^R=^,;DFDS;@`[IGPA10X[H)'=/\MTZ8 M:=2^`*'D0XRQ."Q1WC4/71:\+RA*SI!@3@]8&ISJLMJ4&9%R+J])!#4S+U.U M.1^FOF/:7W2[0 MQ0`T*:6%T)B74E+//S6E444RN\,86'92L<#Z@3T&-MM#$6PK!&6F!31;->IK M`._3?L(Q27PC`F<9;,,XI,EN'CYJ>C8M%XQO&X(1'5S#,KN7&^G3LC'.Q6RL MR0?K[\/1>$TTL+X_U<$1TBRE666X5PU MHC1E!BKO9@6M4=7-B'/^8FX6:K6K.@G,-,$LV5'-CPH!0-6YQ@07UI@\QDZHM M->FYUO8&-C5T*JIJWE`-[);(BC6N?W#!3P'3+\N MTJJ#*E("FWM;::FAUV1P)GZH0X=Q-\K<`MNUA=KR^L-S[GU^)+T+7;4HE"8C M.$P:1[WY644.M?NY6_WF]F1TO$NZZGJ]?E8`/GRI M^^@+XG=G24RZXSWID7G7G,391[Q)4EZ'_\Y[PMGG,$[2,'\NL9#,M2FEJ-W[ M&>39FWD]H&G61X/=(AJ1FP2EQ8R;D1?/*K50+4>:,T4 M*:O5%^*1(']1)N],RP4)$7GJ)6D0QE[ZC"YSO*6G1HBU$>FD7:(BW9\R`]+' M/$<:GS=MD5FAO'V%S]P!E6#E$?XCCO%&>=F@DAHR4"F5;P>5%BE0`%#HH;(7 M0E[VP.@EYQAYM&R3D?5`0&P<[=+D,Z#BU:=E'=0%H5`%T@1@_C;C:JL]_*W'17 M7+W':@U-5\94YXFCM#QX[_=G'-X_D.1J^4B&&_?XRWZ[QNEJTRKYU.6_EC)@ M_+H74-'?K03,'@=Z:->RTE(&XD)0(86=QY(5YX8+':.B]3C:N$(K!A>@A6VH M]PD>D`[#ZGD8[7-E`5DEM1O)PX'R7>D#)P5/(!IZ&'5DG,.-)*);??ZKVXE$ M[S<`[KN*H,75,ZTJ:RW%J81"!]8@I5")<"6IZ-9O:#<$&DY&1MQ.+0(>@1S, M+69YK>`QJBK[M]J<>=G#191\U167Z6:!NCU<#Z-YC[B:'N!&<9TR-J4;J0C$ M9#A1OO$+SJE&UW2"/L#!Q^>?,WJ:J=JGM_3S\+&XKK?;[/H(`IN9[@GY8/K: M4@K$''4FDD-WV%ZDV=M43P,[\!WHG M`]$^(5L_BBZP50]#[<4X\O.W%I3@&C*M&C*NUMOH]_0OG[;B3FA%68A;,%*2 M+@M')`'#WCG>$4@AVW-$/D>8G?N,`_&$M>(EF+'"A"4;6&*8,>&;/6R8*]6> M^A)8R6BL9"XJ5`CL,&X\$K#BQ/'D:'0#[!E>$_@X^IQ?;FJW5T_+!14DC,`T MXT,G"T!H,-!'8F[\BMKY-O69AX0^@*[+?7%HDZ0H*.'5NUJA)MTF?#_@L:!J M](LD/4_VZWRSCY:^G^S5)Q:Z6:#N4-?#:%Z@KJ8'N#U=ITP[H8W(&)S>\L-\ MY2KQBF[F"GO$NFCF3'-4FE,_XI3F^B15_>@%I%-:0U4FZ0&2:AP0C5F^3H`\ ML[0;7\\\P=:K1K-E+BHS6E1B(Y M4-5,*]7IY5>H4-T7R&%/\XW2^@/ZMG68^,P+3]Z_/6$^2+_YA<2+%`NUQHJ! M-UU67^T/TU83AGE]T1P"]4<]]20^&23^GLZ3R$*;J4KMWJKD.9@R09BP'27[ M_/4D9BZ++^-@$*M^4;8CPC=OL)GN78">':-W`N)S7/PKS/2=>;N0Q!+]I7S& M`L!.F%E"/#AT9L@-<0[-2C7902/&B%Z6(EZ1H9\P<\W%@$];#T9Z]D#^HI>? MQ^+<BMPT@YSPRYOM;&7J;P9*R!PT=Z%,BXV62LKGBE&E:W/[;Y M'/!$E5*F/ECRHUH`X&'1ON!>EKROR*"2XR3@O!)<.A&X_G%E!FB0H>,ZQ3LO M#,IY,CXWMHR#5?Z`T\X:UGV%N1)>;*!W!QP320Z$(',U38,2EUA-J=*>DPF; MI"#VD`@U!G8">,*$(?;W*3UZRY,(5\+7_PWJ-&G;!7,[L2O#N@J89K4DX'0C.:K6,1VG,&(5=1HZ%8`N$BERJ"#AN!=AO M`95]^)S*&AT,DF6"?^T]T^3\+O4"^^%SD]F5(-D%S6P(+7(Z$"35:ED/H[D( M8I!4B"O1I!?`0`18C3=WA0C'7"W=DVZCGELK$[(J3@B_V32:E5B'W+-'IF@(P:Y1CN MIKC*U;@)6WRN^+T"4+=C'S`YX+E2C4Q=L]J8Q[E=\3LS4*)C57LD4SD2=R8` M^O2MWT`W.K#'=+ES'*D?_`;ZN]Y(JP%T1^_EQBAZBM<'/IXV/]2J:#4;`:Z? MSI8%''-NAT]CCW<*>\KIR#N#XI_#`1N=300K;@J$#SS@%&7:1R@/T2G(J0!D M`-D@$'5(<24@:56T#4R50)=.8H\&_K`\1%BA=:(\Q+7WS(^;\ZNJ"6(28?+G M:X*"WL5`;U_841)%0]D(`#H(90VQ<2S*F'O^0U*6JK6/%W(!]*`_%X%*&0O$ MI"R*:S%+05#KE\.A$J4>O*PX][7CS,6MF=-@,SX$]LTBT^4_`.8)/@#CVYW# MWXIC0GOR^F^33?[52_$R"(K-RHKF,F.%":$VL,3@:<(W>]@T5TK2F5>LJ.1% M)?,"5>PPH60D8!GG00%^Q%'"'`OZCGOS=&QP/N?^N&+8>,+A<<1XXP>G1OQV M2-F(?U^`DXX6G//"BS#V8G^$T7ZG(*>\T@"R@7=V2''%2[4JVGIK)?`;&.W; M@S\<[6\JM$Z,]F^]"+."&&O/__4N]>*,JI7$!#_![F,?(')D*4.?4V"$3_(R87".CF8:*%25QX5G.3'[9HMK'`1FG5M-! MB'D02M91>.\!CE?GQS5_A+A(TAN\XU-TJTUQE[&F/10\L)&A$X@L*D@9P")" MAS9J^Z*%Q&HN.K]:\$$'`BLP@O8YW<6R3Y]11DLLP3J]RQA,9[9'-2KPN>M/ MVUV4/&-\B]/'T,?R@E=WWA,OU'B#B_E"=D7[$T[]D+8!*]ZUVG5-=$_P'*#[ MT:9JL,;-:F,_9/X[V:9!T+Y+C#\'\0>ACBILWA/BCT/E\XH11OE$=O$/*T3' M'PH5\V=KO2*H6+FZ7M`+.EQ9?[$J2XK5BV4.'4(FH/I+;X9AQJ M;3;8S\F(\>U/`IIZ+="M MU3`O$WS.1X[P&J=A$AR>H%/N.K,1`;5_T1YF3;%N0&6LA! MDL.0H/G0"*!IGB!6?O++1F`?\,0A=\=4ORNKC!/J6=>OZ`>:_.UIU#+@*J)(==,X./CJK;#7%&]2&]KQ)9FQ"L M((]"Y8.Z.P=4$.5UI"K(RK#PNR)QQLWB2_O*N[E$J-M(9C9UXXZ%5Z[:4Y_T.X&NXB?,)! M40Z;[T(.3E4K4WTD`2W\]@?=6`&V%S/_4G!?'67VS,R9],]45N7L@K0%8O)X M_?3RK`#0@&`\Y,W+1/_<5>)8_9S-63;'>9V&,LUY12G&E^4AC-$!U7_H083#7J0_7N&6NIQ3]D(XE7MU=$Z)A758J>_XM;H/O<)VF'ITAVPYOAL M"W..(ADF?QJQ4<1L:02QL^=&H^EL%`X6ZGBP."R].&5A4-.49[K6N7:HD.:W M8@/@:T+F#<4N<:`Y';H.]QIBAM#:NF3 MW`4[?LBT:9-5QZVIH/Y_EF3Y:E,.5S_%>9@_"Z-=S>SP$('.>+UE$V@&+^U`B:ZJ!'C[-YHH57+W`K>(\:, M2F[48%\@)@#&OX9@D\,!F3R]P_Y#G$3)_6$YL@%RG)XL;0/N,4E:"W%](D3'!TH?V+JQR05XGBU\#Q-O?+-L_KQ\(,6UQH M+#>,%7S@U-&IVZ=FM';2+*!DKLQ&Z:1M(TA>/YD;#RMY46JPBVJ M.,6)#1);C`)AGL_9T70SAZ\ M]%Y[-WPW"TR$,($A>GL7_>R>JU>F94P-%L1YG.C:&IH1#[HIKN:25:_2=5_] M1#E@@):PE89I*`?68*V4U!@R[4"X,%6E-O#N8C+PW(LA%XB)J@])%)`F*.;) MOB2Y?CVXFPEJ^=<$2G.UMXL#8'%7KXYD#:EF^CV_M=:)3D&.QKPGL.!WR=X, M8[XQLR-6:![@I`9)1;@5TJ>`"7AWF9?2^T+HQ17L#E9-`%>3`]U)IE&_GE/<0NR$V'Z$(4N+'?0NV$[G6%720QN/;IX(S,?\"`Z M'`3H"M\VS(NI9;J)+J:UDG'L6Q4FMY,!M@IH#_1@7=!<`,1*H:UVLK7#4@9: MTAO71"E.A&DCE+K8;2O$87OMC/)V$MRT6%TH%4W6:YFL4ZGVZ'A;+@KGEV7= M.CIXR*X2+\[$^OUUV3MV_IR>EOI*?J&[MK_@7-.YC",:QH?';!;1L\>0.[N_ MCZ>TNFQB+85Y1R6%;M9"Y\E^G6_V45T^OCYVL$@J,&?&28YRIJ$=>HGYSCSTW#'MA1T=_.FS+#G@LV@R4X" M=W."G?TU44M>8;V\:,6%8>%GG-X3YQ3U(IY"LNI=PO^L,VQE=SM4&(QE#H,N M6FH_2;-;[A`U6Y;,A2U0PZ1I;R,*%,:1D-W,)"T@2H%SX+(*!L%Q25*L^#ZD M_2P$5O=1*P.S.V4,[V6Y!SEA>;N)"%Z.&H^M/C#C!;KXV M!75P(;:.#>*>;#.=#.S-J6G#$8&)`/CG*_)$\C?YBWQ8>QDF?_PO4$L#!!0` M```(`&%^;C_.&UL M550)``,U?\%.-7_!3G5X"P`!!"4.```$.0$``.U=67/CN!%^3U7^`^,\9//@ M0SYFQU,S2=FRO345ST@E>S?)TQ9%0A(R%*$`I(_\^C1X2*1$D.!ED)!KILJR M##31W1^:C4:C\?GO+TO'>$*48>)^.1@M_IT?/S\_'Q$>5L6-3VRR/+P,'K:MHWN+R\/`[^"DT9_L2"_O?$,KU`1X7C,H0M^&^'<;-#_M7A MX/3P;'#TPNP#D(%A?*;$01,T,X(!?/)>5^C+`7;"^__Y)H)%_//*M6]=#WNO7]T9H8,!CF$:NMT`> M#,YIP&,X+T-,\6#1X%;B:MI/9=<@\.^LBSB MPT,FR$+XR9PZ"!YWY8"1XB_!.T)OB#_U9KX3-ZS"3(6'-,HBP)%A[CU5''VR M?[-FS73GF(N#L5)N5QZ-:(!@D!F@)W`:[V$\T:AX]X83,@QI\@)*4GV.RXUQ$C4P:*$(>MH3IZ.;82#!1G_$`S_\&00+4G^#%^M MQ_$(9+?&N?WGWS^*?`.OW`\!F,D:PXM8W;U*8B MKF!@-A_N_;N39 MBG1TIE!'=_!^,IUPJ'?P'M_-99;QRVK6?QU)A5J M:*N=+BJ282O2T<\*=#3T*4U-=;$7(6K:?TV5XBQ2UD=E$^H..X@.87AS0L73 M*=6J_RJ292K2SJ4Z62^(&H;\@HL9&OL>W_/A6JMCVY73217>E>8P7N2<" M77X^W@[HU`_SR&S>205Y!B<\R+,F!Y^3%(V(I!'1K(S-FDK6)/?3,??=F!*]>T<)B1TNPN(ZJRV@),5+/@IO`6"1;T2T["SX?(=>9'C M)S(4.5WT@$AI#H7!SAXC8TS1RL3V[PD+$7&EH&:1NP&R$NJ6SBF4Y7 ME#VF9(6H]SJ&55RP%`;_:L5]=@"^\%TA[J('%$IS*`Q-]]@,;">?`.^W+Y;C M\RC'+X38S]AQ!`B1Z:H'4BIS*@R4]Q@Q!:C02_,RVMV-K/=8NUFNT7?B6J4= MQDTG/9!0@4=A;+_'^$@LI`IAD=E6#S3(LR;>%>@Q"N)$U9Q5@QYZSN$E5FSM MJ&.7%@KWV)QB!WL8\9SUW0,!!5L5LMT[!XZJFQBU&&XA.*DR4CTV7WE$5BY& MG6[<.3S4TJLX;BW!M8Y[&<';,B'2?(@(6NN.D3)LZ[BM$3O8$_2$7+_`C&0W MUATB);C6<2=C:*XP]Y60R=!HZN!YH,H":Y+?27?$5."^6YL=@N-A$0.QM%[O M"$V<\>.G1$=^YODPJ8ZZHJ*F!)K:&@52QV'`\]$$;>^92,EIT#2&U(R#*IX]Y-XAAD[CFEK6;Z@4"*0QTW M9AXIK.9]^EJ(@=V&^J%`DL>ZVR^7(0Y<-.?';[N"A"O;QB$C8Q/;7]THVB/: MZL]NK1\FRC#:K=V59F`Q09Z)763'Q3FO+,M?^@Y'+JS8L85%3F9Q1_W`4I'G M5O=>U!UQC5D/5ND9-8CO">.)MJ/9H_DBSB@J0T4_1#4A`!V/MF25,Y9F]J)Z=)F7E%\H&(N:^`5<.^\H'T!J2NELE?Q/JC2GKLZ% M?%T=XZ?4(_[Z7F>GE7@6"'E$@\':P0IN4TQ>(L0EZMPY5["[!"_]M,\5R4;'?2%!U2;&IRS"&+\Z^,^:40$7;0&@TY++:0E-P5 M)(BK)DKVTAH3DJ43FXR**=XK*>EC2/34!B!5>6TA!*88))*N14X/'4%1QJEH M,F#5"3#D>A2"UOJ"H-B7:#)GN!,`*'8D>E%\N7$H2+H03:8)*]]L#SF7V6T/ M6VJC?5G>6LCM?>,`8]8]KU*!Q=/\@MT;NL9H9D24E=07XT]>CZ8@@BALK63_ MR'00BX[:/B#ZA"W$Q/7R!*T[-R4+%)+:,RK!DB:AOPG"RZD/8^"RB5@7)B_L M-NVSMJ7YT22>%[$H>KW&?^ZW2G-X:"H8E]BI4W(49H6HR6_6'1(67+0;%7TN MNE6AL%^?%5^-.6VB<`S\S?B%)5Q$)1MU3M?5%)BUC"IDL]6D=47'74*VXS<: M+[D4R2\7#1GM-0>&+,>MIK6K.A*%'*`Y!Q%^,^D/Q&6:#Q)Q!VU14I+E5HL. M*8+)+\@%63K\MGM["2MZ+C\//Q48E()>V@*F"M^MIL0K0LW5DE`/_R]0X6@6 M5#H`/K;KB(LRFJ4Z:XNA&NRWFB6O"$K7/L,N8FQ(EE/LA@K=5,Z8H"#Q.Q"Y M`$[R!+2%5$T1M)H=KPA6$P02]"W/IUR\"Y/.,,1]!N5:L74@N>B#N\@GFAV7R,7S83U"`2M^X\C.9;J9E-UQLI] M1UZAZ#\1 MGB_`D%P]P2MOCK[[RRFBH]E..G`>#$K1Z#,\ZC/:1B'#+EB)&^SXGO!(A:!U MGZ%0AJ7&ZC5TTU9$K,N>K"A)I<\@:8+5&#S-)XPI2;\?FFQQYY#GM<=8D(%_ M5B8#GQ,W0NIJBWJLN90OYI'119%7STM/*'.S709A6XM$II@69,L__ZO#QO29YW5I$ZEXJ[L__A1-.R13)!%7`L[ M*"6+1]*,\6GC4?L#SS>3GHZ%G&\0#-["`1#@LX,"1+AV,N%*@%J9KIU#X9N! M91>GE>6EHW6-K^TI%XPOZ/6.MGJBTM'`!9)EP,<=H3?$GWHSWXFOWA:@+*_+ M.\1JR$G'"XCCP#O/%5WR&9;WRLQN_(ZI2A)J]8Q`Z40ZP0V1,!\H2F2M%UX, MF=OA'2F5I:3C1<4@9%X4!=V@\&="K-%]$\6U-20)O".O,:GI6%=_5R2Q(P"J M0?B)'R:5QN!NU\ZAKR8$9#`E*86ZB\."6X4NNX*G,44K$]OQLB9:S<#R.;C? M(O?L7#5B^XBYRG*INW+L"PH#.6S>(.50E]5Y'U$F+8>6;TS[T!54Q:9^;+YR M._](3;O\VS+9>1]1)2V';JT;6\04]8&5U(TMZ9E7?`5T7;)[BL.Z$FIUK=H9 MA,9>1GY)O<)^^X@Q&1&TNLSL#(CJ6[1WXU59&*T>=U<$,?DTA=J99)T#6)L9 M1'5DTD)92N5K2X%(PC-X#60NYA#J'.X:REPLR[(F16MAP1.%P:.Z2"`7F%C> MZ]@Q77[BDY_Q7/$FHOUN:0*=0TY#2,C8VZXGDY:CLHHB%Y&7P2]@X;NS/B#_ M@B8H2,OY=IOP/U!6$V9M.IQ=0MGT24D]3VN M'$*=PUU#'E=9EC6Y[)%?@G'/%\Q3T_KQ2$V7`3?A'7L87!A)$<2"$=_@7M!O M?^!7312M;FYW?FE9>TFY/_"J*9.F]K\S0Q@?%;V39S-DP9K]]@6\$G>.)F!1 M1RZ7TI5K\Q_<2WF"997X<%L9$IW#6MFP16UF=;G^+)/C,0(\V]M)`,(`OCR) MWN.F-K.:U/O.EL,5V&5*7\$$_V8ZPL0MJ;Z:(D6&RX;>3ZL`E#!LZNT94`;[ M@91!8WE6(51N795E>!_\U+))]_1=57]9V9D%?.JX#Y*H7<_YAC6@.)%WJZ'>6)#BMM7TD#4BU%;B M'`=R7R`/^CL'*3WFE.6\J%*6T_@I];"_:E"FD\/F_/3\]/+DXOS\XF1P\5%1 M[8)X9-^):\''36**:V=$>&XPLQS"?(H*>*]+MGM&I*PRLSW/QF6B2]G/4"8C M"C/=BWY)5!2YPR_(#D^HQI>.#@3(JT"IMD63#AP)^'+)7&19]+7],Q+GF-E MS%_"S"S(CFSC69T#<`.OY;<3E/*#+H+B:-?1%)M705U<%! M<:Y)[DB!M/(J(=6D^H[F2FB6EV6K97F[@V1^.WM4+I37-G,]&%]"'P4KK.H$ MW_&;C]\Z8M2QEA,L@+&'[O$3LH<^\\@2T0ERPI7K`J_8+U1\0XU4WW=`DB8D MUJTJ3;676(_(6KC$(?/M\R&5Z;SCK/R2JD!ZW2KJ5!MSOQ!B/V/'`1OO^/Q. MP7\2^F-&J%5S>2^F^X[)\I@L*4T=JT))NBTI`=9S)%.DWE%;WH4L%F`+*5,9 M)U'49$N0)=!?()>!8Q,FCTBF2IR7NL$T^1@C>H[:)(EP$#S18$6V=4EPZ/V]IE45F+'CMI<7F0:! MP`PAWA&*\-P=!O%!ZS51@`,F6?!;N`S>W+02BWW,+RR$/W@>Q5/?"\IMDS!5 M3H"P-QV#Q@A6+T<=*Y#EZ*?\NU1C])7E^FVJB+7A8&\RCH(L?+R,LI),9^,` M2SG4@Q/X!T[TAB#\$M$TUD03;K4*]WE$YZ8;W4"[\?9#XS%.2'$TRQ!#@=?9 M$&TE+\XZ0]\H_!&@<0W#_-&&A#(>TSD#U"B\4F_#MY!<:^N`=NW6!('SJW@V(["^+`X%FZI%O!S#[;G=E)6G\Q(FI*0GC;/'TG M7G'$+K^3DA/.F6.2G]'2_3LWC>54F#KM7(O7GLY>?DLQV"U>3B2HV"8Y=\]W MYVY,R0!21DA+15&B+7X*YJRXN9**2ENC*9J=PO:=FXU%:DG522K%54_GW9`L MESB\,3K817#Y@2,$JP)IQ_AB=PHFB!I`U4B351/+$G$I?XBV'`U%(;OB(19- MYG)$.C?#*ZEZ*YY7E_^>VH+=DRL@`)[Q\FRZ%H^FWQ!_ZLU\)VXH:2$^[%J( MF(*Q>59@*=9/,^!Q1OR\=7,5MB-^-G?"V#TQ798\C[D9?Y`3N1X_M/F.O`*3 MT@SI1M+32NM>9$9J4NNLTLX;ETUM[L\Y5DC4E/V>9D@05A5EP\-Z8 M`BSX.&X0LR@.M%!@`60[J_`FOB$Z!T0DY0LH!=FO2/3K1@]"L03EE M)]V*!@70T^G^%2BX<\R-7>I@7,&4_YBY51A1,B)2"J9'G``,6MSF3'I-49*& MHMIS@G$537F)GIV;WY64NE6?KA+3;SNG/Q_S@4]-AN"7_P-02P,$%`````@` M87YN/Z"&]NKO!0``NRH``!$`'`!B:6]C+3(P,3$P.3,P+GAS9%54"0`#-7_! M3C5_P4YU>`L``00E#@``!#D!``#M6EUOVS84?1^P_\#I91LP69:=?MBP6R1N M4@1PFR#)L+X5M$3;1"C2):DX^?>[I"1;MF5&\AITPPP$B42>>WCO/11Y%6KP M_C%AZ(%(104?>F&K[2'"(Q%3/AMZJ?*QBBCUWK_[^:?!+[[_Y>QFC&(1I0GA M&D628$UBM*1ZCD92*#6EDJ#)$[JA#T2C6S'52PPM.3\Z:75:8?BFU49SK1?] M(%@NERUIL"J'MB*1^'X^VAE6P`YV=E@P7?6,\I$%[Z,P#."GTPY#%';Z)YU^ M]RVZ_K2"?H)8IK0&5D5SDF`$^>!JZ)4<7'9;0L[`JAT&7SZ-;RW.RX#]QXED M=`-N6@J#;D"YTIA'I,`SRN\=<-,]@;!7]#OXW)NPU^L%MM=#&LL9T9]Q0M0" M1V0#/J$B`A2-L$FM#;W=Z[8+?M/=!,_3I-K[6,M`/RU(``@B:;0R$+R&C>#^ MRHXP8F;7A9#)!S+%*=-#[UN*F5710UAK22>I)AN`E*\A("9"`\RYT%C#M+/W MIF6QH'PJ\EMH,-GK2\'('3B!S,6?-Y>N;!A(<`NLUL.1X$HP&IN9>(:94?EV M3F`N>XC&0Z\&;N5*X4Q,IC":=1IF6[N-?+2B@>LR$\JI4,8U"+8)MKE3>)BN M^#M[O9!$`:5-SQ@:`K5^WB7Z&%%G6HX:':"@2 MR,2<<`450*-'LM)(UW+],>G=*_"'_)"L/A[RN-SKJE^NH1M5B8VB$S1 M6DBW@NV>4;`@*%\"&JZH>56_J$&_ M;5#_?M3TGVR5=;6M8?S<)NK4>-\F>E2[QI)+5<2$2B5L>QK>EY(+RN&!H9BM MLYHON760+AU#>%9#L\ZNB.`FYT(KLI*:1[U<>MT0I64:Z512/AO-S2O[CE*5 M&+=&G5V--EA03G,4QR7.K1;1_5RPF$AU_BV%4F);F@J$6YCNKC!ECE]1QG+4 MQ:7+.98<)K&Z)O(6YC'95F6GWZW)R:XF!0,""F0YCHJX%(%WHX1JN]Y#W0W[ MNH;L$=@*=E5Z4R77VOJHP3-E.N8S:IX9I4AE<;[9[];B;65)GC.@C.)_((CY M98[);L@4V4.POCE'&GJ*)@MF#L]LVUR2Z=`S^OC%.=97"+?UF+`"8O@=QW%6 MS.T,Y0,7%%A&.RP[AW1`(A9$:MBL@L+Y@D!3;%_H7!A@C8-=VM.OU#0H_4HE:$/@O)9)=QMGF4.('(A->*5 M)[[[SI^S\^VQB"R1P\3<^86=;YK\L.-WP]:CB@L?F[BP3D(S%PJ[QBY8+D6B MUDP\!#&A]A3;;X=`L->'2AMSX:^-#TA`]1%WG3R4+3]GAB81/9.(\/5A6O2R M2<[)S/PCKIX?3,H-J\9.3+&:6*94^3.,%[75J#0,"-.J:-FG3?X)@=UJS9+P MU77N<#I16N)(>];W]5G%,UC*F*E2AYZ6*4SM;$VR7X/T`0.O)I>:)&;K@B!3 M,*,Z-0P?I4@7!9`"Q$,X)RVHLCY80JB([RQMG,K\,&5?@%`02V(@5]-2;69> M;J_2563/@1PA)8(3C>53[:!<061]D^Q?_=!!)E0[0VOV]G%''O49$]%]*>[# M&2J3DGW5TM<%[KND95\"SE)%.5&JI-EU*J,Y+(W7L"H0$TGV_-R1:,X%$[.G M(O0#;5]V)F1[BVXZ$>K'LBMX\WQ4.P*=2SX[([(I%ZLM=$_ M/MA!D%4,&UL550%``,U?\%.=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`87YN/QN8NGMI"@``@)@``!4`&````````0`` M`*2!VDT``&)I;V,M,C`Q,3`Y,S!?8V%L+GAM;%54!0`#-7_!3G5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`&%^;C]\J2:TR"0``$T=`@`5`!@```````$` M``"D@9)8``!B:6]C+3(P,3$P.3,P7VQA8BYX;6Q55`4``S5_P4YU>`L``00E M#@``!#D!``!02P$"'@,4````"`!A?FX_SG)ZB^03```D2@$`%0`8```````! M````I(&I?0``8FEO8RTR,#$Q,#DS,%]P&UL550%``,U?\%.=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`87YN/Z"&]NKO!0``NRH``!$`&``````` M`0```*2!W)$``&)I;V,M,C`Q,3`Y,S`N>'-D550%``,U?\%.=7@+``$$)0X` <``0Y`0``4$L%!@`````%``4`OP$``!:8```````` ` end XML 25 R11.htm IDEA: XBRL DOCUMENT v2.3.0.15
Earnings Per Share
9 Months Ended
Sep. 30, 2011
Earnings Per Share [Abstract]
Earnings Per Share
Note 4 – Earnings Per Share

Basic income per common share for the three and nine months ended September 30, 2011 and 2010 was calculated by dividing the net income available to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Diluted income per share for the three and nine months ended September 30, 2011 and 2010 was calculated by dividing net income by the weighted average number of shares of Common Sstock outstanding, adjusted for the effect of potentially dilutive securities using the treasury stock method.

The computation of basic income per common share and diluted income per common share was as follows:

(in thousands, except per share data)

Three Months Ended

September 30,

Nine Months Ended

September 30,

2011

2010

2011

2010

Net income – basic and diluted

$358

$808

$1,633

$1,922

Denominator – basic:

Weighted average number

 of common shares

15,640

15,174

15,645

14,958

Basic income per common share

$0.02

$0.05

$0.10

$0.13

Denominator – diluted:

Weighted average number

 of common shares

15,640

15,174

15,645

14,958

Common share equivalents

 of outstanding convertible equity and

 unrecognized compensation expense

743

622

870

772

Weighted average number of

 dilutive common equity shares

16,383

15,796

16,515

15,730

Diluted income per

 common share

$0.02

$0.05

$0.10

$0.12

Options to purchase 536,000 and 576,000 shares of BioClinica's common stock respectively, had been excluded from the calculation of diluted earnings per common share for the nine months ended September 30, 2011 and September 30, 2010, respectively, as they were all antidilutive. Options to purchase 563,000 and 779,000 shares of BioClinica's common stock respectively, had been excluded from the calculation of diluted earnings per common share for the three months ended September 30, 2011 and September 30, 2010, respectively, as they were all antidilutive.
X
- Details
Name: us-gaap_EarningsPerShareAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details
Name: us-gaap_EarningsPerShareTextBlock
Namespace Prefix: us-gaap
Data Type: nonnum:textBlockItemType
Balance Type: na
Period Type: duration
XML 26 R5.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Statements Of Cash Flows (USD $)
In Thousands
9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Cash flows from operating activities:
Net income $ 1,633 $ 1,922
Adjustments to reconcile net income to net cash provided by operating activities, net of acquisition:
Depreciation and amortization 3,310 2,501
Provision for deferred income taxes 829 47
Bad debt recovery, net (15) (9)
Stock based compensation expense 1,019 791
Accretion of acquisition earn-out 114 245
Changes in operating assets and liabilities, net of acquisitions:
(Increase) decrease in accounts receivable (1,603) 278
Increase in prepaid expenses and other current assets (89) (625)
(Increase) decrease in other assets (42) 17
Increase (decrease) in accounts payable 113 (199)
Decrease in accrued expenses and other current liabilities (89) (1,136)
Decrease in deferred revenue (19) (1,127)
Increase in other liabilities 742 368
Net cash provided by operating activities 5,903 3,073
Cash flows from investing activities:
Purchases of property and equipment (1,352) (2,296)
Capitalized software development costs (2,843) (3,783)
Net cash used in investing activities (4,195) (6,079)
Cash flows from financing activities:
Proceeds from sale/leaseback 918 195
Payments under equipment lease obligations (157)
Purchase of treasury stock (784)
Excess tax benefit related to stock options 35
Proceeds from exercise of stock options 138 21
Net cash provided by financing activities 115 251
Effect of exchange rate changes on cash 26 1
Net increase (decrease) in cash and cash equivalents 1,849 (2,754)
Cash and cash equivalents at beginning of period 10,443 14,570
Cash and cash equivalents at end of period 12,292 11,816
Supplemental disclosure of cash flow information:
Cash paid during the period for interest 32 7
Cash paid during the period for income taxes $ 736 $ 1,802
X
- Definition
Accretion of acquisition earn-out.
+ Details
Name: bioc_AccretionOfAcquisitionEarnOut
Namespace Prefix: bioc
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
Additions made to capitalized computer software costs during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16265-109275

+ Details
Name: us-gaap_CapitalizedComputerSoftwareAdditions
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details
Name: us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details
Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: na
Period Type: duration
X
- Definition
The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 289

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

+ Details
Name: us-gaap_DeferredIncomeTaxExpenseBenefit
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The effect of exchange rate changes on cash balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details
Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
Disclosure of the aggregate tax benefit realized from the exercise of stock options and the conversion of similar instruments during the annual period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details
Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details
Name: us-gaap_IncomeTaxesPaidNet
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInAccountsReceivable
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.
+ Details
Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInDeferredRevenue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details
Name: us-gaap_InterestPaid
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The net cash inflow or outflow from financing activity for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details
Name: us-gaap_NetCashProvidedByUsedInFinancingActivities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The net cash inflow or outflow from investing activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details
Name: us-gaap_NetCashProvidedByUsedInInvestingActivities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: na
Period Type: duration
X
- Details
Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details
Name: us-gaap_NetIncomeLoss
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The cash outflow to reacquire common and preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details
Name: us-gaap_PaymentsForRepurchaseOfEquity
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The cash outflow for payments to acquire rented equipment which is recorded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details
Name: us-gaap_PaymentsToAcquireEquipmentOnLease
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details
Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details
Name: us-gaap_ProceedsFromStockOptionsExercised
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_ProvisionForDoubtfulAccounts
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The gross proceeds received from the asset(s) sold in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller less the costs incurred in connection with the transaction, such as closing and deferred financing costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6584642&loc=d3e51843-112757

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 55

-Paragraph 51

-URI http://asc.fasb.org/extlink&oid=6584642&loc=d3e51840-112757

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 98

-Section Appendix A

-Paragraph 28, 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 33

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 55

-Paragraph 50

-URI http://asc.fasb.org/extlink&oid=6584642&loc=d3e51831-112757

+ Details
Name: us-gaap_SaleLeasebackTransactionNetProceeds
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details
Name: us-gaap_ShareBasedCompensation
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: duration
X
- Details
Name: us-gaap_SupplementalCashFlowElementsAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
XML 27 R7.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Statements Of Comprehensive Income (USD $)
In Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Statement of comprehensive income
Net income $ 358 $ 808 $ 1,633 $ 1,922
Equity adjustment from foreign currency translation (47) 166 44 (37)
Total comprehensive income $ 311 $ 974 $ 1,677 $ 1,885
X
- Definition
The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 8, 9, 10, 11, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6508144

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

+ Details
Name: us-gaap_ComprehensiveIncomeNetOfTax
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Details
Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details
Name: us-gaap_NetIncomeLoss
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
X
- Definition
Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569643-111683

+ Details
Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: duration
XML 28 R2.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Balance Sheets (USD $)
In Thousands
Sep. 30, 2011
Dec. 31, 2010
ASSETS
Cash and cash equivalents $ 12,292 $ 10,443
Accounts receivable, net 13,482 11,866
Prepaid expenses and other current assets 2,594 2,501
Deferred income taxes 4,098 3,625
Total current assets 32,466 28,435
Property and equipment, net 15,459 14,029
Intangibles, net 1,963 2,430
Goodwill 34,302 34,302
Deferred income tax 87 128
Other assets 748 705
Total assets 85,025 80,029
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable 2,168 1,983
Accrued expenses and other current liabilities 4,185 4,283
Deferred revenue 13,377 13,395
Current maturities of capital lease obligations 342 168
Current liability for acquisition earn-out 2,000
Total current liabilities 22,072 19,829
Long-term capital lease obligations 1,296 710
Long-term liability for acquisition earn-out 1,886
Deferred income tax 3,107 1,845
Other liabilities 1,621 880
Total liabilities 28,096 25,150
Stockholders' equity:
Preferred stock - $0.00025 par value; authorized 3,000,000 shares, none issued and outstanding at September 30, 2011 and at December 31, 2010
Common stock - $0.00025 par value; authorized 36,000,000 shares, issued and outstanding 15,662,550 shares at September 30, 2011 and 15,631,664 shares at December 31, 2010 4 4
Treasury stock - at cost, shares held: 160,113 at September 30, 2011 and 3,400 at December 31, 2010 (800) (16)
Additional paid-in capital 49,231 48,074
Retained earnings 8,425 6,792
Accumulated other comprehensive income 69 25
Total stockholders' equity 56,929 54,879
Total liabilities and stockholders' equity $ 85,025 $ 80,029
X
- Definition
Short term portion of additional payment from acquisitions based on certain criteria as determined in the acquisition agreements.
+ Details
Name: bioc_CurrentLiabilityForAcquisitionEarnOut
Namespace Prefix: bioc
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Long term portion of additional payment from acquisitions based on certain criteria as determined in the acquisition agreements.
+ Details
Name: bioc_LongTermLiabilityForAcquisitionEarnOut
Namespace Prefix: bioc
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_AccountsPayableCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

+ Details
Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_AdditionalPaidInCapital
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Topic 210

-SubTopic 10

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

-Section S99

-Name Accounting Standards Codification

-Publisher FASB

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_Assets
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Details
Name: us-gaap_AssetsAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details
Name: us-gaap_AssetsCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 7, 10, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_CapitalLeaseObligationsCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 7, 10, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details
Name: us-gaap_CapitalLeaseObligationsNoncurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details
Name: us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_CommonStockValue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details
Name: us-gaap_DeferredRevenueCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31928-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42, 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details
Name: us-gaap_DeferredTaxAssetsNetCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
The noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, is classified according to the expected reversal date of the temporary difference.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31928-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42, 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details
Name: us-gaap_DeferredTaxAssetsNetNoncurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 41, 42

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details
Name: us-gaap_DeferredTaxLiabilitiesNoncurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details
Name: us-gaap_Goodwill
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

+ Details
Name: us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_Liabilities
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 25

+ Details
Name: us-gaap_LiabilitiesAndStockholdersEquity
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Details
Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_LiabilitiesCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_OtherAssetsNoncurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 6

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_OtherLiabilitiesCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details
Name: us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

+ Details
Name: us-gaap_PreferredStockValue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

+ Details
Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details
Name: us-gaap_PropertyPlantAndEquipmentNet
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
X
- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details
Name: us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details
Name: us-gaap_StockholdersEquity
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: credit
Period Type: instant
X
- Details
Name: us-gaap_StockholdersEquityAbstract
Namespace Prefix: us-gaap
Data Type: xbrli:stringItemType
Balance Type: na
Period Type: duration
X
- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Technical Bulletin (FTB)

-Number 85-6

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details
Name: us-gaap_TreasuryStockValue
Namespace Prefix: us-gaap
Data Type: xbrli:monetaryItemType
Balance Type: debit
Period Type: instant
XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.15 Html 9 116 1 false 0 0 false 3 true false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.bioclinica.com/role/DocumentDocumentAndEntityInformation Document And Entity Information false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.bioclinica.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.bioclinica.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 00200 - Statement - Consolidated Statements Of Income Sheet http://www.bioclinica.com/role/StatementConsolidatedStatementsOfIncome Consolidated Statements Of Income false false R5.htm 00300 - Statement - Consolidated Statements Of Cash Flows Sheet http://www.bioclinica.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements Of Cash Flows false false R6.htm 00305 - Statement - Consolidated Statements Of Cash Flows (Parenthetical) Sheet http://www.bioclinica.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical Consolidated Statements Of Cash Flows (Parenthetical) false false R7.htm 00400 - Statement - Consolidated Statements Of Comprehensive Income Sheet http://www.bioclinica.com/role/StatementConsolidatedStatementsOfComprehensiveIncome Consolidated Statements Of Comprehensive Income false false R8.htm 10101 - Disclosure - Interim Financial Statements Sheet http://www.bioclinica.com/role/DisclosureInterimFinancialStatements Interim Financial Statements false false R9.htm 10201 - Disclosure - Restructuring Charges Sheet http://www.bioclinica.com/role/DisclosureRestructuringCharges Restructuring Charges false false R10.htm 10301 - Disclosure - Stockholders' Equity Sheet http://www.bioclinica.com/role/DisclosureStockholdersEquity Stockholders' Equity false false R11.htm 10401 - Disclosure - Earnings Per Share Sheet http://www.bioclinica.com/role/DisclosureEarningsPerShare Earnings Per Share false false R12.htm 10501 - Disclosure - Commitments And Contingencies Sheet http://www.bioclinica.com/role/DisclosureCommitmentsAndContingencies Commitments And Contingencies false false R13.htm 10601 - Disclosure - Accounts Receivable And Allowance For Doubtful Accounts Sheet http://www.bioclinica.com/role/DisclosureAccountsReceivableAndAllowanceForDoubtfulAccounts Accounts Receivable And Allowance For Doubtful Accounts false false R14.htm 10701 - Disclosure - Acquisitions Sheet http://www.bioclinica.com/role/DisclosureAcquisitions Acquisitions false false R15.htm 10801 - Disclosure - Intangible Assets Sheet http://www.bioclinica.com/role/DisclosureIntangibleAssets Intangible Assets false false All Reports Book All Reports Process Flow-Through: 00100 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 00200 - Statement - Consolidated Statements Of Income Process Flow-Through: 00300 - Statement - Consolidated Statements Of Cash Flows Process Flow-Through: 00305 - Statement - Consolidated Statements Of Cash Flows (Parenthetical) Process Flow-Through: 00400 - Statement - Consolidated Statements Of Comprehensive Income bioc-20110930.xml bioc-20110930.xsd bioc-20110930_cal.xml bioc-20110930_lab.xml bioc-20110930_pre.xml true true EXCEL 30 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B9#,Y9C4Q,5]C8C`T7S1E96%?.#4W,5]C,C!A M-&4S9#1E,3,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7T]F7T-O M;3PO>#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I%>&-E;%=O M#I%>&-E;%=O#I7;W)K#I7 M;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V)D,SEF-3$Q7V-B,#1?-&5E85\X-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^,3`M43QS<&%N/CPO'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^43,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\ M=&0@8VQA#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)FYB'0^)FYB3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S"!P3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]B9#,Y9C4Q,5]C8C`T7S1E96%?.#4W,5]C,C!A-&4S9#1E M,3,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F0S.68U,3%?8V(P M-%\T965A7S@U-S%?8S(P831E,V0T93$S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q,#QS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-E&5R8VES92!O9B!S=&]C:R!O<'1I M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S@\&-H86YG92!R871E(&-H86YG97,@;VX@8V%S:#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)W1E>'0M86QI9VXZ(&IU3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[ M(&UA3H@)U1I;65S($YE M=R!2;VUA;BF4Z M(#$Q<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA&-H86YG92!#;VUM M:7-S:6]N+B!#97)T86EN(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T92!D:7-C M;&]S=7)E2!I;F-L=61E9"!I;B!F:6YA;F-I86P@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UA3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S2!F;W(@ M82!F86ER('-T871E;65N="!O9B!T:&4@6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA65A6QE/3-$)V9O;G0M2!I9&5N=&EF:65D(&%N9"!C;W)R96-T960@8VQEF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S3L@=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#$R M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RPGF4Z(#$R<'0[)R!C;&%S3L@=&5X="UI;F1E;G0Z M(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#$R<'0[(&9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)RPGF4Z(#$R<'0[)R!C;&%S M3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA M6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,G+"=S97)I9B<[(&9O;G0M3H@)U1I;65S($YE=R!2;VUA;B2!F;W(@;&5V96P@,R!F86ER('9A;'5E(&UE87-U2!I;B!T:&4@9FER2X@5&AE($-O;7!A;GD@:7,@ M8W5RF4Z(#$Q<'0[)R!C;&%S6QE/3-$)V9O;G0M9F%M:6QY M.B`G0V%L:6)R:26QE/3-$)VUAF4Z(#$R M<'0[)R!C;&%S3H@)U1I;65S)RPGF4Z(#$Q<'0[)R!C;&%S M2P@86UO;F<@;W1H97(@=7!D871E29N8G-P.S$L(#(P,3(@86YD('=I;&P@ M:6UP86-T('1H92!P6QE/3-$ M)V-O;&]R.B`C,68T.3=D.R<@8VQA3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,G+"=S97)I9B<[(&9O;G0M M&ES=&5N8V4@;V8@979E;G1S(&]R(&-I2!O9B!E=F5N=',@;W(@8VER8W5M M2!T;R!P97)F;W)M:6YG('1H92!F:7)S="!S=&5P(&]F M('1H92!T=V\M2=S(&-O;G-O;&ED M871E9"!F:6YA;F-I86P@7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$ M)VUAF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&IUF4Z M(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S2!R96%L:6=N960@:71S(&=L;V)A M;"!R97-O=7)C97,@=&\@96QI;6EN871E(&-E65E('-E=F5R86YC92P@)FYB6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S3L@ M;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0M2!L96%S92!O8FQI9V%T:6]N6UE;G0@:6X@36%Y(#(P,30N/"]F;VYT/CPO<#X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A8W1=/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE M6QE/3-$)V9O;G0M3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N M="UF86UI;'DZ("=4:6UE6QE/3-$)V9O M;G0MF4Z M(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C M;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)V)OF4Z(#$R M<'0[)R!C;&%S3H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)V)OF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA M;BF4Z M(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;BF4Z(#EP M=#LG(&-L87-S/3-$7VUT/D-O;7!R92UH96YS:79E/"]F;VYT/CPO8CX\+W`^ M#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S M6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$ M)V)O'0@,7!T('-O;&ED.R!B;W)D97(M M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I;FF4Z(#$R<'0[ M)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO M;F4[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A M9&1I;FF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,7!T M('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I;FF4Z M(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[ M('!A9&1I;FF4Z(#$R<'0[)R!C;&%S3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#EP=#LG(&-L87-S/3-$7VUT/D)A;&%N8V4@870@1&5C96UB M97(@,S$L(#(P,#D@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O MF4Z(#EP=#LG(&-L87-S/3-$7VUT/C$T+#,Y-#PO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N M93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@ M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N-7!T.R!P861D M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)O M6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S M/3-$7VUT/B9N8G-P.R0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/B9N8G-P.R0T,RPQ M,#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V)OF4Z(#EP=#LG M(&-L87-S/3-$7VUT/C0L,#,Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C M;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C M;&%S6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C M;&%S6QE/3-$)V)OF4Z(#$R<'0[ M)R!C;&%S6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$ M)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/C$R,CPO9F]N=#X\+W`^ M/"]T9#X\+W1R/@T*/'1R/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(Q M+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#EP=#LG(&-L87-S/3-$7VUT/E)E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C M;&%S6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)OF4Z M(#EP=#LG(&-L87-S/3-$7VUT/B@U-2D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C M;&%S6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$R<'0[ M)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$ M7VUT/B@U-2D\+V9O;G0^/"]P/CPO=&0^/"]T6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$R<'0[ M)R!C;&%S6QE/3-$)V)O6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O MF4Z(#EP=#LG(&-L87-S/3-$7VUT M/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP M=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S M/3-$7VUT/C4W.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N M;VYE.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T M.R!W:61T:#H@,3(N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R M+71O<#H@;65D:75M(&YO;F4[(&)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O MF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S M6QE/3-$)V-O M;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE M/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/C(L-#8X/"]F;VYT M/CPO<#X\+W1D/CPO='(^#0H\='(^/'1D('-T>6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R<'0[ M)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Y<'0[)R!C;&%SF4Z(#$R<'0[)R!C M;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP M=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S M2!S=&]C:R`\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C M;&%S6QE/3-$)V)OF4Z(#$R<'0[ M)R!C;&%S6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG M(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C M:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R<'0[)R!C M;&%S6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP M=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z M(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[ M)R!C;&%S6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/C0V/"]F M;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^/'1D('-T>6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R M<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)R!C;&%S6QE/3-$ M)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)V)OF4Z M(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/B@U-"D\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)R!C;&%S6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG M(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$ M7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/C(L-S4S/"]F;VYT/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z M(#EP=#LG(&-L87-S/3-$7VUT/C(L-S4S/"]F;VYT/CPO<#X\+W1D/CPO='(^ M#0H\='(^/'1D('-T>6QE/3-$)V)O6QE/3-$)VUA MF4Z(#$R<'0[)R!C;&%S'0@,7!T('-O;&ED.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B'0@,7!T('-O M;&ED.R!B;W)D97(M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B'0@,7!T('-O;&ED.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT M/B9N8G-P.R0H,38I/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O M'0@,7!T('-O;&ED.R!B;W)D M97(M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Y<'0[)R!C;&%S'0@ M,7!T('-O;&ED.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S'0@ M,7!T('-O;&ED.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R M<'0[)R!C;&%S&5R8VES960@/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/C$R-#PO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N M93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@ M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N-7!T.R!P861D M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)O M6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S M/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP M=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S M/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)OF4Z M(#EP=#LG(&-L87-S/3-$7VUT/C8T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)R!C;&%S6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$ M7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)R!C;&%S6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R<'0[)R!C;&%SF4Z M(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C M;&%S6QE/3-$)V)OF4Z(#$R<'0[ M)R!C;&%S6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L M87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S2!S=&]C:R`\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C M;&%S6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z M(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;BF4Z M(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L M87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#EP=#LG(&-L87-S/3-$7VUT/D5Q=6ET>2!A9&IU2!T6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z M(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT M/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Y<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/C0T/"]F M;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^/'1D('-T>6QE/3-$)V)O6QE/3-$)VUAF4Z(#$R M<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z M(#$R<'0[)R!C;&%S6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A M9&1I;FF4Z M(#EP=#LG(&-L87-S/3-$7VUT/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O'0@,7!T('-O;&ED M.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I;FF4Z(#EP=#LG(&-L87-S/3-$7VUT M/BT\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Y<'0[)R!C;&%S6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I M;FF4Z(#EP M=#LG(&-L87-S/3-$7VUT/C$L-C,S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)V)O'0@,7!T('-O;&ED.R!B M;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O'0@,7!T('-O;&ED M.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I;FF4Z(#EP=#LG(&-L87-S/3-$ M7VUT/C$L-C,S/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^/'1D('-T>6QE M/3-$)V)O6QE/3-$)VUAF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$ M7VUT/C$U+#8V,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N M;VYE.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T M.R!W:61T:#H@,3(N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R M+71O<#H@;65D:75M(&YO;F4[(&)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O MF4Z(#EP=#LG(&-L87-S/3-$7VUT/B9N8G-P.R0T/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)V)OF4Z(#EP=#LG(&-L M87-S/3-$7VUT/B9N8G-P.R0T.2PR,S$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y<'0[ M)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S MF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Y M<'0[)R!C;&%S6QE M/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT/B9N8G-P.R0X+#0R M-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!M961I=6T@;F]N93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D M:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@ M,3(N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D M:75M(&YO;F4[(&)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)OF4Z M(#EP=#LG(&-L87-S/3-$7VUT/B9N8G-P.R0V.3PO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R M9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@,&EN.R!P M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N-7!T.R!P861D:6YG+7)I M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)OF4Z(#$R<'0[)R!C M;&%S6QE/3-$)V)OF4Z(#EP=#LG(&-L87-S/3-$7VUT M/B9N8G-P.R0U-BPY,CD\+V9O;G0^/"]P/CPO=&0^/"]T6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$ M)V)O6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Q,7!T.R<@8VQA&%C="!N=6UB97(@ M;V8@2!T;R!R97!U2!T:6UE+B`\+V9O;G0^/"]P/@T*#0H\ M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@ M,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P=#L@9F]N="UF86UI;'DZ("=4:6UE M6QE/3-$)V9O;G0MF4Z(#$R<'0[)R!C;&%S'0@,7!T('-O;&ED.R!B;W)D97(M M'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.3`^#0H-"CQP('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1EF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@ M;65D:75M(&YO;F4[('!A9&1I;F'0M:6YD96YT.B`P:6X[(&UA3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M M(&YO;F4[('!A9&1I;F6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,'!T M.R<@8VQA6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E MF4Z(#$R<'0[)R!C;&%S&EM871E($1O;&QA'0@,7!T('-O;&ED.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,34S+CEP=#L@<&%D9&EN9RUR:6=H=#H@ M-2XT<'0[(&)O'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L M:6=N/3-$=&]P('=I9'1H/3-$,C`U/@T*#0H\<"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@ M,3)P=#L@9F]N="UF86UI;'DZ("=4:6UE'0@,7!T('-O M;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M.3`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN M9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P=#L@9F]N="UF86UI;'DZ M("=4:6UEF4Z(#$P<'0[)R!C;&%S'0@ M,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I M9'1H/3-$.3`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T M97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P=#L@9F]N="UF M86UI;'DZ("=4:6UEF4Z(#$P<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@ M,3)P=#L@9F]N="UF86UI;'DZ("=4:6UEF4Z(#$P<'0[ M)R!C;&%S'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(W/@T*#0H\<"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P M:6X@,&EN(#$R<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RPG MF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Q,'!T.R<@8VQA'0@,7!T('-O;&ED.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE M9G0Z(#4N-'!T.R!W:61T:#H@,34S+CEP=#L@<&%D9&EN9RUR:6=H=#H@-2XT M<'0[(&)O'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N M/3-$=&]P('=I9'1H/3-$,C`U/@T*#0H\<"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P M=#L@9F]N="UF86UI;'DZ("=4:6UE'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P M('=I9'1H/3-$.3`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P=#L@9F]N M="UF86UI;'DZ("=4:6UEF4Z(#$P<'0[)R!C;&%S'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N M/3-$=&]P('=I9'1H/3-$.3`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P M=#L@9F]N="UF86UI;'DZ("=4:6UEF4Z(#$P<'0[)R!C M;&%S6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ M(#!I;B`P:6X@,3)P=#L@9F]N="UF86UI;'DZ("=4:6UEF4Z(#$P<'0[)R!C;&%S'0@,7!T('-O;&ED.R!P861D:6YG M+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3(W/@T*#0H\<"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!I;CL@ M;6%R9VEN.B`P:6X@,&EN(#$R<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RPGF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Q,'!T.R<@8VQA'0@,7!T('-O;&ED.R!P861D:6YG+6)O='1O;3H@,&EN.R!P M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,34S+CEP=#L@<&%D9&EN9RUR M:6=H=#H@-2XT<'0[(&)O'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C`U/@T*#0H\<"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I M;B`P:6X@,3)P=#L@9F]N="UF86UI;'DZ("=4:6UE'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.3`^#0H-"CQP('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I M;B`P:6X@,3)P=#L@9F]N="UF86UI;'DZ("=4:6UEF4Z M(#$P<'0[)R!C;&%S'0M:6YD96YT.B`P:6X[(&UA3H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('!A9&1I M;F'0M:6YD96YT M.B`P:6X[(&UA3H@)U1I M;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[ M('!A9&1I;F'0M M:6YD96YT.B`P:6X[(&UA3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%SF4Z(#$P<'0[)R!C;&%S'0@,7!T M('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H M/3-$.3`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT M+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,3)P=#L@9F]N="UF86UI M;'DZ("=4:6UEF4Z(#$P<'0[)R!C;&%S6QE/3-$)V)O M'0@,7!T('-O;&ED.R!B;W)D97(M;&5F M=#H@;65D:75M(&YO;F4[('!A9&1I;FF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[ M('!A9&1I;F'0M M:6YD96YT.B`P:6X[(&UA3H@)U1I;65S($YE=R!2;VUA;B'0@,7!T('-O;&ED.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N M/3-$=&]P('=I9'1H/3-$,3(W/@T*#0H\<"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#$R M<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RPGF4Z(#$R<'0[)R!C;&%S'1087)T7V)D,SEF-3$Q7V-B,#1?-&5E85\X-3'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA3H@)U1I;65S($YE M=R!2;VUA;B3H@ M)U1I;65S($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S3L@;6%R M9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0M2!D:79I9&EN9R!T:&4@;F5T(&EN8V]M M92!A=F%I;&%B;&4@=&\@0V]M;6]N(%-T;V-K:&]L9&5R2!T:&4@=V5I M9VAT960@879E2!T:&4@=V5I9VAT960@ M879E3L@=&5X="UI;F1E;G0Z(#!I M;CL@;6%R9VEN.B`Q,G!T(#!I;B`P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RPGF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN M.B`Q,G!T(#!I;B`P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RPGF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B"`A:6UP;W)T86YT.R!F;VYT+7-I>F4Z(#$P M<'0[)R!C;&%S'0M:6YD96YT.B`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`P:6X[(&UAF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C M;&%SF4Z(#$P<'0[)R!C;&%S6QE/3-$)V)O3H@)U1I;65S($YE=R!2;VUA;B'0@,7!T('-O;&ED.R!B;W)D97(M3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I M;65S($YE=R!2;VUA;B'0M:6YD96YT.B`P:6X[(&UA MF4Z(#$R<'0[)R!C;&%S'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R M<'0[)R!C;&%SF4Z(#$P<'0[)R!C;&%S6QE/3-$)W!A9&1I;FF4Z(#$P<'0[)R!C;&%S'0M:6YD M96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C M;&%S6QE/3-$)V9O;G0M M3L@=&5X="UI;F1E;G0Z M(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE M6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN M9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;F'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE M9G0Z(#4N-'!T.R!W:61T:#H@,3(N.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT M<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2 M;VUA;B'0@,7!T('-O;&ED.R!B;W)D97(MF4Z M(#$R<'0[)R!C;&%S3L@=&5X M="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI M;'DZ("=4:6UE6QE/3-$ M)V)O6QE/3-$)VUAF4Z(#$R M<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B3H@ M)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[ M(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W M:61T:#H@,3(N.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX] M,T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N M.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2 M;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W M:61T:#H@,3(N.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX] M,T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N M.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2 M;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P M:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[)R!C;&%S3L@=&5X="UI;F1E;G0Z(#!I;CL@ M;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)W!A9&1I;FF4Z(#$R<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UA MF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;FF4Z(#$R<'0[)R!C;&%S3L@ M=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF M86UI;'DZ("=4:6UE6QE M/3-$)W!A9&1I;FF4Z(#$R<'0[ M)R!C;&%S3L@=&5X="UI;F1E M;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4 M:6UE6QE/3-$)W!A9&1I M;F'0^)FYB M'0M:6YD M96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C M;&%S6QE/3-$)W!A9&1I;F'0^)FYB3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@ M,W!X(&1O=6)L93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[ M(&UAF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S6QE/3-$)V)O'0@,W!X(&1O=6)L93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE M.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W M:61T:#H@-C'0@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!C;&%S6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[ M)R!C;&%S3L@=&5X="UI;F1E M;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4 M:6UE6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R M<'0[)R!C;&%S3H@)U1I M;65S($YE=R!2;VUA;B'0^)FYB3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX],T1R:6=H M=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N.35P=#L@ M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX],T1R:6=H=#XF;F)S<#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,&EN.R!P M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N.35P=#L@<&%D9&EN9RUR M:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I M;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H M=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N.35P=#L@ M<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX],T1R:6=H=#XF;F)S<#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,&EN.R!P M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(N.35P=#L@<&%D9&EN9RUR M:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I M;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!C;&%S M3L@=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN M(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)W!A9&1I;FF4Z(#$R<'0[)R!C;&%S6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B'0@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M)R!C;&%S3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C M;&%S3H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)V9O;G0M'0@86QI9VX],T1R:6=H=#XF;F)S<#L\ M+W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B'0@ M86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^ M#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^#0H-"CQP('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@,7!T('-O M;&ED.R!B;W)D97(MF4Z(#$R<'0[)R!C;&%S M3L@=&5X="UI;F1E;G0Z(#!I M;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z M(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B'0@,7!T('-O;&ED.R!B;W)D97(M'0^)FYB3H@)U1I;65S M($YE=R!2;VUA;B6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!C;&%S3L@=&5X="UI M;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ M("=4:6UE6QE/3-$)W!A M9&1I;FF4Z(#$R<'0[)R!C;&%S M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N M=#H@,&EN.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@,7!T('-O;&ED.R!B;W)D97(M3L@=&5X="UI M;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ M("=4:6UE6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B'0@,7!T('-O;&ED.R!B;W)D M97(M'0^)FYB3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O M;G0M'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N M-'!T.R!W:61T:#H@,3(N.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A M9&1I;F3H@)U1I;65S($YE=R!2;VUA;B'0@ M86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T M:#H@,3(N.35P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S M($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C M;&%SF4Z(#$R<'0[)R!C;&%S3L@=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@ M,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V)O'0@ M,W!X(&1O=6)L93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B"!D;W5B;&4[(&)OF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B&-L=61E9"!F2P@87,@=&AE>2!W97)E(&%L;"!A M;G1I9&EL=71I=F4N/"]F;VYT/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[ M(&UA3H@)U1I;65S($YE M=R!2;VUA;BF4Z M(#$Q<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)VUA MF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S'!I2!T;R!B;W)R;W<@)FYB2!P87ES(&$@9F5E(&]F(#`N,C4E('!E M'1087)T7V)D,SEF-3$Q7V-B,#1?-&5E85\X-3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M9&5C;W)A=&EO;CH@ M;F]N93LG(&-L87-S/3-$7VUT/B`\+V9O;G0^/"]F;VYT/CPO9F]N=#XF;F)S M<#L\+W`^#0H-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M'!O3L@ M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)T-A;&EBF4Z(#$Q<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S3H@)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)VUAF4Z(#$R<'0[ M)R!C;&%SF4Z M(#$Q<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I M;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0MF4Z(#$R<'0[)R!C;&%S M6QE/3-$)V9O M;G0M6QE/3-$)VUAF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0MF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE M=R!2;VUA;BF4Z M(#$R<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M2`Q+"`R,#$Q(#PO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,&EN.R!P861D M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XU:6X[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)W!A9&1I;F6QE/3-$ M)V9O;G0MF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0MF4Z(#$R<'0[)R!C;&%S6QE/3-$)W!A9&1I M;F6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)VUA MF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S3L@;6%R9VEN.B`P:6X@,&EN M(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0M3H@)U1I;65S($YE M=R!2;VUA;B3L@;6%R M9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B2!H96QD(%1R86Y396YD82!);G1EF4Z(#$Q<'0[)R!C M;&%S2!R961U8VEN9R!S='5D>2!D=7)A=&EO M;G,@86YD(&-O3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S2!P M;W1E;G1I86P@:6YD96UN:69I8V%T:6]N(&-L86EM2!O9F9E2!S:&]R="!S86QE(&]R(&]T:&5R=VES92!D:7-P;W-E(&]F M(&%N>2!S:&%R97,@;V8@=&AE($-O;7!A;GDG6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M+C5I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE M6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B2!A;F0@:7,@;F]T(&EN9&EC871I=F4@;V8@=&AE M(')E6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S3L@=&5X="UI;F1E;G0Z(#!I;CL@;6%R9VEN.B`P:6X@,&EN M(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$ M)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@8F]R9&5R M+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(N-7!T.R!P861D:6YG+7)I9VAT M.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)OF4Z(#$R<'0[)R!C;&%S6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+7-I M>F4Z(#$Q<'0[)R!C;&%S6QE/3-$)W!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O M;G0M3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S'0@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$Q<'0[)R!C;&%SF4Z(#$Q M<'0[)R!C;&%S3H@ M)U1I;65S($YE=R!2;VUA;BF4Z M(#$R<'0[)R!C;&%S6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2 M;VUA;B'0@86QI9VX],T1R:6=H=#XF;F)S<#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T M.R!W:61T:#H@,C(N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN M9RUT;W`Z(#!I;CLG('=I9'1H/3-$,S`^#0H-"CQP('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,&EN.R!M87)G:6XZ(#!I;B`P M:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G M:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!I;B`P:6X@ M,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z M(#$R<'0[)R!C;&%SF4Z M(#$Q<'0[)R!C;&%S3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`P:6X[(&UAF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S2!E>'!E;G-E9"!A;&P@8V]S=',@6QE/3-$)V9O;G0MF4Z(#$Q<'0[)R!C;&%S3H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W!A9&1I;F3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M3L@ M;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S6QE/3-$ M)W!A9&1I;F3L@;6%R9VEN M.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0MF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M M6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU MF4Z(#$R<'0[)R!C;&%S MF4Z(#$Q<'0[ M)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI M;'DZ("=4:6UE6QE/3-$)V9O;G0M"!D;W5B;&4[(&)O'0@,7!T('-O;&ED.R!B;W)D97(M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ M(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P:6X[(&UA3H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V9O;G0M6EN9R!V86QU97,L('=H:6-H(&%P<')O>&EM871E(&9A M:7(@=F%L=64@9VEV96X@=&AE('-H;W)T+71E'!E8W1E9"!T;R!A6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P:6X[(&UA3H@)U1I M;65S($YE=R!2;VUA;B65A M3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE M6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N M="UF86UI;'DZ("=4:6UE6QE/3-$)V9O M;G0M3H@)U1I;65S($YE=R!2;VUA;B2XF;F)S<#LF;F)S<#L@5&AE M('!U2!A9W)E960@=&\@<&%Y('5P('1O M(&%N(&%D9&ET:6]N86P@)FYB2!R96-O2P@;V8@86-C6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R M9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P:6X[(&UA3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$P<'0[)R!C;&%S3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI M;'DZ("=4:6UE6QE/3-$)V9O;G0MF4Z(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4 M:6UE6QE/3-$)V9O;G0MF4Z M(#$R<'0[)R!C;&%S6QE/3-$)V9O;G0M3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@ M9F]N="UF86UI;'DZ("=4:6UE6QE/3-$ M)V9O;G0M6UE;G0@ M;VX@96%R;BUO=70@;VYE(#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R M+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,6EN.R!P861D:6YG+7)I9VAT.B`U M+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)O6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S3L@;6%R9VEN.B`P:6X@,&EN M(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V9O;G0M3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,W!X(&1O M=6)L93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,6EN.R!P861D M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)O MF4Z(#$R<'0[ M)R!C;&%S6QE M/3-$)V9O;G0M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)W1E>'0M86QI M9VXZ(&IUF4Z(#$R<'0[ M)R!C;&%SF4Z(#$Q<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2 M;VUA;BF4Z M(#$Q<'0[)R!C;&%S6QE/3-$)V)OF4Z(#$P<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S3H@)U1I;65S($YE M=R!2;VUA;BF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Q,7!T.R<@8VQA6QE/3-$ M)W!A9&1I;F3L@;6%R9VEN.B`P:6X@,&EN(#!P M=#L@9F]N="UF86UI;'DZ("=4:6UE6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQAF5D(&EN=&%N9VEB;&4@87-S971S.CPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!M961I=6T@;F]N93L@ M8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@,&EN M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-S8N-7!T.R!P861D:6YG M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)O6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@ M)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$R<'0[)R!C;&%S6QE/3-$ M)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N M="US:7IE.B`Q,7!T.R<@8VQA6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%SF4Z(#$Q<'0[)R!C;&%S M6QE/3-$)W!A9&1I;F3L@;6%R9VEN.B`P M:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@ M8VQA6QE/3-$)W!A9&1I;FF4Z(#$Q<'0[)R!C;&%S3H@)U1I M;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@ M8VQA6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N M="UF86UI;'DZ("=4:6UE6QE/3-$)W!A9&1I;FF4Z(#$R<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI M9VXZ(&IUF4Z(#$R<'0[ M)R!C;&%S6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V-O;&]R.B!B;&%C:SL@ M9F]N="US:7IE.B`Q,7!T.R<@8VQA6QE/3-$)W!A9&1I;F6QE/3-$)V)OF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R M.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&IUF4Z(#$R M<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO M;F4[('!A9&1I;FF4Z(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US M:7IE.B`Q,7!T.R<@8VQA3H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W!A9&1I;F3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE M6QE/3-$)V)O M'0@,W!X(&1O=6)L93L@8F]R9&5R+6QE M9G0Z(&UE9&EU;2!N;VYE.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-S8N-7!T.R!P861D:6YG+7)I9VAT.B`U M+C1P=#L@8F]R9&5R+71O<#H@;65D:75M(&YO;F4[(&)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE M=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A M9&1I;F3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@ M9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V)OF4Z(#$R<'0[)R!C M;&%S6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S3H@)U1I M;65S($YE=R!2;VUA;B3H@)U1I;65S M($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI M;'DZ("=4:6UE6QE/3-$)V-O;&]R.B!B M;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA"!D;W5B;&4[(&)O MF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W!A M9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@ M9F]N="UF86UI;'DZ("=4:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA3L@;6%R9VEN.B`P:6X@,&EN(#!P M=#L@9F]N="UF86UI;'DZ("=4:6UE6QE M/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA3H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA6QE/3-$)W!A9&1I;F3H@)U1I;65S($YE=R!2;VUA M;BF4Z(#$Q M<'0[)R!C;&%S6QE/3-$)V9O;G0M3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@ M9F]N="UF86UI;'DZ("=4:6UE6QE/3-$ M)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA6QE/3-$)W1E>'0M M86QI9VXZ(&IUF4Z(#$R M<'0[)R!C;&%S6QE/3-$)W!A9&1I;FF4Z(#$R<'0[)R!C;&%S M6QE/3-$)V9O M;G0M6QE/3-$ M)V-O;&]R.B!B;&%C:SLG(&-L87-S/3-$7VUT/B`\+V9O;G0^/"]F;VYT/CPO M<#X\+W1D/CPO='(^#0H\='(^/'1D('-T>6QE/3-$)W!A9&1I;F3H@)U1I M;65S($YE=R!2;VUA;BF4Z(#$Q<'0[)R!C;&%S6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M M87)G:6XZ(#!I;B`P:6X@,'!T.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;BF4Z M(#$Q<'0[)R!C;&%S3L@ M;6%R9VEN.B`P:6X@,&EN(#!P=#L@9F]N="UF86UI;'DZ("=4:6UE6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE M.B`Q,7!T.R<@8VQA6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$R<'0[)R!C;&%S6]N9"`\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@F4Z M(#$R<'0[)R!C;&%S6QE/3-$)V-O;&]R.B!B;&%C:SL@9F]N="US:7IE.B`Q,7!T.R<@8VQA M6QE/3-$)W!A9&1I;F3H@)U1I;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!M87)G:6XZ(#!I;B`P:6X@,'!T.R!F M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B9#,Y9C4Q,5]C8C`T7S1E96%?.#4W,5]C,C!A-&4S9#1E,3,-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F0S.68U,3%?8V(P-%\T965A M7S@U-S%?8S(P831E,V0T93$S+U=O&UL#0I# M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I# M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'1087)T7V)D,SEF-3$Q7V-B,#1?-&5E85\X-3

Consolidated Statements Of Cash Flows (USD $) In Thousands	9 Months Ended
Consolidated Statements Of Cash Flows (USD $) In Thousands	Sep. 30, 2011	Sep. 30, 2010
Cash flows from operating activities:
Net income	$ 1,633	$ 1,922
Adjustments to reconcile net income to net cash provided by operating activities, net of acquisition:
Depreciation and amortization	3,310	2,501
Provision for deferred income taxes	829	47
Bad debt recovery, net	(15)	(9)
Stock based compensation expense	1,019	791
Accretion of acquisition earn-out	114	245
Changes in operating assets and liabilities, net of acquisitions:
(Increase) decrease in accounts receivable	(1,603)	278
Increase in prepaid expenses and other current assets	(89)	(625)
(Increase) decrease in other assets	(42)	17
Increase (decrease) in accounts payable	113	(199)
Decrease in accrued expenses and other current liabilities	(89)	(1,136)
Decrease in deferred revenue	(19)	(1,127)
Increase in other liabilities	742	368
Net cash provided by operating activities	5,903	3,073
Cash flows from investing activities:
Purchases of property and equipment	(1,352)	(2,296)
Capitalized software development costs	(2,843)	(3,783)
Net cash used in investing activities	(4,195)	(6,079)
Cash flows from financing activities:
Proceeds from sale/leaseback	918	195
Payments under equipment lease obligations	(157)
Purchase of treasury stock	(784)
Excess tax benefit related to stock options		35
Proceeds from exercise of stock options	138	21
Net cash provided by financing activities	115	251
Effect of exchange rate changes on cash	26	1
Net increase (decrease) in cash and cash equivalents	1,849	(2,754)
Cash and cash equivalents at beginning of period	10,443	14,570
Cash and cash equivalents at end of period	12,292	11,816
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	32	7
Cash paid during the period for income taxes	$ 736	$ 1,802

Consolidated Balance Sheets (USD $) In Thousands	Sep. 30, 2011	Dec. 31, 2010
ASSETS
Cash and cash equivalents	$ 12,292	$ 10,443
Accounts receivable, net	13,482	11,866
Prepaid expenses and other current assets	2,594	2,501
Deferred income taxes	4,098	3,625
Total current assets	32,466	28,435
Property and equipment, net	15,459	14,029
Intangibles, net	1,963	2,430
Goodwill	34,302	34,302
Deferred income tax	87	128
Other assets	748	705
Total assets	85,025	80,029
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	2,168	1,983
Accrued expenses and other current liabilities	4,185	4,283
Deferred revenue	13,377	13,395
Current maturities of capital lease obligations	342	168
Current liability for acquisition earn-out	2,000
Total current liabilities	22,072	19,829
Long-term capital lease obligations	1,296	710
Long-term liability for acquisition earn-out		1,886
Deferred income tax	3,107	1,845
Other liabilities	1,621	880
Total liabilities	28,096	25,150
Stockholders' equity:
Preferred stock - $0.00025 par value; authorized 3,000,000 shares, none issued and outstanding at September 30, 2011 and at December 31, 2010
Common stock - $0.00025 par value; authorized 36,000,000 shares, issued and outstanding 15,662,550 shares at September 30, 2011 and 15,631,664 shares at December 31, 2010	4	4
Treasury stock - at cost, shares held: 160,113 at September 30, 2011 and 3,400 at December 31, 2010	(800)	(16)
Additional paid-in capital	49,231	48,074
Retained earnings	8,425	6,792
Accumulated other comprehensive income	69	25
Total stockholders' equity	56,929	54,879
Total liabilities and stockholders' equity	$ 85,025	$ 80,029